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ABSTRACT  
 
Brittney Pauline Ciszek: Unraveling the Complexities of Idiopathic Pain Disorders:  
From Mouse to Man  
(Under the direction of Andrea G. Nackley) 
 
Idiopathic pain disorders (IPDs) are common in the population, yet poorly understood 
and managed. It is generally accepted that IPDs result from variability in genetic and 
environmental factors that impact the expression of pain-relevant genes, such as catechol-
O-methyltransferase (COMT; an enzyme that metabolizes catecholamines). Human genetic 
variants coding for reduced levels of COMT are associated with increased experimental pain 
and IPD risk. Preclinical work in our lab has further shown that COMT-dependent pain is 
mediated via β2- and β3-adrenergic receptors (ARs) and downstream signaling mediators. 
Emerging evidence also implicates a role for microRNAs, regulators of gene expression, in 
IPDs and adrenergic signaling. Yet, more work is required to elucidate the contribution of 
distinct populations of βARs and microRNAs to persistent pain in preclinical and clinical 
settings. Thus, the present studies aim to 1) determine which βAR-enriched tissues drive 
COMT-dependent pain and 2) identify specific microRNAs associated with COMT-
dependent and idiopathic pain. To identify a site-of-action for COMT-dependent pain, we 
measured the ability of peripheral, spinal, and supraspinal β2- and β3-AR antagonists to 
block the development of pain initiated by a COMT inhibitor and to reverse pain established 
in COMT-/- mice. Peripheral antagonist administration blocked pain produced by COMT 
pharmacologic inhibition, but not gene knockdown. This suggests that peripherally-located 
β2- and β3-ARs initiate, but do not maintain COMT-dependent pain. Next, to elucidate the 
role of microRNAs in persistent pain, we examined whole blood microRNA expression 
profiles collected from rats receiving the COMT inhibitor or from patients with IPDs. Results 
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demonstrated that COMT-dependent pain and IPDs are each associated with significant 
microRNA dysregulation. Clinical results further demonstrated that microRNA expression 
profiles differentiate IPD patients into two subtypes with distinct pain phenotypes, 
psychological characteristics, and biological correlates. Collectively, the results presented in 
these studies suggest that βARs and microRNAs represent novel targets for the treatment of 
idiopathic pain. Peripherally-acting βAR antagonists may be beneficial in acute clinical 
settings to prevent the development of idiopathic pain among susceptible individuals. 
MicroRNAs and/or microRNA inhibitors may also represent novel treatments for established 
pain as well as to diagnose and differentiate IPD subtypes. !
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CHAPTER 1 
 
INTRODUCTION 
 
1.1  The Persistent Pain Epidemic 
1.1.1  Definition and Impact of Persistent Pain 
The International Association for the Study of Pain (IASP) describes pain as “an 
unpleasant sensory and emotional experience associated with actual or potential tissue 
damage, or described in terms of such damage.”1 Pain exists prior to tissue damage as a 
warning sign, motivating an individual to withdraw from a stimulus that could cause further 
damage and encouraging the individual to avoid similar stimuli in the future. In the presence 
of tissue damage pain promotes protection of the injured region, allowing healing to occur.1 
Acute pain is therefore important and necessary for protection of the body.1 In fact, 
Congenital Insensitivity to Pain (CIP) is a rare condition in which a person is unable to 
perceive pain and is therefore extremely susceptible to wounds and injuries, resulting in 
reduced life expectancy and increased susceptibility to disease.2 In contrast, some 
individuals experience exaggerated pain in response to an acute stimulus or spontaneous 
pain in the absence of a stimulus. This type of pain, which is neither protective nor adaptive, 
is a hallmark of chronic pain conditions. 
Chronic pain, commonly referred to as persistent pain, is defined by the IASP as pain 
that exists for an extended duration.1 Persistent pain conditions represent one of the nation’s 
most significant healthcare problems, affecting over 100 million Americans and costing the 
United States economy over $600 billion every year. Patients with persistent pain conditions 
experience uncontrollable and debilitating symptoms nearly six days of the week, often 
lasting for over five years. In fact, persistent pain affects more Americans than heart 
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disease, cancer, stroke and diabetes combined, accounting for 20% of medical visits and 
10% of prescription drug sales.3-5  
Persistent pain conditions may be categorized as neuropathic, inflammatory, or 
idiopathic. Neuropathic pain results from injury or disease that affects the peripheral, spinal, 
and/or supraspinal nervous systems. It is often accompanied by maladaptive changes to the 
somatosensory nervous system1 such as alterations in action potential firing, synaptic 
transmission, synaptic connectivity and circuiting, and neuroimmune interactions. These 
alterations lead to amplification of pain. Examples of neuropathic pain include conditions 
such as chemotherapy-induced peripheral neuropathy, diabetic neuropathy, and spinal cord 
injury.6 Animal studies utilize peripheral or spinal nerve ligations (SNLs) to mimic 
neuropathic pain conditions in humans.7  
 Inflammatory pain is characterized by an ongoing inflammatory response and 
nociceptive activation that may or may not exist as a result of tissue damage or injury. For 
example osteoarthritis is a persistent inflammatory condition that can develop as a result of 
trauma or infection to the joint, whereas rheumatoid arthritis is an autoimmune condition. 
Other examples of inflammatory pain conditions include complex regional pain syndrome 
(CRPS) and endometriosis. Animal studies utilize injections of inflammatory agents such as 
carrageenan, capsaicin, or complete Freund’s adjuvant (CFA) to mimic inflammatory pain 
conditions.7  
In contrast to neuropathic and inflammatory pain, idiopathic pain exists without 
underlying neural or tissue damage. Idiopathic pain is heterogeneous in nature and can be 
described as burning, itching, stinging, irritating, stabbing, and/or sharp. Pain severity and 
type can vary with factors such as age, gender, culture, and economic status.8-10 Idiopathic 
pain disorders (IPDs) such as vestibulodynia (VBD), irritable bowel syndrome (IBS), 
temporomandibular disorder (TMD), and fibromyalgia (FM) are an example of idiopathic 
pain. Currently there are no existing animal models for idiopathic pain. Many models utilize 
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the aforementioned neuropathic and inflammatory animal pain models (i.e., SNLs, 
carrageenan injections) to study IPDs. These do not adequately represent the absence of 
neural and/or tissue damage that defines IPDs. This topic is discussed in greater detail in 
Section 1.3.3. 
1.1.2  Characteristics of Idiopathic Pain Disorders 
While clinical manifestations of idiopathic pain are heterogeneous, IPDs are 
characterized by a state of pain amplification, psychological distress, and enhanced 
inflammation: 
i.   Pain Amplification 
As previously mentioned, IPDs are characterized by pain amplification that occurs in 
the absence of an apparent cause.11 The pain may be continuous or intermittent and it may 
be provoked, only present with an accompanying stimulus (i.e., sexual intercourse or 
tampon insertion in VBD) or spontaneous, occurring in the absence of a stimulus.12 Pain 
may be localized to one area of the body in IPDs such as TMD, VBD, IBS, low back pain, 
and migraines; or it can be distributed across several regions of the body in IPDs such as 
FM. Persistent idiopathic pain at one site often co-occurs with pain in one or more distinct 
regions of the body.13 Additionally, IPD patients often report enhanced widespread bodily 
pain as well as decreased thresholds in response to stimuli at various sites. For example, 
TMD patients are more likely to report a history of headaches or back pain, and often 
possess a greater number of irritable bowel syndrome symptoms.14 Patients with migraines 
report skin hypersensitivity as well as decreased pain thresholds at various sites of the 
body.15  
ii.   Psychological Mood 
Patients with IPDs also frequently suffer from severe psychological and 
socioeconomic consequences in addition to their physiological symptoms.16,17 Depression is 
one of the many psychiatric comorbidities that is observed alongside idiopathic pain, and it 
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has been linked to back pain,18 migraines,19 FM,20 VBD21 and IBS.22 Uncontrolled pain at 
severe levels, particularly when in coexistence with depression, increases the risk of 
suicide.23 Anxiety and anhedonia are also among psychological conditions that commonly 
coexist with IPDs.24,25 Physical and emotional pain are thought to share neural pathways 
and connectivity, which could explain why psychological distress frequently co-occurs with 
IPDs. For example, exposing a subject to noxious heat and unpleasant pictures causes 
overlapping activation of the brain.26 In line with this, psychological conditions such as 
depression are known to intensify pain sensitivity,27 while positive emotions can help to 
decrease pain perception.28 The relationship between a psychological condition such as 
depression and physical pain is bidirectional. Each can intensify the other, leading to a 
vicious “mutual maintenance” cycle that promotes distress and disability in IPD patients.25,29 
This mutually reinforcing relationship makes treatment an even greater challenge for 
clinicians. 
iii.   Immune Response  
IPDs are also associated with abnormalities in immune signaling. In a healthy 
individual an interactive network of organs, factors, and cytokines, which comprise the 
immune system, work to defend the body from pathogens and disease. Cells that serve the 
immune system include mononuclear cells (macrophages, monocytes, T cells, natural killer 
(NK) cells, leukocytes) and granulocytes (neutrophils, eosinophils, basophils). Immune cells 
secrete cytokines, which are small messenger proteins that can alter the behavior of 
surrounding cells by influencing processes such as cell activation, division, or movement.30 
Following injury, immune cells are activated within minutes.  
In a healthy individual, pro-inflammatory cytokines such as monocyte chemotactic 
protein (MCP-1), interleukin-1β (IL-1β), IL-6, and tumor necrosis factor α (TNFα) and anti-
inflammatory cytokines such as IL-1 receptor antagonist (IL-1ra or IL-RN), IL-4, and IL-10 
work together in a concerted balance to regulate inflammatory processes following tissue 
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damage. In patients with IPDs, cytokine expression is altered.31 For example, TMD is 
associated with elevated levels of MCP-1 and IL1-ra,32 FM with elevated levels of IL-6 and 
IL-8,33 and VBD with elevated levels of TNFα. A reduction in anti-inflammatory cytokine 
levels has similarly been associated with IPDs, particularly when the pain is widespread or 
exists at multiple sites.32,33 Collectively, these studies suggest that immune cell 
dysregulation, and/or an imbalance between pro- and anti- inflammatory cytokines, may 
facilitate the development of IPDs.34 Cytokine accumulation following injury may lead to 
IPDs via peripheral and/or central sensitization.35 
Peripheral sensitization begins when inflammatory mediators such as cytokines 
interact with primary afferent neurons in the tissue. Primary afferent Aβ fibers are 
responsible for transmitting non-noxious stimuli, whereas Aδ and C fibers transmit noxious 
signals. Aδ fibers are lightly myelinated with a small diameter, responsible for sharp pain 
immediately following injury. C fibers are unmyelinated with a very small diameter, 
responsible for slow, burning pain. Aδ and C fibers synapse with second-order afferent 
neurons in the dorsal horn of the spinal cord, relaying sensory information to supraspinal 
structures including the thalamus and the brainstem.36 Following exposure to inflammatory 
mediators and/or damaged tissue, nociceptor sensitivity is enhanced. Activation thresholds 
are reduced, resulting in amplified nociceptor responsiveness.36,37 Many pathways, such as 
the mitogen-activated protein kinase (MAPK)38 and cyclic adenosine monophosphate kinase 
(cAMP-PKA)39 pathways are expected to play a role in the sensitization downstream from 
enhanced pro-inflammatory cytokine production. In an healthy individual, peripheral 
sensitization is usually coupled to the presence of an acute peripheral noxious stimuli.40 
Peripheral sensitization that continues to exist in the absence of a stimulus, however, is 
pathological and is associated with IPD onset and idiopathic pain localized to the area of 
sensitization.41,42   
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Sustained or repetitive activation of primary afferents can also alter central pathways, 
leading to central sensitization. In central sensitization, neurotrophic factors such as 
substance P and brain-derived neurotrophic factor (BDNF) induce long-lasting spinal 
excitability. Further, wide diameter Aβ fibers, which normally transmit non-noxious signals, 
begin to act like C fibers. As a result, normally innocuous stimuli such as light touch or 
pressure becomes painful.36,37,40 Central sensitization is a normal response that can be 
induced in healthy individuals via mechanical, thermal, or chemical activation of nociceptors. 
This sensation generally lasts for many hours beyond the inducing stimulus. Unsurprisingly, 
central sensitization can also become pathological, if it exists for an extended or persistent 
duration.42 Central sensitization may explain why patients with one IPD are susceptible to 
developing IPDs at separate, distinct areas. Further, it may explain why patients with IPDs 
such as TMD,43 FM,44 neck pain,45 and headache46 demonstrate widespread mechanical 
and/or thermal pain sensitivity. To summarize, IPDs are associated with immunological 
abnormalities and pathological peripheral and central sensitization. 
1.1.3 Vestibulodynia Represents a Common, yet Understudied Idiopathic Pain 
Disorder 
 
VBD is an understudied IPD characterized by debilitating pain or discomfort to the 
vulvar region and is a main focus of the studies outlined in Chapter 4 of this dissertation. 
Like other pain conditions, VBD exists in the absence of a visible cause or inciting 
neurological disorder.47 The vulvar pain experienced by patients with VBD is often described 
as burning, stinging, irritating, or raw48 and is associated with substantial disability.49 The 
pain may be provoked by sexual intercourse or activities such as walking, or it may be 
completely unprovoked and continuous in the absence of a stimulus.50 Like other IPDs, VBD 
can have a significant effect on a woman’s psychological health. In addition to the common 
psychological comorbidities outlined in section 1.1.2, women with VBD commonly suffer 
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from problems with body image, sexual function, and social relationships, leading to a 
significant decrease in their quality of life.49-51 
Despite the physical and emotional characteristics of VBD, patients frequently fail to 
seek treatment for fear of neglect or skepticism.52 Many professionals in the medical 
community believe that VBD is solely a psychological problem, and others misdiagnose 
and/or mistreat patients as a result of not understanding of the condition.49 Though studies 
by the National Institutes of Health (NIH) report that over 15% of American women seek 
treatment for VBD, population-based studies predict that close to 40% of women actually 
suffer from the condition.52 In this sense research and care for VBD is far behind that for 
conditions such as TMD and FM. A greater awareness and understanding of VBD is 
necessary not only to improve treatment for this condition, but also to encourage individuals 
suffering from vulvar pain to seek care for their symptoms.53  
1.1.4  Current Treatment Strategies for VBD and Related Idiopathic Pain Disorders 
Current pharmacological treatments for VBD and other IPDs are rarely effective and 
often associated with adverse side effects that can be severe and at times life threatening. 
Opioids, one of the most commonly prescribed drugs for idiopathic pain, reduce pain by 
activating opioid receptors, thus mimicking the actions of endorphins.54 Unfortunately opioids 
are associated with several adverse side effects including dependence, addiction, 
gastrointestinal problems, altered mental state, muscle rigidity, nausea and respiratory 
depression.55-58 Furthermore, long-term use of opioids is associated with increased pain 
sensitivity and may actually enhance pain further through a phenomenon known as opioid-
induced hyperalgesia.59,60  
Non-steroidal anti-inflammatory drugs (NSAIDs), also commonly prescribed for 
patients with IPDs such as VBD, reduce pain by inhibiting cyclooxygenases (COX-1 and 
COX-2) and subsequently preventing the synthesis of pro-inflammatory prostaglandins. 
NSAID use has been associated with gastrointestinal ulcers, renal dysfunction, 
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cardiovascular risk, impaired hemostasis and asthma.61 Many of the other drugs used for the 
treatment of idiopathic pain, such as tricyclic antidepressants, selective serotonin reuptake 
inhibitors (SSRIs), antiepileptic drugs, and cannabinoids, are mitigated by similar side 
effects and marginal efficacy.61 Topical applications of substances or drugs such as 
estrogen, lidocaine jelly, nitroglycerine, amitriptyline, baclofen, or capsaicin or injections of 
triamcinolone or botulinum toxin A may help to reduce pain in patients, but the relief is often 
short-lived.50 Current research is focused on the development of drugs as well as non-
pharmacological treatment strategies to overcome these limitations. 
Non-pharmacological interventions for IPDs can be behavioral, cognitive, integrative 
or physical in nature.62 Unlike drugs, which target the biological causes of pain, these 
interventions work to address the psychological and social consequences of idiopathic 
pain.63 Examples include behavioral therapy, cognitive-behavioral therapy, hypnosis, guided 
imagery, diaphragmatic breathing, muscle relaxation, mindfulness-based stress reduction, 
acupuncture, stretching, exercising, and physical therapy.62 VBD-specific examples include 
physical therapy that targets the pelvic floor, pelvic floor surface electromyography and 
biofeedback, a low-oxalate diet with calcium citrate supplementation, surgery (e.g., localized 
excision, vestibulectomy, perineoplasty), and sexual counseling.50 Though non-
pharmacological interventions for IPDs usually are not sufficiently effective alone, they can 
be used in combination with pharmacologic treatment strategies to enhance drug efficacy.62 
Still, future research is necessary to develop better therapeutics as well as to understand 
individual variability that may impact the efficacy of treatment for VBD and other IPDs. 
 
1.2  Known Causes and Correlates 
1.2.1  Environmental Factors  
Alterations in pain, mood, and inflammation that are observed in patients with IPDs 
are likely due to both environmental and genetic factors. In some cases IPDs are thought to 
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develop as a result of a previous trauma, injury, or event. For example, 30-50% of patients 
suffer from idiopathic pain between one and one half and two years after a surgery such as 
hernia repair, amputation, mastectomy, or thoracotomy.64-67 The presence of severe acute 
pain in post-operative patients 24 hours following surgery, both at rest and following 
movement, can be predictive of IPDs later in life.65 Infections have also been associated with 
IPDs.68,69 Many VBD patients have a history of frequent yeast infections.50,70 Other 
environmental stressors that commonly lead to idiopathic pain or IPDs include car 
accidents,71,72 bone fractures,73,74 physical abuse,75 sexual abuse,76,77 and cancer.78-80 
Scientists hypothesize that traumatic events or environmental factors such as these may 
result in inflammation or nerve damage that never resolves.81 Chapter 1.1.2 provides a 
detailed description of possible mechanisms that may facilitate idiopathic pain following 
traumatic events or injuries. Collectively, these studies provide strong evidence for a 
relationship between environmental stressors and idiopathic pain. Despite this evidence, the 
development of an IPD cannot be attributed to environmental factors alone.  
1.2.2  Genetic Factors  
Not all individuals develop one or more debilitating IPDs following an event such as 
surgery or a car accident. This may be explained by genetics which, in conjunction with the 
environmental factors listed above, can also play a vital role in the development of idiopathic 
pain. Hundreds of pain- and analgesia-relevant genes have been identified from gene 
microarray studies. Acute, inflammatory, cancer, musculoskeletal, neuropathic, idiopathic, 
visceral, widespread, and experimental pain phenotypes have been associated with various 
genes. Mouse studies predict that the heritability for nociceptive and analgesic sensitivity is 
somewhere between 28-76%.82,83 
The most popular candidate genes for pain include those that code for catechol-O-
methyltransferase (COMT), GTP cyclohydrolase 1 (GCH1), human lymphocyte antigen 
(HLA), serotonin receptor 2A (HTR2A), IL-1A, IL-1B, IL-1RA, µ opioid receptor (OPRM1), 
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solute carrier family 6 member 4 (SLC6A4), transient receptor potential cation channel V1 
(TRPV1), and TNF. Unsurprisingly, many of these genes are involved in the activation or 
expression of receptors (e.g., OPRM1, TRPV1), molecules (e.g., ILs, TNF) or pathways 
involved in pain processing.81 COMT is one of the most widely studied genes in the context 
of pain. COMT is of particular interest to the studies outlined in this dissertation and is 
discussed further in Chapter 1.3. Of note, genetic associations have also been established 
for several psychological traits and conditions that can influence pain perception and the 
susceptibility of developing IPDs (See Chapter 1.1.2 for more information on the 
psychological traits and conditions associated with IPDs). For example the heritability of 
depression is estimated to be within 50-70%. Genes that contribute to pain perception 
and/or a pained psychological state may influence an individual’s susceptibiltiy of developing 
persistent idiopathic pain and IPDs. 
1.2.3  Epigenetic Factors 
Environmental stressors or factors may be involved in the activation of idiopathic 
pain or onset of IPDs in individuals who have genetic predispositions. Perhaps the best 
evidence of this comes from studies that demonstrate significant differences in inflammatory 
and persistent pain phenotypes in monozygotic twins.84,85 Though twins may have identical 
or similar epigenomes at birth, they are later subjected to environmental differences and, 
consequentially, epigenetic differences that may or may not activate their genetic 
predisposition to develop idiopathic pain.86  
The field of epigenetics explores the interactions between genes and the 
environment. Emerging evidence suggests that epigenetic mechanisms can silence 
expression of genes that are pro- or anti-nociceptive, thus altering pain pathways.86,87 
Factors such as those listed in Chapter 1.2.1 as well as environmental toxins, medications, 
diet, psychological stressors, age, nutrition, and social context can alter epigenetic 
processes, including DNA methylation, histone acetylation, and RNA interference.74,88-90 
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Epigenetic modifications like these likely play a pivotal role in the development of IPDs, as 
they can impact pro- and anti-inflammatory cytokine expression, steroid responsiveness, 
and opioid sensitivity.86 To summarize, IPDs are a product of genetic and environmental 
factors, an interaction that is important to consider in future studies (Figure 1.1).91 
i. MicroRNAs 
MicroRNAs (miRNAs) are a type of epigenetic regulation that may affect pain-
relevant processes.67 MiRNAs are small, non-coding pieces of RNA that are usually 
nineteen to twenty-five nucleotides in length and can regulate gene expression by binding to 
downstream mRNA targets.92 Primary miRNAs (pri-miRNAs) are initially transcribed in the 
nucleus, then processed into precursor pre-miRNAs by the “Drosha” endonuclease. 
Intracellular transport protein exportin 5 facilitates the export of pre-miRNAs into the 
cytoplasm, where they are converted into mature miRNAs by the endonuclease “Dicer”. 
Double-stranded, mature miRNAs become single-stranded following attachment to the RNA-
induced silencing complex (RISC). At this point miRNAs can regulate gene expression, 
either by completely binding to their downstream mRNA targets and thereby cleaving the 
transcript or by incompletely binding and thereby inducing translational repression.92,93 
MiRNAs represent a complex regulatory network, as each individual miRNA binds to several 
downstream mRNAs and, similarly, each mRNA transcript complements several miRNAs.92 
Dysregulation of miRNAs can cause subsequent dysregulation of downstream 
pathways and processes, often resulting in disease. MiRNA dysregulation has been 
observed in various conditions including multiple sclerosis,94 peripheral artery disease,95 
major depressive disorder,96 cardiovascular disease,97 liver injury,98 and cancer.99 MiRNAs 
may represent a therapeutic target for many of these conditions. In fact, phase two clinical 
trials are currently assessing the efficacy of a miRNA-based therapeutic for the treatment of 
cancer. The aim of this therapeutic, known as “miRNA replacement therapy,” is to re-
introduce miRNAS into diseased cells where they are downregulated.100 MiRNAs may also 
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be used in the future to diagnose disease. Circulating miRNAs are stable in serum and 
plasma, making them ideal biomarkers.101 
ii.   MicroRNAs Associated with Pain and Inflammation 
Dysregulation of miRNAs that are involved in pain- and inflammation-relevant 
processes may facilitate the development of persistent idiopathic pain.93 Several miRNAs 
are known to play a role in the development and normal function of the immune system. 
Abnormal immune system function can lead to overproduction of inflammatory mediators 
(i.e., cytokines), contributing to IPDs.102,103 Many studies have confirmed the importance of 
miRNAs in regulating immune cell development and fine-tuning the immune cell response.  
Granulocytes (neutrophils, eosinophils, basophils) and mononuclear cells 
(monocytes, lymphocytes, macrophages) each play important roles in defending the body 
(see Chapter 1.2.2). MiR-223 plays an important role in granulocyte differentiating, as well 
as in the development and function of neutrophils, which act as the first line of defense 
against pathogens. Other miRNAs, including miR-17-5p, miR-20a, miR-106a, and miR-424 
are involved in the regulation and differentiation of monocytopoiesis, or the production of 
mononuclear cells. Several different miRNAs are either upregulated or downregulated in 
response to pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharide 
(LPS) stimulation in mononuclear cells. Activation of toll-like receptors (TLR2, TLR4, TLR5) 
or inflammatory cytokines (IL-1 β) affects the expression of miR-146a and miR-147 in 
mononuclear cells. MiR-21 and miR-9 are each responsible for the negative regulation of 
LPS-activated inflammatory signaling. MiR-155 and miR-17-92 play distinct roles in 
lymphocyte development and function.104 Let-7i and miR-125b are decreased during innate 
immune responses. A summary of miRNA regulation of immune cells can be found in Figure 
1.3A.  
MiRNAs have also been directly linked to the expression of inflammatory cytokines. 
Many miRNAs, including miR-29a,105 miR-146a,106 miR-124,107 and miR-93108 are involved in 
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the regulation of inflammatory cytokine secretion. Additionally, miRNAs are regulators of 
nuclear factor kappa-light-chain-enhancer of B cells (NF-κB), which controls inflammatory 
genes and cytokine secretion and is chronically active in many inflammatory diseases.109,110 
Collectively this demonstrates that miRNAs play an important role in the immune system 
and can alter the immune response.  
Aberrant miRNA profiles have been observed in various rodent models of pain and 
inflammation. This includes inflammatory pain models such as CFA,111,112 carrageenan,113 
and capsaicin112 injections as well as neuropathic pain models such as peripheral nerve 
ligations and SNLs.112,114,115 Rodent studies have also linked miRNA expression to 
nociceptor excitability and pain thresholds.116 Furthermore, intrathecal injections of miR-103 
and miR-124, which were previously identified as regulators of pain signaling, have been 
shown to prevent and alleviate pain in rodent models.117,118 These are the first studies to 
support the use of miRNAs as treatment for pain.119  
MiRNA dysregulation has similarly been associated with pain-related diseases in 
humans. For example, miR-146a is significantly upregulated in peripheral knee joint tissues 
of osteoarthritis (OA) patients. It regulates pain-related factors, modulates inflammatory 
molecules, and may be used in the future as a treatment target for OA.120 Likewise, miRNA 
dysregulation has been linked to rheumatoid arthritis104 and complex regional pain syndrome 
(CRPS). In CRPS, miRNA profiles can be used to stratify patients into sub-groups that may 
respond to treatment plans differently.121 More recently, miRNA dysregulation has been 
linked to IPDs such as fibromyalgia,122 bladder pain syndrome (BPS),123 and migraines.124 A 
list of additional pain-relevant animal models and clinical conditions that have been linked to 
miRNA dysregulation is shown in Figure 1.3B.  
To summarize, miRNA dysregulation plays an important role in many pain-relevant 
processes and conditions. The dysregulation of pain-regulating miRNAs may facilitate the 
development of idiopathic pain.93 Additional research is required to understand the 
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relationship between miRNAs and pain and how that relationship might be exploited to 
develop more effective therapeutic strategies for IPDs. The studies presented in this 
dissertation aim to elucidate the role of miRNAs in idiopathic pain, utilizing experiments in an 
animal model as well as in clinical IPDs. 
 
1.3  The Contribution of Catechol-O-methyltransferase 
1.3.1  Catechol-O-methyltransferase and Persistent Pain  
As discussed in Chapter 1.2.1, there is strong evidence of a role for COMT in 
persistent and idiopathic pain. COMT is an enzyme that metabolizes catecholamines such 
as dopamine, epinephrine, and norepinephrine. Its active site consists of an S-adenosyl-L-
methionine (AdoMet) binding site and a catalytic site. In the presence of Mg2+ COMT 
catalyzes the transfer of the AdoMet methyl group to one of the two hydroxyl groups of the 
catechol. The COMT gene codes for two forms: membrane bound (MB-COMT) and soluble 
(S-COMT). S-COMT is dominantly expressed in the majority of tissues; however, in the 
brain 70% of total COMT is MB-COMT.125 COMT expression varies across tissue types as a 
result of tissue-specific transcription factor-mediated gene regulation.126 
Decreased activity of COMT has been directly linked to pain-relevant conditions such 
as facial pain.127,128 Diminished COMT activity leads to abnormalities in catecholamine levels 
and physiology,125 which have also been linked to pain and IPDs. In fact, previous studies 
have utilized catecholamine excretion as a measure of pain-relevant conditions such as 
rheumatoid arthritis.129 Patients with FM demonstrate increased levels of norepinephrine, 
which increase further in response to enhanced pro-inflammatory cytokine expression.130,131 
Patients with myofacial pain132,133 and chronic bladder pain134 similarly demonstrate 
sustained elevation of catecholamines and augmented sympathetic signaling. 
Catecholamine abnormalities have also been linked to psychological characteristics 
associated with IPDs, such as stress,129,135 anxiety,136,137 and depression.138 
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1.3.2 Catechol-O-methyltransferase is Influenced by Genetic and Environmental 
Factors 
 
Historically, COMT research has focused on a common single nucleotide 
polymorphism (SNP) in the gene locus (rs4680), which causes a valine (Val) to methionine 
(Met) substitution at codon 158 and leads to a four-fold reduction of the enzyme. Individuals 
with the Met/Met genotype have reported higher sensory and affective pain ratings and have 
a higher regional density of µ-opioid receptors. Additionally, this polymorphism can influence 
the efficacy of morphine treatment for pain.139 This polymorphism alone, however, has not 
been able to fully account for individual variation in pain sensitivity, as results across studies 
have been largely inconsistent.140  
Our laboratory has also demonstrated the importance of haplotypes consisting of 
rs4680 along with three other common SNPs (rs6269, rs4633, rs4818, and rs4680) to 
persistent pain. We identified three haplotypes in the COMT gene locus, which account for 
variation in pain sensitivity among individuals: the G_C_G_G haplotype, associated with a 
low pain sensitivity (LPS) phenotype;  the A_T_C_A haplotype, associated with an average 
pain sensitivity (APS) phenotype; and the A_C_C_G haplotype, associated with a high pain 
sensitivity (HPS) phenotype. The LPS haplotype provides 4.8 times higher levels of COMT 
activity compared with the APS haplotype. The HPS haplotype provides 11.4 times lower 
levels of COMT activity compared with the LPS haplotype. In addition to increased 
experimental pain sensitivity, the HPS phenotype is associated with TMD onset. During a 
three-year observational period, individuals with only HPS and/or APS haplotypes were 
more than twice as likely to develop TMD than those with at least one LPS haplotype.141 
Individuals with HPS COMT haplotypes are also more likely to develop pain or IPDs 
following traumatic events such as surgeries,142,143 car accidents,144 and orthodontic 
treatment.90 Additionally, COMT haplotypes are associated with variance in pain severity for 
patients with FM145,146 as well as postsurgical shoulder pain.143  
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Variability in the COMT gene also determines efficacy in the treatment of pain 
disorders by propranolol, a non-selective beta-adrenergic receptor (βAR) antagonist that 
effectively blocks COMT-dependent mechanical and thermal pain in rodents147 and is 
commonly used to treat chronic daily headaches in the clinic.148 Propranolol substantially 
improves experimental and clinical pain in TMD subjects not carrying a LPS haplotype. The 
pain is however only moderately improved in LPS heterozygotes, and not affected at all in 
LPS homozygotes.140  
To summarize, decreased COMT activity levels lead to increased catecholamine 
levels, resulting in heightened pain sensitivity (Figure 1.2). Genetic variability in the COMT 
gene signficantly alters an individual’s response to experimental pain, susceptibility to IPDs 
and responsiveness to treatment. This is an important consideration that must be 
considered by clinicians who treat individuals with idiopathic pain. Future research should 
focus on elucidating the mechanisms underlying COMT-dependent pain. 
1.3.3 An Animal Model of COMT-Dependent Pain  
Though animal models have been instrumental in developing a better understanding 
of the mechanisms underlying pain, many existing models do not accurately reflect human 
IPDs. Instead, they often utilize inflammatory agents to provoke pain. Many of these models 
require persistent injections or applications of the chosen drug or chemical. Other animal 
models induce pain by inflicting nerve damage. These models, though useful for the study of 
inflammatory or neuropathic pain, do not accurately represent IPDs (Chapter 1.1.1). As a 
result, many potential analgesics have failed in the clinic despite strong efficacy in a pre-
clinical animal model.7 Our laboratory has developed a rat model of persistent idiopathic 
pain in which a COMT inhibitor is administered to rats to mimic the endogenously low levels 
of COMT activity observed in patients (Chapters 1.3.1 and 1.3.2 explore the role of COMT in 
persistent idiopathic pain.) We believe this model represents a clinically-relevant form of 
pain that more closely mimics the experience of humans with IPDs than is the case for other 
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animal models that rely on repeated administration of noxious stimuli. We have utilized this 
model to gain a better understanding of the mechanisms underlying COMT-dependent pain. 
Consistent with clinical IPDs, administration of a COMT-inhibitor to rats results in 
mechanical and thermal pain and alters cognitive-affective behaviors linked to pain (e.g., 
avoidance of painful heat and bright light).147,149,150 Because catecholamines stimulate the 
sympathetic nervous system via activation of adrenergic receptors (ARs), pharmacologic 
studies were utilized to assess the efficacy of alpha (α1 and α2) and beta (β1, β2, and β3) 
adrenergic as well as dopaminergic receptor antagonists in blocking OR486-induced pain. 
Results demonstrated that OR486-induced pain is blocked by the non-selective β-
adrenergic receptor (βAR) antagonist propranolol or by the combined administration of 
selective β2- and β3AR antagonists. In contrast OR486-induced pain is not blocked by β1-
adrenergic, α-adrenergic, or dopaminergic receptor antagonists.147 These results are in line 
with those from clinical studies, showing that propranolol alleviates pain among FM and 
TMD patients.140,151 Collectively these studies suggest that increased catecholamine levels, 
resulting from reduced COMT activity, drive pain via β2- and β3ARs.  
i.   β-Adrenergic Receptors and COMT-Dependent Pain 
ARs are G protein-coupled receptors (GPCRs), responsible for transmitting signals 
from extracellular ligands to the intracellular environment to control various cellular events 
and physiological processes. Though several ARs exist—alpha-adrenergic (α1 and α2), beta-
adrenergic (β1, β2, and β3) and dopaminergic—only β2- and β3ARs are known to contribute 
to COMT-dependent pain (see Chapter 1.3.3). βARs were first discovered in 1948 and have 
been heavily studied in the context of heart disease. Though βAR antagonists, otherwise 
known as β-blockers, were developed for the treatment of heart failure in 1975,152 it was not 
long before their efficacy was discovered for pain reduction in conditions such as arthritis 
and joint pain.153-155 Today they represent a promising possibility for the treatment of IPDs 
such as TMD and FM.140,151  
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Like all GPCRs, βARs have seven transmembrane-spanning α-helices, which fold to 
create three extracellular and three intracellular loops. Upon activation β2- and β3ARs couple 
to the Gs guanine nucleotide-binding protein (G protein), activating adenylyl cyclase and 
thereby leading to the formation of cAMP and activation of PKA. This represents a specific 
and rapid signaling cascade.156,157 Gs interaction sites for both β2- and β3ARs are located in 
the membrane proximal regions of the second and third intracellular loops as well as at the 
carboxy-terminal domains.157 Although many of the actions of both β2- and β3ARs are 
mediated by Gs proteins, studies have demonstrated that both receptor types can also 
couple to Gi proteins, leading to the activation of extracellular signal-regulation kinase (ERK) 
and MAPK pathways.156,158 
 β2- and β3ARs are expressed in peripheral and central regions where they could 
drive pain. β2ARs are located on peripheral terminals159-163 and cell bodies164-166 of primary 
afferent nociceptors, keratinocytes,167-169 immune cells,170-173 and adipocytes174 in the 
periphery and neurons175,176 and glial cells177 in the central nervous system. β3ARs are 
located on primary afferent nociceptors,178 adipocytes,174 and immune cells171,172 in the 
periphery and noradrenergic neurons in the brain.179 A site of action for the β2- and β3ARs 
that mediate COMT-dependent pain has yet to be determined. The studies presented in this 
dissertation aim to identify a site of action for the βARs receptors that mediate COMT-
dependent pain using clinically-relevant rodent models of COMT-dependent pain that 
improve upon those used in prior studies. 
ii. MicroRNAs and COMT-Dependent Pain 
  It is important to note that miRNAs, which are discussed in detail in Chapter 1.2.3, 
may also play a role in COMT-dependent pain. It is likely that COMT-dependent pain is 
associated with the dysregulation not only of miRNAs involved in pain and immune 
processes, but also of those responsible for the regulation of catecholaminergic and/or βAR 
signaling. For example, previous studies have demonstrated a role for the miRNA let-7 in 
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regulating β2AR expression.180 Furthermore, βAR stimulation induces expression of miR-
21181 as well as miR-199a-5p.182 It is thought that the cardioprotective effects of βAR 
antagonist propranolol are in part a result of miR-1 downregulation.183 Several miRNAs have 
been associated with reduced catecholamine sensitivity in the heart, a characteristic of 
chronic heart failure.184 Though many ongoing studies are examining the relationship 
between miRNAs and βAR-mediated cardiac disease; the relationship between miRNAs, 
βAR signaling, and COMT-dependent pain has yet to be studied.  
The studies presented in this dissertation aim to elucidate the role of miRNAs not only in 
persistent idiopathic pain, but also specifically in COMT-dependent pain. 
 
1.4 Summary and Specific Aims 
 Though IPDs are heterogeneous in nature, they are generally characterized by a 
physical state of pain amplification, psychological distress, and enhanced inflammation 
(Chapter 1.1.2). Persistent idiopathic pain manifests without an apparent cause, but it is 
facilitated by both environmental (Chapter 1.2.1) and genetic (Chapter 1.2.2) factors. One 
gene of particular interest codes for COMT and has been linked to increased pain sensitivity 
and susceptibility to developing IPDs (Chapter 1.3). Though studies have demonstrated that 
COMT-dependent pain is mediated via β2- and β3ARs, the site of action whereby these 
receptors mediate COMT-dependent pain remains unknown (Chapter 1.3.3). Chapters 2 
and 3 therefore aimed to determine the site of action whereby β-adrenergic systems drive 
persistent COMT-dependent pain. We hypothesized that peripheral, spinal, and supraspinal 
βARs would contribute to COMT-dependent pain. We found that peripheral but not spinal or 
supraspinal β2- and β3ARs contribute to the initiation, but not the maintenance, of COMT-
dependent pain. 
 Epigenetic modifications such as miRNA regulation can be initiated by environmental 
factors and may also facilitate the development of idiopathic pain, particularly in genetically 
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susceptible individuals (Chapters 1.2.3 and 1.3.3). Though emerging evidence suggests a 
role for miRNAs in idiopathic pain, the relationship between miRNAs and COMT-dependent 
pain has not been widely studied. Chapter 4 aimed to identify miRNAs associated with IPDs. 
We hypothesized that miRNA dysregulation would be associated with idiopathic pain in a 
clinical setting. As hypothesized, we observed miRNA dysregulation in patients with IPDs. 
We also found that miRNAs may be useful for distinguishing between separate subtypes of 
IPDs. Collectively, the present studies may help to inform future care for patients by 
elucidating the etiologies and identifying targets for treatment of idiopathic pain. 
 
 !!!!!!!!!!!
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Figure 1.1 Idiopathic pain disorders are influenced by environmental and genetic 
factors. This model depicts environmental and genetic factors that determine an individual’s 
psychological profile and pain amplification status. These two domains can influence the risk 
of onset and maintenance of IPDs in patients. Adapted from: “Idiopathic pain disorders: 
Pathways of vulnerability” by L.L. Diatchenko, 2006, PAIN.91 Abbreviations: brain-derived 
neurotrophic factor (BDNF), catechol-O-methyltransferase (COMT), cyclic AMP responsive 
element-binding protein 1 (CREB1), idiopathic pain disorder (IPD), I kappa B kinase (IKK), 
monoamine oxidase (MAO), N-methyl-D-aspartate (NMDA), transient receptor potential 
vanilloid (TRPV). 
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Figure 1.2 Decreased COMT activity is associated with idiopathic pain disorders. 
Genetic variability in the COMT gene can result in decreased levels of COMT activity and 
subsequently increased levels of circulating catecholamines (e.g., epinephrine, 
norepinephrine), contributing to the development of IPDs. Abbreviations: catechol-O-
methyltransferase (COMT), idiopathic pain disorders (IPDs). 
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Figure 1.3 MicroRNA dysregulation can affect immune cell function and is associated 
with pain-relevant animal models and clinical conditions. (A) MiRNAs play an important 
role in the development and function of immune cells, subsequently fine-tuning the innate 
immune response and protecting the host from injury. Dysregulation of the miRNAs that are 
involved with immune system regulation may result in chronic inflammation and pain. 
Adapted from: “MicroRNA, a new paradigm for understanding immunoregulation, 
inflammation, and autoimmune diseases” by R. Dai and S.A. Ahmed, 2011, Translational 
Research.104 (B) MiRNA dysregulation has been associated with various animal models of 
pain as well as clinical pain-relevant conditions. Blue = animal models of pain, red = clinical 
pain conditions, purple = animal models of pain in addition to clinical pain conditions. 
Adapted from: “MicroRNAs as modulators and biomarkers of inflammatory and neuropathic 
pain” by H.H. Andersen, M. Duroux, and P. Gazerani, 2014, Neurobiology of Disease. 
Abbreviations: complete Freund’s adjuvant (CFA), complex regional pain syndrome (CRPS), 
microRNA (miR).
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CHAPTER 2 
 
PERSISTENT CATECHOL-O-METHYLTRANSFERASE-DEPENDENT PAIN IS INITIATED 
BY PERIPHERAL BETA-ADRENERGIC RECEPTORS 1,2 
 
2.1 Introduction 
 
 Idiopathic pain disorders (IPDs) including fibromyalgia (FM), headache, 
temporomandibular disorder (TMD), and vestibulodynia (VBD) constitute a significant 
healthcare problem, affecting over 100 million Americans.185-191 These disorders occur more 
frequently in females than males192 and are chronic in nature, characterized by pain that 
occurs daily and spans years. While the mechanisms underlying IPDs are poorly 
understood, emerging evidence indicates a role for adrenergic pathways. Patients exhibit 
increased levels of catecholamines131-133 alongside diminished activity of catechol-O-
methyltransferase (COMT),127,128 a ubiquitously expressed enzyme that metabolizes 
catecholamines to their inactive derivatives.125 An increase in catecholaminesis is similarly 
observed in patients with inflammatory conditons such as arthritis and complex regional pain 
syndrome (CRPS).193-195 Furthermore, functional variants in the COMT gene that reduce 
COMT activity128,196,197 are associated with increased susceptibility to FM,145,146,198-200 
TMD,141 and experimental pain141,201 as well as impaired response to treatment.139,202 It is 
estimated, based on the frequency of allele variation, that nearly two-thirds of patients with 
persistent pain disorders possess the low-activity COMT variants.203,204  
 Consistent with clinical disorders, our lab found that administration of the COMT 
inhibitor OR486 in rodents produces increased hypersensitivity at multiple body sites and 
alters cognitive-affective behaviors linked to pain (e.g., avoidance of painful heat and bright 
light).147,149,150 Pharmacologic studies further revealed that OR486-induced pain is blocked 
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by administration of the non-selective βAR antagonist propranolol or by combined 
administration of selective β2- and β3AR antagonists.147,149,150 These results are in line with 
those from clinical studies, showing that propranolol alleviates pain among FM and TMD 
patients.140,151 Collectively, these studies suggest that increased catecholamine levels, 
resulting from reduced COMT activity, drive pain via β2- and β3ARs.  
 β2- and β3ARs are G protein-coupled receptors (GPCRs) expressed in peripheral 
and central regions where they could mediate pain perception and/or processing. β2ARs are 
located on peripheral terminals159-163 and cell bodies164-166 of primary afferent nociceptors, 
keratinocytes,167-169 immune cells,170-173 and adipocytes174 in the periphery; and neurons175,176 
and glial cells177 in the central nervous system. β3ARs are located on primary afferent 
nociceptors,178 adipocytes,174 and immune cells171,172 in the periphery and noradrenergic 
neurons in the brain.179 Thus, the aim of this study was to determine a site-of-action for 
COMT-dependent pain. We hypothesized that peripheral, spinal, and/or supraspinal β2- and 
β3ARs contribute to persistent COMT-dependent pain.  
 To test this hypothesis, we employed a clinically-relevant model of persistent COMT-
dependent pain and evaluated responses to mechanical and thermal stimuli in 
adrenalectomized rats, lacking peripheral epinephrine, and in intact rats receiving 
continuous delivery of βAR antagonists via intraplantar (i.pl.), intrathecal (i.t.), or 
intracerebroventricular (i.cv.) routes. Potential sexual dimorphism in the contribution of 
adrenergic systems to persistent COMT-dependent pain was also assessed.   
 Results demonstrated that male and female rats receiving sustained OR486 
exhibited COMT-dependent mechanical and thermal pain, persisting for two-weeks. In 
contrast, adrenalectomized rats failed to develop OR486-induced pain. Furthermore, i.pl., 
but not i.t. or i.c.v., administration of the non-selective βAR antagonist propranolol, β2AR 
antagonist ICI118,551, or β3AR antagonist SR59230A blocked OR486-induced pain. These 
findings demonstrate the importance of peripheral β2- and β3ARs in mediating persistent 
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pain, and suggest that peripherally-acting βAR antagonists may provide an effective 
treatment option for patients with persistent pain disorders. 
 
2.2 Materials and Methods 
 
2.2.1  Animals 
Adult male and female Sprague-Dawley rats (N=24 intact, N=24 adrenalectomized 
and N=23 sham) were purchased (Charles River Laboratories, Raleigh, NC) for the first set 
of experiments. For subsequent βAR antagonist experiments, adult male Sprague-Dawley 
rats (N=111) were bred in-house. Rats weighed between 200 and 400g for all experimental 
studies. Rats had ad libitum access to standard laboratory chow and water. 
Adrenalectomized rats were provided with saline water (0.9%) to compensate for the loss of 
sodium in urine due to the absence of aldosterone. All animal procedures were approved by 
the Institutional Animal Care and Use Committee (IACUC) at the University of North 
Carolina at Chapel Hill (UNC). Though rodent models of pain only partially correlate with 
human conditions, rats were chosen for these experiments because an extensive body of 
literature exists regarding nociceptive pathways and behavior in this species, and because 
rat pain behavior assays are readily available and well characterized.7,205,206 
2.2.2  General Experimental Conditions 
First, the effects of sustained COMT inhibition on pain were evaluated in intact rats 
receiving the COMT inhibitor OR486 or vehicle systemically for a two-week period via a 
2002 Alzet osmotic pump (Durect Corporation, Cupertino, CA). Next, the contribution of 
peripheral adrenergic systems to persistent OR486-induced pain was evaluated in 
adrenalectomized rats, lacking peripheral epinephrine, or sham rats receiving OR486 or 
vehicle systemically for two-week period via an osmotic pump. Finally, the contribution of 
peripheral, spinal and supraspinal βARs to persistent OR486-induced pain was evaluated in 
separate groups of intact rats receiving i.pl., i.t. or i.c.v.. βAR antagonists alongside systemic 
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delivery of OR486 or vehicle for a two-week period via an osmotic pump. The βAR 
antagonists were delivered via a catheter attached to a separate 2002 Alzet osmotic pump. 
Animals were handled and habituated to the experimenter and environment for four 
days prior to testing. Responses to punctuate mechanical and thermal stimuli were 
assessed in intact and adrenalectomized animals 1 day prior to and on days 1, 3, 5, 7, 9, 11, 
and 13 following pump implantation. For βAR antagonist experiments, pain behaviors were 
assessed one day prior to and on days 2, 4, 6, 8, 10, 12, and 14 following pump 
implantation. The rest day between surgery and testing allowed animals to fully recover from 
catheter implantation. On baseline and testing days, rats were habituated to the mechanical 
and thermal testing environments for ten to fifteen minutes. Though we were unable to 
eliminate all environmental factors (e.g., season, humidity, noise) from this study, we 
minimized others (e.g., experimenter consistency, testing time of day, cage density) that 
were in our control.207,208 Animals were randomly assigned to groups, were tested by a 
single, blinded experimenter at a consistent time of day (morning), and were housed with 
one to two other rats. The primary outcome reported in this study is behavioral changes, in 
the form of mechanical allodynia, mechanical hyperalgesia, and thermal hyperalgesia, which 
are described in detail below under their respective subtitles.  
2.2.3  Drug Preparation 
OR486 (Tocris, Ellisville, MO) was dissolved in a 5:3:2 ratio of dimethylsulfoxide 
(DMSO), 0.9% saline, and ethanol.147 For peripheral experiments βAR antagonists 
propranolol hydrochloride (Tocris, Ellisville, MO), ICI-118,511 (Tocris, Ellisville, MO), and 
SR59230A (Tocris, Ellisville, MO) were each dissolved in 5:3:2 ratios of DMSO, 0.9% saline, 
and ethanol. For i.t. and i.c.v. experiments, βAR antagonists were dissolved in 0.9% saline. 
Drug solutions were injected into pumps, which were placed in 15mL conical tubes 
containing sterile 0.9% saline and primed overnight in a dry heat bath (Lab Armor, 
Cornelius, OR) at 37 degrees Celsius. All pumps (other than those for i.t. delivery) were 
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attached to corresponding catheters prior to priming. Subcutaneous delivery of OR486 was 
at a constant rate of 15mg/kg/day for a two-week period. Peripheral delivery of propranolol 
hydrochloride was at 9mg/kg/day, ICI-118,511 was at 1.5mg/kg/day, and SR59230A was at 
1.67mg/kg/day. I.t. delivery of propranolol hydrochloride was at 50ug/day for the low dose 
experiments and 100ug/day for the high dose experiments, ICI-118,511 was at 30ug/day, 
and SR59230A was at 20ug/day. I.c.v. delivery of propranolol hydrochloride was at 
50ug/day for the low dose experiments and 100ug/day for the high dose experiments, ICI-
118,511 was at 30ug/day, and SR59230A was at 20ug/day. 
2.2.4  Surgical Procedures 
For all surgical procedures, rats were anesthetized by isoflurane inhalation (5% 
induction, 1.5-5% maintenance). Incision sites were shaved and disinfected with ethanol and 
betadine. Sterile technique was employed throughout the duration of all procedures 
according to IACUC requirements. Stainless steel wound clips (Braintree Scientific, 
Braintree, MA) were used to close the wounds.  
For systemic delivery of OR486, a small incision was made over the left shoulder 
blade of the rat. Hemostats were used to create a small subcutaneous pocket, in which the 
pump was placed.  
For i.pl. delivery of βAR antagonists, a modified version of the protocol published by 
Haddad et al209 was used. Pumps were attached to a 15cm, Y-shaped, bifurcated 3F 
silicone catheter (SAI Infusion Technologies, Libertyville, IL). The pump was implanted 
subcutaneously over the right shoulder blade and a stainless steel 10G X 20cm semi-blunt 
tip trocar (SAI Infusion Technologies, Libertyville, IL) was used to subcutaneously route the 
catheter ends to incisions made at either hind paw. The catheter ends were attached to the 
plantar fascia using 4-0 silk sutures (Oasis Medical, Mettawa, IL).  
For i.t. delivery210 of βAR antagonists, a small incision was made on the nape of the 
neck, and scissors and hemostats were used to lift muscle and expose the atlanta-occipital 
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membrane. The membrane was carefully incised using the tip of scissors, causing the 
escape of cerebral spinal fluid (CSF). A 27.3cm, polyurethane Alzet Short Rat IT Catheter 
(Durect Corporation, Cupertino, CA) was inserted into the intrathecal space, dorsal to the 
spinal cord. The other end of the catheter was sutured to surrounding tissue and attached to 
the osmotic pump, which was subcutaneously implanted over the right shoulder blade. Four 
animals did not wake up following i.t. surgery. These animals were replaced in future i.t. 
groups to account for the decrease in sample size.  
For i.c.v. delivery211 of βAR antagonists, pumps were attached to a 38-gauge 
stainless steel cannula via a short vinyl catheter (Alzet Brain Infusion Kit 2, Durect 
Corporation, Cupertino, CA). The cannula was implanted into the right lateral ventricle (from 
the bregma: -0.8mm anteroposterior, -1.6mm mediolateral, -5mm dorsoventral) and was 
cemented to two anchoring screws on the skull. The attached pump was subcutaneously 
implanted over the right shoulder blade.  
2.2.5  Assessment of Behavioral Responses to Mechanical and Thermal Stimuli 
Paw withdrawal threshold was assessed using the von Frey up-down method.212 
Nine calibrated and logarithmically spaced von Frey monofilaments (bending forces: 0.40, 
0.68, 1.1, 2.1, 3.4, 5.7, 8.4, 13.2, and 15.0g; Stoelting, Wood Dale, IL) were applied to the 
plantar hind paw. First, the middle filament (3.4g) was applied to the hind paw for three 
seconds. If the rat responded with a withdrawal, an incrementally lower filament was 
applied. In the absence of a withdrawal, an incrementally higher filament was applied. A 
series of six total responses were recorded for each paw. Results were entered into the Paw 
Flick module within the National Instruments LabVIEW 2.0 software (LabVIEW, Austin, TX), 
which uses a logarithmic algorithm to determine the gram force value that would elicit paw 
withdrawal in 50% of trials (10(Xf+kδ)/10,000, where Xf = value [in log units] of the final von 
Frey hair used; k = tabular value of positive and negative responses, and δ = mean 
difference [in log units] between stimuli). Mechanical allodynia was defined as a heightened 
! 30 
response to a normally innocuous stimulus, as determined by a decrease in paw withdrawal 
threshold.  
Mechanical hyperalgesia was assessed using a 15.0g von Frey filament. This 
filament was chosen as a normally noxious stimulus, as it has a gram force value well over 
the 50% withdraw threshold for animals tested in the present study. The filament was 
applied to the hind paw ten times for a duration of one second, with an interstimulus interval 
of one second.147 The number of paw withdrawals (which could range from 0-10) was 
recorded for each hind paw at each time point. Mechanical hyperalgesia was defined as an 
increase in the number of paw withdrawals in response to a normally noxious mechanical 
stimulus. 
Thermal hyperalgesia was assessed using the Hargreaves method.213 Animals were 
placed in Plexiglass chambers and a radiant beam of light was applied to the hind paw 
through a glass floor heated to 30 degrees Celsius. Paw withdrawal latencies were recorded 
in duplicate per paw. If the second latency recorded was not within ±4 seconds of the first, a 
third measure was recorded. The 2 latencies closest in value were averaged to determine 
overall latency to withdrawal. Thermal behavioral data is reported in text and figures as the 
difference in paw withdrawal latency from baseline (Day 0). Thermal hyperalgesia was 
defined as a decrease in paw withdrawal latency in response to a noxious thermal stimulus.  
2.2.6  Statistical Analyses 
Sample sizes were selected based on their ability in previous, similarly structured rat 
studies to accurately demonstrate behavioral differences between groups.147,149,150 
Mechanical allodynia, mechanical hyperalgesia, and thermal hyperalgesia data were 
analyzed by 2-way analysis of variance (ANOVA for Group X Time). In ANOVA analyses, 
Groups correspond to the separate groups on the graph of interest, as denoted by different 
symbols and names (e.g., groups in Figure 1 = Veh and OR486). Post-hoc comparisons 
were performed using the Bonferroni test, which corrected for multiple comparisons. 
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Statistical significance was defined as P<0.05. All statistical analyses were performed using 
GraphPad Prism (GraphPad Software, La Jolla, CA). 
 
 
2.3 Results 
 
2.3.1  Sustained COMT inhibition produces persistent pain   
Genetic and pharmacologic alterations resulting in reduced COMT activity are 
associated with increased experimental pain and likelihood of developing persistent pain 
disorders. Acute administration of the COMT inhibitor OR486 results in enhanced 
mechanical and thermal pain in rats.147 To evaluate the effects of sustained COMT inhibition 
on pain, responses to mechanical and thermal stimuli were measured in separate groups of 
rats receiving systemic OR486 (15mg/kg/day) or vehicle over a two-week period. Compared 
to rats receiving vehicle, those receiving OR486 exhibited mechanical allodynia (group: 
p<0.0001; group x day: p=0.0043; Figure 2.1A), mechanical hyperalgesia (group: p<0.0001; 
group x day: p=0.0109; Figure 2.1B), and thermal hyperalgesia (group: p<0.0001; group x 
day: p<0.0001; Figure 2.1C) beginning on day 1 and lasting throughout the duration of the 
experiment. Sexual dimorphism was not observed, as both male and female rats developed 
mechanical allodynia (male group: p<0.0001; female group: p<0.0001; Figure 2.2A), 
mechanical hyperalgesia (male group, p<0.0053; female group: p<0.0001; Figure 2.2B), and 
thermal hyperalgesia (male group: p<0.0001; female group: p<0.0001; Figure 2.2C). See 
Figure 2.2 for all sexual dimorphism data in intact rats. 
2.3.2  Adrenalectomized rats fail to develop persistent COMT-dependent pain 
Previous work has demonstrated that acute COMT-dependent pain is mediated via 
β2- and β3ARs, which are located in peripheral, spinal, and supraspinal regions where they 
could potentially drive pain transmission. To evaluate the potential contribution of peripheral 
adrenergic systems to COMT-dependent pain, separate groups of adrenalectomized rats 
(lacking peripheral epinephrine) or sham surgery rats received systemic OR486 
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(15mg/kg/day) or vehicle over a two-week period and responses to mechanical and thermal 
stimuli were measured. Compared to sham rats receiving vehicle, those receiving OR486 
developed mechanical allodynia (group: p<0.0001; group x day: p<0.0001; Figure 2.3A), 
mechanical hyperalgesia (group: p<0.0001; group x day: p=0.0044; Figure 2.3B), and 
thermal hyperalgesia (group: p=0.0005; group x day: p<0.0001; Figure 2.3C). In contrast, 
adrenalectomized rats did not develop mechanical allodynia, mechanical hyperalgesia, or 
thermal hyperalgesia. 
Sexual dimorphism was not observed, as both male and female sham rats 
developed mechanical allodynia (male group: p<0.0001; female group: p<0.0001; Figure 
2.4A), mechanical hyperalgesia (male group: p=0.0053; female group: p<0.0001; Figure 
2.4B), and thermal hyperalgesia (male group: p<0.0001; female group: p<0.0001; Figure 
2.4C). Both male and female adrenalectomized rats failed to develop mechanical allodynia 
(Figure 2.4D), mechanical hyperalgesia (Figure 2.4E), and thermal hyperalgesia (Figure 
2.4F). See Figure 2.4 for all sexual dimorphism data in sham and adrenalectomized rats. 
2.3.3  Peripheral βAR antagonist administration prevents the development of 
persistent COMT-dependent pain 
 
Adrenalectomized rats fail to develop persistent pain following COMT inhibition, 
suggesting a peripheral adrenergic site of action. To further investigate this hypothesis, 
pharmacological methods were used to determine the contribution of peripheral, spinal, and 
supraspinal βARs to persistent COMT-dependent pain (Figure 2.5). First, the contribution of 
peripheral βARs to mechanical and thermal pain was evaluated in separate groups of rats 
receiving sustained i.pl. administration of propranolol (9mg/kg/day), ICI-118,551 
(1.5mg/kg/day), SR59230A (1.67mg/kg/day), or vehicle alongside sustained systemic 
administration of OR486 (15mg/kg/day) or vehicle over a two-week period. Peripheral 
antagonist doses were selected based on the results from a preliminary study that evaluated 
the ability of three different doses per antagonist to reduce or block COMT-dependent pain.  
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Compared to rats receiving vehicle, those receiving sustained i.pl. administration of 
the non-selective βAR antagonist propranolol, the β2AR antagonist ICI-118,511, or the β3AR 
antagonist SR59230A alongside systemic OR486 did not develop mechanical allodynia 
(group: Figure 2.5A, p<0.0001; Figure 2.5D, p<0.0001; Figure 2.5G, p<0.0001) or 
mechanical hyperalgesia (group: Figure 2.5B, p<0.0001; Figure 2.5E, p<0.0001; Figure 
2.5H, p<0.0001). Rats receiving sustained i.pl. administration of the β3AR antagonist 
SR59230A also did not develop OR486-induced thermal hyperalgesia (group: Figure 2.5I, 
P<0.0001). In contrast, rats receiving propranolol (Figure 2.5C) or ICI-118,551 (Figure 2.5F) 
alongside OR486 exhibited a 15% decrease in paw withdrawal latency from baseline, similar 
to rats receiving vehicle. Animals receiving sustained i.pl. administration of βAR antagonists 
alongside systemic vehicle failed to develop mechanical allodynia (Figure 2.10A), 
mechanical hyperalgesia (Figure 2.10B), or thermal hyperalgesia (Figure 2.10C). See Figure 
2.10 for control data demonstrating no effect of antagonists on pain irrespective of 
administration route. 
2.3.4   Intrathecal βAR antagonist administration does not alter persistent COMT-
dependent pain 
 
Next, the contribution of spinal βARs to mechanical and thermal pain was evaluated 
in separate groups of rats receiving sustained i.t. administration of propranolol (50ug/day), 
ICI-118,551 (30ug/day), SR59230A (20ug/day), or vehicle alongside sustained systemic 
administration of OR486 (15mg/kg/day) or vehicle over a two-week period (Figure 2.6). 
Intrathecal delivered antagonist doses were selected based on their ability to block 
hypersensitivity or pain-relevant behaviors in other rat models when administered i.t..214-216 
Similar to animals receiving vehicle, those receiving sustained i.t. administration of the non-
selective βAR antagonist propranolol, the β2AR antagonist ICI-118,511, or the  β3AR 
antagonist SR59230A alongside systemic OR486 exhibited mechanical allodynia (group: 
Figure 2.6A, p<0.0001; Figure 2.6D, p<0.0001; Figure 2.6G, p<0.0001), mechanical 
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hyperalgesia (group: Figure 2.6B, p=0.0002; Figure 2.6E, p<0.0001; Figure 2.6H, 
p=0.0018), and thermal hyperalgesia (group: Figure 2.6C, p<0.0001; Figure 2.6F, p<0.0001; 
Figure 2.6I, p<0.0001). Animals receiving sustained i.t. administration of βAR antagonists 
alongside systemic vehicle failed to develop mechanical allodynia (Figure 2.10D), 
mechanical hyperalgesia (Figure 2.10E), or thermal hyperalgesia (Figure 2.10F). Animals 
receiving SR59230A alongside vehicle did exhibit transient elevations in paw withdrawal 
threshold on days 2 (Veh/Veh 4.47±0.63 vs Veh/SR 10.80±3.26, mean+SEM) and 10 
(Veh/Veh 3.50±0.73 vs Veh/SR 10.97±3.13) likely due to higher baseline values (Veh/Veh 
4.76±0.55 vs Veh/SR 8.54±2.59) and increased inter-group variability as compared to 
control animals (Figure 2.10D). 
To confirm that i.t. βAR antagonists were unable to block OR486-induced pain, we 
performed a duplicate set of experiments using a higher dose of the non-selective βAR 
antagonist propranolol (100ug/day). Similar to the original dose, i.t. administration of the 
higher dose did not block OR486-induced mechanical allodynia (group: p<0.0001; Figure 
2.7A), mechanical hyperalgesia (group: p=0.0011; Figure 2.7B), or thermal hyperalgesia 
(group: p<0.0001; Figure 2.7C). See Figure 2.7 for all i.t. high dose propranolol data. 
2.3.5   Intracerebroventricular βAR antagonist administration does not alter persistent 
COMT-dependent pain 
 
Finally, the contribution of supraspinal βARs to mechanical and thermal pain was 
evaluated in separate groups of rats receiving sustained i.c.v. administration of propranolol 
(50ug/day), ICI-118,551 (30ug/day), SR59230A (20ug/day), or vehicle alongside sustained 
systemic administration of OR486 (15mg/kg/day) or vehicle over a two-week period (Figure 
2.8). I.c.v. antagonist doses were selected based on their ability to block pain or related 
behaviors in other rat models.214-216 Similar to animals receiving vehicle, those receiving 
sustained i.c.v. administration of the non-selective βAR antagonist propranolol, the β2AR 
antagonist ICI-118,511, or the β3AR antagonist SR59230A alongside systemic OR486 
! 35 
exhibited mechanical allodynia  (group: Figure 2.8A, p<0.0001; Figure 2.8D, p<0.0001; 
Figure 2.8G, p<0.0001), mechanical hyperalgesia (group: Figure 2.8B, p<0.0001; Figure 
2.8E, p<0.0001; Figure 2.8H, p<0.0001), and thermal hyperalgesia (group: Figure 2.8C, 
p<0.0001; Figure 2.8F, p<0.0001; Figure 2.8I, p<0.0001). Animals receiving sustained i.c.v. 
administration of βAR antagonists alongside systemic vehicle failed to develop mechanical 
allodynia (Figure 2.10G), mechanical hyperalgesia (Figure 2.10H), or thermal hyperalgesia 
(Figure 2.10I). Animals receiving SR59230A alongside vehicle did exhibit transient 
elevations in paw withdrawal frequency on days 2 (Veh/Veh 1.88±0.40 vs Veh/SR 
4.62±0.86) and 8 (Veh/Veh 2.00±0.46 vs Veh/SR 5.00±1.20), likely due to increased inter-
group variability as compared to control animals (Figure 2.10H). 
To confirm that i.c.v. βAR antagonists are unable to block OR486-induced pain, we 
performed a duplicate set of experiments using a higher dose of the non-selective βAR 
antagonist propranolol (100ug/day). Similar to the original dose, i.c.v. administration of the 
higher dose did not block OR486-induced mechanical allodynia (group: p<0.0001; Figure 
2.9A), mechanical hyperalgesia (group: p<0.0001; Figure 2.9B), or thermal hyperalgesia 
(group: p<0.0001; Figure 2.9C). See Figure 2.9 for all i.c.v. high dose propranolol data. 
 
2.4 Discussion 
 
Though the mechanisms underlying IPDs are not well described, emerging evidence 
suggests a role for adrenergic pathways. Employing a rodent model of sustained COMT 
inhibition that mimics abnormalities in catecholamine signaling observed in patients with 
these disorders, we demonstrate that COMT-dependent pain is mediated via peripherally, 
but not spinally or supraspinally, located β2- and β3ARs.  
In previous studies, we established a causal link between low COMT and pain. We 
demonstrated that a single injection of the COMT inhibitor OR486 produces mechanical and 
thermal pain, similar to that produced by intraplantar carrageenan. Subsequent 
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pharmacological studies further demonstrated that the development of acute OR486-
induced pain requires activation of β2- and β3ARs.147,149 Within hours, administration of 
OR486 results in increased circulating levels of nitric oxide (NO) and the pro-inflammatory 
cytokines tumor necrosis factor-α (TNFα), interleukin 1β (IL-1β), interleukin 6 (IL-6), and 
chemokine (C-C motif) ligand 2 (CCL2),149which are nociceptive transmitters implicated in 
persistent pain. Individuals with FM, headache, and TMD exhibit increased levels of these 
molecules,32,217-219 which elicit pain by reducing nociceptor firing thresholds.220-230 NO and 
pro-inflammatory cytokines also elicit pain by working synergistically to potentiate one 
another’s biosynthesis, as observed in the OR486 model.149   
Here, we utilized a more clinically-relevant model of sustained COMT inhibition, 
characterized by enhanced sensitivity to noxious stimuli and altered pain-relevant cognitive-
affective behaviors that persist over a two-week period, to determine the site-of-action 
whereby βARs mediate persistent COMT-dependent pain. The contribution of peripheral 
adrenergic systems was first examined in adrenalectomized rats. We found that, compared 
to sham surgery rats, adrenalectomized rats lacking peripheral epinephrine fail to develop 
OR486-induced mechanical and thermal pain. This finding is in line with those from previous 
studies showing that adrenalectomized rats have blunted pain following formalin 
administration231 or chronic constriction injury.232 Together, these results suggest that 
peripherally circulating catecholamines contribute to the transmission of pain in models of 
inflammatory and neuropathic pain as well as persistent pain disorders. This conclusion is 
further supported by studies that have demonstrated increased urinary catecholamines in 
patients with myofacial pain132 and increased circulating plasma catecholamines in women 
with FM.131 Of note, adrenalectomy also results in a reduction of circulating corticosterone 
levels.233,234 Increased corticosterone levels following stress235 or nerve injury236,237 have 
been implicated in analgesia, and pronociception, respectively. Thus, future experiments 
examining peripheral catecholamines should utilize adrenal medullectomized animals or 
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should provide supplemental corticosterone to adrenalectomized animals to rule out 
corticosterone-mediated effects.  
As previous preclinical and clinical studies have reported sex-specific differences in 
COMT-related phenotypes238-242 and as males and females exhibit different COMT 
expression patterns,243,244 we examined the contribution of peripheral adrenergic systems to 
COMT-dependent pain in both sexes. Counter to our expectation, male and female rats 
exhibited a comparable increase in mechanical and thermal pain following sustained 
systemic OR486 administration, which was blocked by suppressing peripheral adrenergic 
tone. Despite these findings, no single study can rule out the possibility of sex-specific 
effects, so we recommend that future studies and clinical applications related to COMT-
dependent pain should continue to consider possible sex-specific effects. 
The independent contribution of peripheral, spinal, and supraspinal βARs to 
persistent COMT-dependent pain were next examined in separate groups of intact rats 
receiving targeted delivery of the non-selective βAR antagonist propranolol, the β2AR 
antagonist ICI-118,551, or the β3AR antagonist SR59230A alongside systemic OR486. We 
found that peripheral, but not spinal or supraspinal, administration of propranolol, ICI-
118,511, or SR59230A blocked the development of OR486-induced pain throughout the 
duration of the testing period. While all three antagonists blocked the development of 
mechanical pain, only SR59230A blocked the development of thermal pain. These findings 
significantly extend those from acute COMT inhibition studies,147,149 demonstrating that 
peripheral β2- and β3ARs both contribute to the development of persistent mechanical pain, 
while peripheral β3ARs independently contribute to the development of persistent thermal 
pain following sustained COMT inhibition.  
The peripheral contribution of β2ARs to pain is in line with results from previous 
studies demonstrating that epinephrine activates β2ARs located on the peripheral terminals 
of primary afferent nociceptors, increasing their excitability and producing a hyperalgesic 
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state.159-163 Also, elevated plasma norepinephrine activates β2ARs to promote visceral 
hypersensitivity.162 In humans, variants of the β2AR gene known to influence receptor 
expression are associated with increased risk of TMD.245  
The contribution of peripheral β3ARs to persistent pain is more novel. Peripherally 
expressed β3ARs are known for their ability to regulate norepinephrine-induced changes in 
metabolism and thermoregulation.157 In 2010, it was discovered that β3ARs are expressed 
on primary afferent nociceptors, where they drive norepinephrine-induced ATP release and 
contribute to neuropathic pain.246 Recently, β3ARs have also been shown to mediate 
formalin-induced TMJ pain.247 In contrast to acute COMT-dependent thermal pain, which 
requires coincident activation of both β2- and β3ARs,147 persistent COMT-dependent thermal 
pain requires independent activation of peripheral β3ARs. Unlike most GPCRs, including 
β2ARs, β3ARs do not undergo desensitization after agonist stimulation.248,249 Thus, β3ARs 
are uniquely positioned to stimulate downstream effectors for prolonged periods of time.    
In addition to their location on primary afferent nociceptors, β2- and β3ARs are 
expressed on numerous peripheral cell types where they could potentially mediate pain, 
including: immune cells involved in adaptive responses (T-cells, mast cells, and 
macrophages), adipocytes, keratinocytes, and satellite glia. T-cells, mast cells, and 
macrophages are immune cells in the periphery that express βARs and, following their 
activation by epinephrine or norepinephrine, orchestrate inflammatory responses. Increased 
catecholamine levels following stress or pharmacologic manipulation lead to activation of T-
cells, increased expression of β2- and β3ARs,173 and production of IL-1, IL-6, and CCL2.250 
T-cell infiltration in the spinal dorsal horn of adult rats has been shown to contribute to 
hypersensitivity following nerve injury.251,252 In line with these findings, patients with FM have 
more activated T-cells circulating in blood compared to healthy controls.253 Epinephrine 
activates mast cells and stimulates release of IL-1β, IL-6, and other pro-inflammatory 
cytokines in a β2AR-dependent manner.170 Increased activation of mast cells has been 
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observed in numerous persistent pain disorders, including FM, headache, vestibulodynia, 
and irritable bowel syndrome.254-259 Agonist activation of β2ARs expressed on macrophages 
in vitro results in activation of intracellular kinases and release of IL-6. Further, sustained 
systemic administration of epinephrine in mice results in β2AR-mediated increases in 
macrophage activation and IL-6 production.171,172  
Adipocytes are cells in the periphery that express both β2- and β3ARs and specialize 
in storing energy as fat.174 They also interface with immune cells to regulate inflammatory 
responses.260 Notably, adipocytes produce 30% of the IL-6 circulating in the body261 and 
studies have shown that activation of β3ARs on adipocytes produces a robust increase in IL-
6 levels in plasma262 as well as in TNFα,263 CCL2,264 and NO265 levels in vitro. 
Keratinocytes and satellite glial cells reside near the peripheral terminals and cell 
bodies, respectively, of primary afferent nociceptors. While a direct link between βAR 
activation on these cell types and pain has yet to be established, catecholamine-induced 
activation of keratinocyte β2ARs results in increased intracellular kinase activation and IL-6 
release.167-169 Similarly, activation of satellite glia by catecholamines results in βAR-mediated 
increases in intracellular cyclic nucleotides that facilitate neuronal-glial communication.266   
Collectively, these findings demonstrate the importance of β2- and β3ARs located on 
immunoregulatory cells in the periphery to persistent COMT-dependent pain, accounting for 
clinical observations that βAR antagonists provide pain relief for patients with idiopathic pain 
disorders such as FM and TMD,140,151,267 as well as inflammatory conditions such as arthritis, 
rosacea, and CRPS.154,268-270 While these findings seem inconsistent with the ability of 
antidepressants to alleviate persistent pain by increasing synaptic levels of catecholamines, 
it is important to note that the analgesic effect of antidepressants is associated with 
descending inhibition of pain via actions at α2ARs or D2DARs in the spinal dorsal horn.271,272 
Thus, catecholamines can exert divergent influences on nociception as a function of 
localization and net influence on neuronal excitability. Future studies are required to identify 
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the specific cell type(s) in the periphery that express βARs and, upon activation, release pro-
inflammatory molecules that initiate persistent hypersensitivity. By determining where, when 
and how β2- and β3ARs and their downstream effectors mediate COMT-dependent pain, the 
field will better understand the diverse nature of catecholamine signaling so that patients 
suffering from disorders resulting from reduced COMT and/or elevated catecholamines 
receive the most relevant treatments. 
 While the studies herein utilized a clinically-relevant rodent model of sustained 
COMT inhibition, additional mechanistic studies will implement a COMT-/- mouse model to 
more accurately represent the endogenously low levels of COMT activity observed in pain 
patients. Future studies are also necessary to elucidate the specific cell signaling pathways 
responsible for the initiation and maintenance of β2- and β3AR-mediated pain. Finally, 
clinical studies are required to evaluate the efficacy of peripheral β2- and β3AR antagonist 
therapy in patients with persistent pain disorders and related conditions.  
 In conclusion, we utilized a clinically-relevant animal model that portrays 
characteristics of patients with persistent pain disorders to demonstrate that both male and 
female rats are susceptible to the development of persistent COMT-dependent pain, which 
is mediated via peripherally located β2- and β3ARs. These findings suggest that peripheral 
β2- and β3AR antagonist therapy may be an effective option for the treatment of persistent 
pain disorders as well as those with overlapping peripheral β-adrenergic mechanisms (e.g., 
complex regional pain syndrome273). 
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Figure 2.1 Sustained administration of the COMT inhibitor OR486 leads to mechanical 
and thermal pain. Compared to vehicle, sustained systemic OR486 administration 
produces (A) mechanical allodynia, (B) mechanical hyperalgesia, and (C) thermal 
hyperalgesia. N=12 (6M, 6F) per group. Data are expressed as mean ± SEM. ***P<0.001, 
**P<0.01 different from vehicle. Abbreviations: Baseline (BL), Vehicle (Veh). 
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Figure 2.2 Sustained administration of the COMT inhibitor OR486 leads to increased 
mechanical and thermal pain in male and female rats. Compared to vehicle, sustained 
OR486 administration produces (A) mechanical allodynia, (B) mechanical hyperalgesia, and 
(C) thermal hyperalgesia in males and females. N=6 per group. Data are expressed as 
mean ± SEM. ***P<0.001, **P<0.01, *P<0.05 different from Veh/M; †††P<0.001, ††P<0.01, 
†P<0.05 different from Veh/F. Abbreviations: Baseline (BL), catechol-o-methyltransferase 
(COMT), Female (F), Male (M), Vehicle (Veh). 
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Figure 2.3 Adrenalectomized rats fail to develop OR486-induced pain. In Shm, but not 
Adx animals, sustained systemic OR486 administration produces (A) mechanical allodynia, 
(B) mechanical hyperalgesia, and (C) thermal hyperalgesia. N=11 (5M, 6F) for Shm/Veh 
and N=12 (6M, 6F) for all other groups. Data are expressed as mean ± SEM. ***P<0.001, 
**P<0.01, *P<0.05 different from Shm/Veh. Abbreviations: Adrenalectomized (Adx), 
Baseline (BL), Sham (Shm), Vehicle (Veh). 
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Figure 2.4 Male and female adrenalectomized rats fail to develop OR486-induced pain. 
In Shm animals, sustained systemic OR486 administration produces (A) mechanical 
allodynia, (B) mechanical hyperalgesia, and (C) thermal hyperalgesia. In contrast, Adx 
animals fail to develop OR486-induced (D) mechanical allodynia, (E) mechanical 
hyperalgesia, or (F) thermal hyperalgesia. N=5-6 per group. Data are expressed as mean ± 
SEM. ***P<0.001, **P<0.01, *P<0.05 different from Veh/M; †††P<0.001, ††P<0.01, †P<0.05 
different from Veh/F. Abbreviations: Adrenalectomized (Adx), Baseline (BL), Female (F), 
Male (M), Sham (Shm), Vehicle (Veh). 
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Figure 2.5 Peripheral administration of βAR antagonists blocks OR486-induced pain. 
Peripheral delivery of the non-selective βAR antagonist propranolol alongside sustained 
systemic OR486 administration prevents (A) mechanical allodynia and (B) mechanical 
hyperalgesia, but does not alter (C) thermal hyperalgesia. Similarly, peripheral delivery of 
the β2AR antagonist ICI-118,551 alongside sustained systemic OR486 administration 
prevents (D) mechanical allodynia and (E) mechanical hyperalgesia, but does not alter (F) 
thermal hyperalgesia. Finally, peripheral delivery of the β3AR antagonist SR59230A 
alongside sustained systemic OR486 administration prevents (G) mechanical allodynia, (H) 
mechanical hyperalgesia, and (I) thermal hyperalgesia. N=9 per group. Data are expressed 
as mean ± SEM. ***P<0.001, **P<0.01, *P<0.05 different from Veh/Veh. Abbreviations: 
Baseline (BL), Beta-Adrenergic Receptor (βAR), ICI-118,551 (ICI), propranolol (Prop), 
SR59230A (SR), Vehicle (Veh). 
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Figure 2.6 Intrathecal administration of βAR antagonists does not alter OR486-
induced pain. Intrathecal delivery of the non-selective βAR antagonist propranolol (A-C), 
β2AR antagonist ICI-118,551 (D-F), or the β3AR antagonist SR59230A (G-I) alongside 
sustained systemic OR486 administration does not alter mechanical or thermal sensitivity. 
N=4 per group. Data are expressed as mean ± SEM. ***P<0.001, **P<0.01, *P<0.05 
different from Veh/Veh. Abbreviations: Baseline (BL), Beta-Adrenergic Receptor (βAR), ICI-
118,551 (ICI), propranolol (prop), SR59230A (SR), Vehicle (Veh). 
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Figure 2.7 Intrathecal administration of high dose propranolol does not alter OR486-
induced pain. Intrathecal delivery of a high dose of the non-selective βAR antagonist 
propranolol (100ug/day) alongside sustained OR486 administration does not alter (A) 
mechanical allodynia, (B) mechanical hyperalgesia, or (C) thermal hyperalgesia. N=4 for 
Veh/Veh, OR486/Veh, and OR486/Prop; and N=2 for OR486/Prop HD. Data are expressed 
as mean ± SEM. ***P<0.001, **P<0.01, *P<0.05 different from Veh/Veh. Abbreviations: 
Baseline (BL), Beta-Adrenergic Receptor (βAR), High Dose (HD), Propranolol (Prop), 
Vehicle (Veh). 
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Figure 2.8 Intracerebroventricular administration of βAR antagonists does not alter 
OR486-induced pain. Supraspinal delivery of the non-selective βAR antagonist propranolol 
(A-C), β2AR antagonist ICI-118,551 (D-F), or the β3AR antagonist SR59230A (G-I) 
alongside sustained systemic OR486 administration does not alter mechanical or thermal 
sensitivity. N=4-5 per group.  Data are expressed as mean ± SEM. ***P<0.001, **P<0.01, 
*P<0.05 different from Veh/Veh. Abbreviations: Baseline (BL), Beta-Adrenergic Receptor 
(βAR), ICI-118,551 (ICI), propranolol (prop), SR59230A (SR), Vehicle (Veh). 
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Figure 2.9 Intracerebroventricular administration of high dose propranolol does not 
alter OR486-induced pain. Intracerebroventricular delivery of a high dose of the non-
selective βAR antagonist propranolol (100ug/day) alongside sustained OR486 
administration does not alter (A) mechanical allodynia, (B) mechanical hyperalgesia, or (C) 
thermal hyperalgesia. N=3-4 per group. Data are expressed as mean ± SEM. ***P<0.001, 
**P<0.01, *P<0.05 different from Veh/Veh. Abbreviations: Baseline (BL), Beta-Adrenergic 
Receptor (βAR), High Dose (HD), Propranolol (prop), Vehicle (Veh). 
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Figure 2.10 Sustained peripheral, intrathecal, or intracerebroventricular 
administration of βAR antagonists, in the absence of systemic administration of 
OR486, does not alter pain. (A-C) Peripheral, (D-F) i.t., or (G-I) i.c.v. delivery of the non-
selective βAR antagonist propranolol, β2AR antagonist ICI-118,551, or β3AR antagonist 
SR59230A does not alter (A,D,G) mechanical allodynia, (B,E,H) mechanical hyperalgesia, 
or (C,F,I) thermal hyperalgesia. N=8-9 per group. **P<0.01, *P<0.05 different from Veh/Veh. 
Abbreviations: Baseline (BL), Beta-Adrenergic Receptor (βAR), ICI-118,551 (ICI), 
intracerebroventricular (i.c.v.), intrathecal (i.t.), propranolol (prop), SR59230A (SR), Vehicle 
(Veh). 
 
 
 
 
 
 
0 2 4 8 10 12 14
0
5
10
15
20
Day
50
%
 P
aw
 W
ith
dr
aw
al
Th
re
sh
ol
d 
(g
) Veh / Prop
Veh / ICIVeh / Veh
Veh / SR
*
0 2 4 8 10 12 14
0
2
4
6
8
Day
# 
Pa
w
 W
ith
dr
aw
al
s
**
*
*
0 2 4 8 10 12 14
-2
0
2
4
6
Day
W
ith
dr
aw
al
 L
at
en
cy
 (s
) 
D
iff
er
en
ce
 fr
om
 B
L
****** * *
0 2 4 6 8 10 12 14
-2
0
2
4
6
Day
W
ith
dr
aw
al
 L
at
en
cy
 
D
iff
er
en
ce
 fr
om
 B
L 
(s
)
*** ****
0 2 4 6 8 10 12 14
0
2
4
6
8
Day
# 
Pa
w
 W
ith
dr
aw
al
s
0 2 4 6 8 10 12 14
0
5
10
15
20
Day
50
%
 P
aw
 W
ith
dr
aw
al
Th
re
sh
ol
d 
(g
)
** **
*
Mechanical 
Allodynia
Mechanical 
Hyperalgesia
Thermal 
Hyperalgesia
A B C
D E F
G H I
0 2 4 6 8 10 12 14
0
5
10
15
20
Day
50
%
 P
aw
 W
ith
dr
aw
al
Th
re
sh
ol
d 
(g
)
0 2 4 6 8 10 12 14
0
2
4
6
8
Day
# 
Pa
w
 W
ith
dr
aw
al
s
*
*
0 2 4 6 8 10 12 14
-2
0
2
4
6
Day
W
ith
dr
aw
al
 L
at
en
cy
 
D
iff
er
en
ce
 fr
om
 B
L 
(s
)
Pe
rip
he
ra
l
IT
IC
V
! 52!
 
 
 
 
 
 
CHAPTER 3 
 
MECHANICAL AND THERMAL PAIN IN CATECHOL-O-METHYLTRANSFERASE 
KNOCKOUT MICE IS NOT MAINTAINED BY BETA-ADRENERGIC RECEPTORS 
 
3.1 Introduction 
 Idiopathic pain disorders (IPDs), such as fibromyalgia (FM), temporomandibular 
disorder (TMD) and vestibulodynia (VBD) are characterized by pain that often occurs daily 
and spans years. These conditions affect nearly 100 million Americans and cost the US 
economy over $600 billion annually,191 thus represent a significant healthcare problem. 
Though the mechanisms underlying IPDs are not well understood, adrenergic pathways are 
known to play an important role. Patients exhibit increased levels of catecholamines131-133 
along with decreased activity of catechol-O-methyltransferase (COMT),127,128 a ubiquitously 
expressed enzyme that metabolizes catecholamines to their inactive derivatives.125 
Functional variants in the COMT gene, which reduce COMT activity,128,196,197 are associated 
with increased experimental pain141,201 as well as risk of developing an IPD.141,145,146,198-200 It 
is estimated, based on the frequency of allele variation, that nearly two-thirds of patients 
with persistent idiopathic pain possess the low-activity COMT variant.203,204 Refer to Chapter 
2.1 for more information regarding the association between COMT and pain. 
 As demonstrated in Chapter 2, the initiation of COMT-dependent pain is mediated 
via peripherally located β2- and β3- adrenergic receptors (βARs). This was demonstrated 
using a pharmacological model of COMT-dependent pain in rats. Male and female rats 
receiving sustained administration of the COMT inhibitor OR486 exhibited mechanical and 
thermal pain that persisted for the duration of the study. Adrenalectomized rats, lacking
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peripheral adrenal catecholamines, failed to develop OR486-induced pain. Furthermore, 
peripheral, but not spinal or supraspinal, coadministration of β2- and β3AR antagonists were 
able to block OR486-induced pain.274 These findings demonstrate the importance of 
peripheral β2- and β3ARs in initiating persistent COMT-dependent pain. 
Though the previous studies described in Chapter 2 utilize a clinically relevant rodent 
model of sustained COMT inhibition, OR486 delivery was limited to two weeks.274 One way 
to more closely model the etiology of persistent pain due to low activity COMT alleles is 
through use of genetic knockdown of COMT. In the present study, we utilize a COMT-/- 
mouse model in order to observe pain behaviors in animals that express endogenously low 
COMT activity levels throughout their lifespan. The aim was to determine whether pain 
response varied according genotype and if so, whether genetic COMT-dependent pain was 
mediated via peripheral βARs. We hypothesized that, similar to rats receiving the COMT 
inhibitor, COMT-/- mice would exhibit mechanical and thermal pain mediated via peripherally 
located β2- and β3ARs.  
To test this hypothesis, we evaluated responses to mechanical and thermal stimuli in 
female and male COMT+/+, +/-, and -/- mice. As predicted, male and female COMT -/- mice 
exhibited mechanical and thermal pain that persisted for the duration of the study. 
Surprisingly, COMT+/- mice did not exhibit pain in response to mechanical and thermal 
stimuli. Next, we coadministered β2- and β3AR antagonists peripherally via a bifurcated 
intraplantar catheter to COMT+/+ and -/- mice over a 2-week period. Unlike the 
pharmacologic rat model, peripherally delivered β2- and β3AR antagonists were unable to 
block pain in the -/- mice. These findings demonstrate that though β2- and β3ARs play a vital 
role in the initiation of COMT-dependent pain, they do not contribute to the maintenance of 
established COMT-dependent pain. This is important knowledge for clinicians who treat 
persistent pain associated with abnormalities in catecholamine signaling. 
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3.2 Materials and Methods 
3.2.1  Animals 
The Gogos laboratory at Columbia University (New York, NY) provided adult male 
and female COMT+/- mice, which expectedly display disruption of the COMT gene.238 
Heterozygote mice were intercrossed in-house to create wildtype (COMT+/+; N=24), 
heterozygote (COMT+/-; N=13), and knockout (COMT-/-; N=26) mice for the present study. 
Mice weighed between 15 and 30g for all experimental studies. Mice had ad libitum access 
to standard laboratory chow and water. All animal procedures were approved by the 
Institutional Animal Care and Use Committee (IACUC) at the University of North Carolina at 
Chapel Hill (UNC). Though rodent models of pain only partially correlate with human 
conditions, mice were chosen for these experiments because an extensive body of literature 
exists regarding nociceptive pathways and behavior in this species, and because mouse 
pain behavior assays are readily available and well characterized.7,205,206 Further, COMT-/- 
mice allow us to study COMT-dependent pain in animals that have had COMT deficiencies 
throughout development. This mimics inherent COMT deficiencies observed in patients with 
persistent pain.141,145,146,198-200 
 
3.2.2  General Experimental Conditions 
As previous work274 (See Chapter 2) in our lab has demonstrated a role for β2- and 
β3-ARs in the initiation of COMT-dependent pain, the present study aimed to investigate 
whether these receptors are required for the maintenance of established COMT-dependent 
pain, using COMT-/- mice. First, responses to punctuate mechanical and thermal stimuli 
were measured in COMT+/+, +/-, and -/- mice to determine if knockdown of the COMT gene 
leads to enhanced pain behaviors in mice, as pharmacologic COMT inhibition does in the rat 
model (Chapter 2).274 Next, the contribution of peripheral β2- and β3-ARs to persistent 
COMT-dependent pain was evaluated in COMT+/+ and -/- mice receiving simultaneous 
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intraplantar (i.pl.) delivery of the β2AR antagonist ICI-118,511 and the β3-AR antagonist 
SR59230A. The antagonists were delivered to the hindpaws via a subcutaneous (s.c.) 
bifurcated catheter attached to a 1002 Alzet osmotic pump. The contribution of β2- and β3-
ARs to persistent COMT-dependent pain were further evaluated in COMT+/+ and -/- mice 
by acute intraperitoneal (i.p.) injection of a bolus dose of ICI-118,511 and SR59230A. 
Animals were handled and habituated to the experimenter and environment for 4 
days prior to testing. For the persistent study, responses to punctuate mechanical stimuli 
were assessed in mice 1 day prior to and on days 1, 3, 5, 7, 9, 11, and 13, and responses to 
heat stimuli were measured prior to and on days 1, 7, and 13, following pump implantation. 
For the acute study, responses to punctuate mechanical stimuli were assessed in mice prior 
to and 30, 60, 90, and 120 minutes, and responses to heat stimuli were measured prior to 
and 60 and 120 minutes, following injection. Thermal behaviors were not assessed at every 
timepoint to avoid the possibility of hypersensitivity of the hindpaws as a result of this 
relatively invasive thermal pain measurement. On baseline and testing days, mice were 
habituated to the mechanical and thermal testing environments for 15-30 minutes. Animals 
were randomly assigned to groups, housed with 1-2 other mice, and tested by a single, 
blinded experimenter at a consistent time in the morning. The primary outcome reported in 
this study is behavioral changes, in the form of mechanical allodynia, mechanical 
hyperalgesia and thermal hyperalgesia, which are described in detail below. 
 
3.2.3  Drug Preparation 
For the persistent study, βAR antagonists ICI-118,511 (ICI; Tocris, Ellisville, MO) and 
SR59230A (SR; Tocris, Ellisville, MO) were dissolved together in a 5:3:2 ratio of DMSO, 
0.9% saline, and ethanol. Drug solution or Vehicle (Veh) was injected into Alzet pumps, and 
pumps were connected to bifurcated catheters. Each pump/catheter system was placed into 
a 15mL conical tube containing sterile 0.9% saline and primed overnight in a dry heat bath 
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(Lab Armor, Cornelius, OR) at 37 degrees Celsius. Peripheral delivery of ICI was at a 
constant rate of 5.113mg/kg/day and peripheral delivery of SR was at a constant rate of 
0.511mg/kg/day. 
For the acute study, βAR antagonists ICI and SR were dissolved together in a 1:4 
ratio of DMSO and 0.9% saline. A bolus dose of ICI (5.113mg/kg) and SR (0.511mg/kg) was 
provided via i.p. injection. 
 
3.2.4  Surgical Procedures 
Mice were anesthetized by isoflurane inhalation (4-5% induction, 1.5-3% 
maintenance). Hair was removed from incision sites by plucking, and incision sites were 
disinfected with ethanol and betadine. Sterile technique was employed throughout the 
duration of all procedures according to IACUC requirements. Stainless steel wound clips 
(Braintree Scientific, Braintree, MA) were used to close the wounds.  
For i.pl. delivery of βAR antagonists, a modified version of the protocol published by 
Haddad et al209 was used. Pumps were attached to a 7.4cm custom-made Y-shaped, 
bifurcated 3F-silicone catheter (SAI Infusion Technologies, Libertyville, IL). A small incision 
was made over the shoulder blades and hemostats were used to create a small s.c. pocket. 
The pump was implanted into the pocket, with the delivery port facing caudally. Small 
incisions were made over each hindlimb and a stainless steel 14G X 8.5cm semi-blunt 
trocar (SAI Infusion Technologies, IL) was used to route each catheter end from the incision 
at the shoulder blades to an incision made at either hindlimb. Each side of the bifurcated 
section of the catheter was sloped similarly towards its respective hindpaw, to ensure equal 
resistance on each side. The catheter ends were attached to fascia in the hindlimbs using 4-
0 silk sutures (Oasis Medical, IL). Hemostats were then used to create small subcutaneous 
pockets in the hindlimbs, towards the hindpaws, creating resistance-free regions in which 
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each catheter end could be placed. Catheter ends were trimmed to fit into their respective 
subcutaneous pockets.   
 
3.2.5  Assessment of Behavioral Responses to Mechanical and Thermal Stimuli 
Mechanical allodynia was assessed using a 0.275g von Frey filament (Stoelting, 
Wood Dale, IL). This filament was chosen as a normally innocuous stimulus, as it has a 
gram force value under the withdraw threshold for normal wildtype mice. The filament was 
applied to the hind paw 10 times for a duration of 1 second each, with an interstimulus 
interval of 1 second.147 The number of paw withdrawals (which could range from 0-10) was 
recorded for each hind paw at each time point. Mechanical allodynia was defined as an 
increase in the number of paw withdrawals in response to a normally innocuous mechanical 
stimulus. Mechanical hyperalgesia was tested similarly, but with a 4.000g von Frey filament. 
This filament was chosen as a normally noxious stimulus, as it has a gram force value well 
over the withdraw threshold for normal wildtype animals. Mechanical hyperalgesia was 
defined as an increase in the number of paw withdrawals in response to a normally noxious 
mechanical stimulus. 
Paw withdrawal threshold was assessed using the von Frey up-down method.212 
Nine calibrated and logarithmically spaced von Frey monofilaments (bending forces: 0.005, 
0.225, 0.275, 0.667, 1.627, 4.000, 6.824, 11.706, and 14.647g; Stoelting, Wood Dale, IL) 
were applied each plantar hind paw. First, the middle filament (1.627g) was applied to the 
hind paw for 1 second. If the mouse responded with a withdrawal, an incrementally lower 
filament was applied. In the absence of a withdrawal, an incrementally higher filament was 
applied. A series of 6 total responses were recorded for each paw. Results were entered 
into the Paw Flick module within the National Instruments LabVIEW 2.0 software (LabVIEW, 
Austin, TX), which uses a logarithmic algorithm to determine the gram force value that would 
elicit paw withdrawal in 50% of trials (10(Xf+kδ)/10,000, where Xf = value [in log units] of the 
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final von Frey hair used; k = tabular value of positive and negative responses, and δ = mean 
difference [in log units] between stimuli). Mechanical pain was defined as a decrease in paw 
withdrawal threshold.  
Thermal hyperalgesia was assessed using the Hargreaves method.213 Animals were 
placed in Plexiglass chambers and a radiant beam of light was applied to the hind paw 
through a glass floor. Paw withdrawal latencies were recorded in duplicate per paw. If the 
second latency recorded was not within ±4 seconds of the first, a third measure was 
recorded. The 2 latencies closest in value were averaged to determine overall latency to 
withdrawal. Thermal hyperalgesia was defined as a decrease in paw withdrawal latency in 
response to a noxious thermal stimulus.  
 
3.2.6  Assessment of Non-Evoked Behavioral Responses  
Weight was measured in grams using an animal weighing scale (Kent Scientific, 
Torrington, CT). Temperature was measured using a rectal thermoprobe (Physitemp, 
Clifton, NJ). Grip strength was measured using a calibrated dual sensor grip strength meter 
(Stoelting, Wood Dale, IL). Left and right paws were measured separately and summed 
together. Grip strength was measured 3 times at each time-point and the average was 
calculated to create an aggregate score. 
 
3.2.7  Statistical Analyses 
Sample sizes were selected based on their ability in previous, similarly structured 
rodent studies to accurately demonstrate behavioral differences between groups.147,149,150 
Mechanical allodynia, mechanical hyperalgesia, and thermal hyperalgesia data were 
analyzed by 2-way analysis of variance (ANOVA for Group X Time). In ANOVA analyses, 
Groups correspond to the separate groups on the graph of interest, as denoted by different 
symbols and names. Post-hoc comparisons were performed using the Bonferroni test, which 
! 59 
corrected for multiple comparisons. Statistical significance was defined as P<0.05. All 
statistical analyses were performed using GraphPad Prism (GraphPad Software, La Jolla, 
CA). 
 
3.3 Results 
3.3.1  Genetic COMT deficiencies produce mechanical and thermal pain  
Genetic and pharmacologic alterations resulting in reduced COMT activity are 
associated with increased experimental pain and likelihood of developing persistent pain 
disorders. Both acute147 and persistent274 (chapter 2) administration of the COMT inhibitor 
OR486 results in enhanced mechanical and thermal pain in rats. To evaluate the effects of 
genetic COMT deficiencies on pain, responses to mechanical and thermal stimuli were 
measured in separate groups of COMT+/+, +/- and -/- mice over a 2-week period. 
Compared to COMT+/+, COMT-/- mice exhibited mechanical allodynia (group: p<0.0001; 
group x day: p=0.4753; Figure 3.1A) and mechanical hyperalgesia (group: p<0.0001; group 
x day: p=0.9953; Figure 3.1B); as well as decreased thresholds in response to mechanical 
(group: p<0.0001; group x day: p=0.9777; Figure 3.1C) and thermal (group: p<0.0001; group 
x day: p=0.4248; Figure 3.1D) stimuli throughout the duration of the experiment. COMT+/- 
mice did not exhibit enhanced pain as compared to +/+ mice. COMT+/+, +/- and -/- mice did 
not exhibit differences in weight (Figure 3.2A), temperature (Figure 3.2B) or grip strength 
(Figure 3.2C). 
Sexual dimorphism was not observed, as both male and female COMT-/- mice 
developed mechanical allodynia (male group: p<0.0001, Figure 3.2A; female group: 
p<0.0001, Figure 3.2E) and mechanical hyperalgesia (male group, p<0.0001, Figure 3.2B; 
female group: p<0.0001, Figure 3.2F); and demonstrated decreased mechanical (male 
group: p<0.0001, Figure 3.2C; female group: p<0.0001, Figure 3.2G) and thermal (male 
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group: p<0.0001, Figure 3.2D; female group: p<0.0001, Figure 3.2H) thresholds. See Figure 
3.2 for all sexual dimorphism data. 
3.3.2  Peripheral βAR antagonist administration does not alter persistent COMT-
dependent pain in COMT-/- mice 
 
Next, the contribution of peripheral β2/3ARs to mechanical and thermal pain was 
evaluated in separate groups of COMT+/+ and -/- mice receiving sustained i.pl. 
administration of ICI (5.113mg/kg/day) and SR59230A (0.551mg/kg/day) or vehicle over a 
two-week period (Figure 3.4). Peripherally delivered antagonist doses were selected based 
on their ability to block acute pharmacologic COMT-dependent pain behaviors in previous 
rodent studies.147 As previous studies were conducted in rats, a prediction model 
considering interspecies pharmacodynamics and pharmacodynamics was used to 
determine the optimal dose for each antagonist in mice.275 Similar to COMT-/- mice 
receiving vehicle, -/- mice receiving sustained i.pl. coadministration of the β2AR antagonist 
ICI-118,511 and β3AR antagonist SR59230A exhibited mechanical allodynia (group: 
p<0.0001; group x day: p=0.1442; Figure 3.4A) and hyperalgesia (group: p<0.0001; group x 
day: p=0.9976; Figure 3.4B); as well as decreased mechanical (group: p<0.0001; group x 
day: p=0.9756; Figure 3.4C) and thermal (group: p<0.0001; group x day: p=0.6512; Figure 
3.4D) thresholds; as compared to +/+ mice. 
To confirm that peripheral β2/3ARs antagonists were unable to reverse COMT-
dependent pain, we performed an acute study in which we injected COMT-/- mice with a 
bolus dose of ICI (5.113mg/kg) and SR (0.551mg/kg). Similar to the persistent study, 
COMT-/- mice receiving acute ICI-SR (i.p.) also exhibited mechanical allodynia (group: 
p<0.0001; group x time: p= 0.0584; Figure 3.5A) and hyperalgesia (group: p<0.0001, group 
x time: 0.2887; Figure 3.5B); and decreased mechanical (group: p<0.0001; group x time: 
0.4686; Figure 3.5C) and thermal (group: p<0.0001; group x time: 0.9806; Figure 3.5D) 
thresholds; as compared to +/+ mice. See Figure 3.5 for all acute study data. 
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3.4 Discussion 
 IPDs are associated with abnormalities in adrenergic pathways, such that patients 
exhibit increased levels of catecholamines alongside diminished activity of COMT. Work by 
our group and others has shown that diminished activity of COMT is due, at least in part, to 
polymorphic variation in the corresponding COMT gene. To model the etiology of idiopathic 
pain in patients possessing the low activity COMT alleles, the present study utilized COMT-/- 
mice that express endogenously low levels of COMT throughout their lifespan. The results 
reveal that COMT -/- mice exhibit consistent levels of mechanical and thermal pain 
evaluated over a two-week period. Furthermore, β2- and β3AR antagonists known to block 
the development of persistent pain due to COMT pharmacologic inhibition are unable to 
reverse persistent pain due to COMT gene knockdown. 
In the present study, we found that COMT-/- mice exhibit robust increases in 
response to mechanical and thermal stimuli that remain stable over time. This is in line with 
results from previous studies demonstrating that COMT-/- mice have increased thermal pain 
sensitivity and stress responses.239,276,277 COMT-deficient mice also demonstrate increases 
in impulsive,278 aggressive,238 and fear277,279 behaviors, impairments in cognitive 
performance278 and emotional reactivity,238 and abnormalities in immune cell expression.280 
Meanwhile, mice with overexpression of COMT have blunted thermal pain and stress 
responses.239  
 As previous preclinical and clinical studies have reported sex-specific differences in 
COMT-related phenotypes238-242 and as males and females exhibit different COMT 
expression patterns,243,244 we examined COMT-dependent pain in both sexes. Results 
demonstrated that both male and female COMT-/- mice exhibit comparable increases in 
pain behaviors as compared to wildtype mice. This is consistent with results from Chapter 2, 
which demonstrated no sex-specific differences for pharmacologically induced COMT-
dependent pain behaviors in rats.274 However, this study was not specifically designed nor 
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statistically powered to find such effects, if indeed they exist, and  future studies and clinical 
applications related to COMT-dependent pain should continue to consider possible sex-
specific effects. 
The present study also examined a non-evoked pain behavior, grip strength, in 
COMT-/- mice in attempt to capture spontaneous, unprovoked pain. Grip strength has been 
used in previous literature as a measure of non-evoked pain or discomfort281,282 and we 
therefore hypothesized that COMT-/- mice would have decreased grip strength in 
comparison to wildtype mice. Interestingly, no difference in grip strength was found between 
genotypes. This may suggest that COMT-/- mice do not experience spontaneous pain. In 
contrast, this behavioral assay may not be relevant for an animal model of idiopathic pain. 
Limitations to the grip strength assay are that it may be more of a measure of function or 
motor skills than of pain,283-287 and that it may be a more effective marker of inflammatory or 
joint pain, rather than idiopathic pain that results from genetic variance.281,282,288 Future 
studies should utilize non-evoked pain assays that might be more relevant to idiopathic pain, 
such as the grimace scale.289  
As β2- and β3ARs are known to mediate the initiation of COMT-dependent pain, we 
next examined the ability of coadministration of β2- and β3AR antagonists to block the 
maintenance of pain in COMT-/- mice. We found that coadministration of β2- and β3AR 
antagonists is unable to reverse mechanical and thermal pain observed in COMT-/- mice. 
This contradicts earlier rat studies that have demonstrated a role for β2- and β3ARs in the 
initiation of acute147,149 and persistent274 COMT-dependent pain. The discrepant findings 
may be due to 1) a distinct role for βARs in the development versus maintenance of COMT-
dependent pain, 2) the duration of COMT inhibition, and/or 3) compensatory effects that 
sometimes accompany genetic manipulation. 
The inability of β2- and β3AR antagonists to reverse pain in COMT-/- mice may be 
because they are more important for the development of pain than they are for the 
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maintenance of pain. In the pharmacologic rat model, peripheral β2- and β3AR antagonists 
were provided alongside the COMT inhibitor. Though this demonstrates their efficacy in 
blocking the development of COMT-dependent pain, it does not provide evidence that βAR 
antagonist treatment can reverse pain. Future studies should therefore examine the efficacy 
of peripheral β2- and β3AR antagonist treatment in the pharmacologic rat model, after 
COMT-dependent pain has already been established. 
Another explanation for the negative effect of βAR antagonists on pain in COMT-/- 
mice could be because COMT-/- mice may possess developmental abnormalities. 
Catecholamines and catecholamine enzymes are present at early developmental stages.290 
The importance of catecholamine and βAR signaling in embryonic development has been 
demonstrated in various animal models.291,292 In both animals and humans, levels of 
catecholamines can be represented by a “U” curve. Moderate levels of catecholamines are 
ideal, whereas very high or low levels are associated with deficits in neural circuitry, 
physiological reactivity, and executive function, particularly in response to stress.293 In 
COMT-/- mice and patients with genetic COMT-dependent pain, increased catecholamine 
levels may lead to physiological changes beginning during early development. These early 
developmental changes would not be present in the pharmacologic rat model of COMT-
dependent pain or in non-genetic COMT-dependent clinical pain. This could explain why 
COMT-/- mice are unresponsive to βAR antagonist treatment. Future studies should assess 
the efficacy of βAR antagonists in inducible COMT-/- mice to determine if βAR antagonists 
block pain in COMT-/- mice that have developed normally as COMT+/+ mice.  
Finally, COMT-/- mice have more dramatic and continuous decreases in COMT than 
the pharmacologic rat model. As a result, ongoing pain signaling and overstimulation of 
βARs in COMT-/- mice may cause long-term impairments to various pathways and systems. 
For example, we know that COMT-dependent pain is accompanied by increases in 
inflammatory mediators such as nitric oxide (NO), interleukin 6 (IL-6), and tumor necrosis 
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factor-α (TNFα).149 Circulating inflammatory mediators can result in the release of various 
growth factors (e.g., granulocyte-macrophage colony-stimulating factor, nerve growth factor) 
and neuropeptides (e.g., substance P, histamine, calcitonin gene-related peptide) that are 
involved with the maintenance of hyperalgesia.294 This “inflammatory soup” can activate 
various other downstream pathways that promote pain, such as the mitogen-activated 
protein kinase (MAPK) pathway, and can ultimately result in transcription of nociceptive 
molecules and the hyper-excitability of nociceptive fibers.295,296 Long-term impairments in 
signaling of these and other pathways may cause βAR antagonist administration to be 
ineffective for treatment of pain in COMT-/- mice. These same impairments are likely not 
present in the pharmacologic model, in which continuous βAR signaling is not present and 
COMT deficiencies are transient. Future studies should aim to identify downstream 
pathways affected by COMT abnormalities. 
MicroRNAs may be helpful in identifying affected pathways downstream of COMT-
dependent pain in future studies. MicroRNAs (miRNAs) are small, non-coding pieces of 
RNA that can regulate gene expression by binding to downstream mRNA transcripts.297 
MiRNA dysregulation has been implicated in several diseases, including disorders related to 
pain and inflammation.93,298 MiRNAs also play a role in catecholamine and βAR signaling.181-
184 Identifying miRNA expression profiles for the pharmacologic rat model of COMT-
dependent pain, the genetic mouse model of COMT-dependent pain, and clinical pain 
conditions may help us to identify pathways that are affected for different types and stages 
of persistent COMT-dependent pain. Successful treatment of COMT-dependent pain may 
require targeting βARs in addition to pathways affected by genetic and/or environmental 
COMT abnormalities. Thus, the study of miRNA expression profiles as they relate to COMT-
dependent pain may help to identify better therapeutic options. 
In conclusion, we utilized a clinically relevant, genetic animal model of COMT-
dependent pain to demonstrate that, though the initiation of COMT-dependent pain is 
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mediated via peripherally located β2- and β3ARs, the maintenance is not. It remains possible 
that βAR antagonist treatment may be most effective for preventing the development of non-
genetic COMT-dependent pain, particularly following an environmental event such as a car 
accident or surgery. Though βAR antagonist treatment may be beneficial to a subset of 
patients, alternative multi-target treatment plans may be necessary for those with genetic 
COMT-dependent pain, who may have substantial downstream abnormalities as a result of 
early developmental problems or persistent pain signaling. Future work in this area may help 
to stratify COMT-dependent patients into treatment subgroups, as well as to inform 
clinicians on how to most effectively utilize βAR antagonists for the treatment of persistent 
pain. 
 
3.5 Acknowledgements 
The authors thank SAI-Infusion Technologies for their assistance with catheter 
design. 
 
 
 
3.6 Footnotes 
1 This work was funded by R01 NS072205 to A.N and P01 NS045685 to A.N 
(NIH/NINDS, Bethesda, MD, USA 20892). 
 
 
 
 
 
 
 
 
! 66 
 
Figure 3.1 COMT-/-, but not COMT +/-, mice have enhanced mechanical and thermal 
pain. Compared to COMT +/+ and +/- mice, -/- mice demonstrate an increase in (A) 
mechanical allodynia and (B) hyperalgesia; and a decrease in (C) mechanical and (D) 
thermal thresholds. N=10-13 per group (5-7F and 4-6M). Data are expressed as mean ± 
SEM. ***P<0.001, **P<0.01, *P<0.05 different from WT. Abbreviations: catechol-O-
methyltransferase (COMT), female (F), grams (g), heterozygote (HET, +/-), knockout (KO, -
/-), male (M), seconds (s), wildtype (WT, +/+). 
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Figure 3.2 Enhanced mechanical and thermal pain sensitivity occurs in both male and 
female COMT -/- mice. Compared to COMT +/+ and +/- mice, -/- mice demonstrate an 
increase in (A,E) mechanical allodynia and (B,F) hyperalgesia; and a decrease in (C,G) 
mechanical and (D,H) thermal thresholds; in both males and females. N=5-7 per group. 
Data are expressed as mean ± SEM. ***P<0.001, **P<0.01, *P<0.05 different from WT. 
Abbreviations: catechol-O-methyltransferase (COMT), female (F), heterozygote (HET, +/-), 
knockout (KO, -/-), male (M), paw withdrawal (PW), seconds (s), wildtype (WT, +/+). 
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Figure 3.3 COMT +/+, +/-, and -/- mice display no differences in weight, temperature, or 
grip strength. Compared to COMT +/+ and +/- mice, -/- mice demonstrate no difference in 
(A) weight, (B) temperature, or (C) grip strength. N=10-13 per group (5-7F and 4-6M). Data 
are expressed as mean ± SEM. Abbreviations: catechol-O-methyltransferase (COMT), 
female (F), grams (g), heterozygote (HET, +/-), knockout (KO, -/-), male (M), wildtype (WT, 
+/+). 
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Figure 3.4 Sustained peripheral administration of β2/3AR antagonists does not alter 
COMT-dependent pain in COMT-/- mice. Peripheral coadministration of the β2AR 
antagonist ICI-118,551 and the β3AR antagonist SR59230A fails to reduce (A) mechanical 
allodynia and (B) hyperalgesia or increase (C) mechanical or (D) thermal threshold. N=6-11 
per group (5-7F and 1-5M). Data are expressed as mean ± SEM. ***P<0.001, **P<0.01, 
*P<0.05 different from WT/Veh. Abbreviations: female (F), grams (g), heterozygote (HET, +/-
), ICI-118,551 (ICI), knockout (KO, -/-), male (M), seconds (s), SR59230A (SR), Vehicle 
(Veh), wildtype (WT, +/+). 
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Figure 3.5 Acute administration of β2/3AR antagonists does not alter COMT-dependent 
pain in COMT-/- mice. Acute i.p. delivery of the β2AR antagonist ICI-118,551 and the β3AR 
antagonist SR59230A in a bolus dose does not block (A) mechanical allodynia or (B) 
hyperalgesia; nor does it affect (C) mechanical or (D) thermal threshold of COMT-/- mice. 
N=4-5 per group (2F and 2-3M). Data are expressed as mean ± SEM. ***P<0.001, **P<0.01, 
*P<0.05 different from WT/Veh. Abbreviations: female (F), grams (g), heterozygote (HET, +/-
), ICI-118,551 (ICI), intraperitoneal (i.p.), knockout (KO, -/-), male (M), seconds (s), 
SR59230A (SR), Vehicle (Veh), wildtype (WT, +/+). 
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CHAPTER 4 
 
MICRORNA EXPRESSION PROFILES DIFFERENTIATE IDIOPATHIC PAIN DISORDER 
SUBTYPES 1,2 
 
4.1 Introduction 
Vestibulodynia (VBD) is an idiopathic pain disorder (IPD), characterized by entry 
dyspareunia, tenderness to touch and presence of erythema on the vulvar vestibule, that 
affects up to 15% of women in the United States.299,300 VBD often co-occurs with other IPDs 
including irritable bowel syndrome (IBS; 35%)301, temporomandibular disorder (TMD; 
78%),299 and fibromyalgia (FMS; 17%).301 VBD and related IPDs represent a significant 
healthcare problem, together affecting up to one billion adults worldwide.302 Current 
treatment regimens remain ineffective due to the conditions’ uncertain etiology and 
heterogeneous clinical manifestation.299 To understand the nature of these complex 
conditions and improve standards of care, the identification of unique biological signatures 
and pathways that map onto distinguishing clinical features is required.  
While clinical manifestations are heterogeneous, VBD and related IPDs are 
associated with a state of pain amplification, psychological distress and enhanced 
inflammation.91 In VBD, pain is localized to the pelvis, possibly due to altered permeability or 
cellular composition of the mucosa.299 Women with VBD demonstrate higher levels of 
anxiety and somatization as well as enhanced production of pro-inflammatory cytokines.300 
Compared to individuals with one IPD, those with co-occurring IPDs exhibit increased 
psychological distress299 and imbalances in pro- and anti-inflammatory mediators possibly 
indicative of abnormalities in central pain processing.32 MicroRNAs (miRNAs) represent 
biological determinants of pain, mood, and inflammation. miRNAs are small, noncoding 
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pieces of RNA that control gene expression by inhibiting protein translation or degrading 
downstream target mRNAs.297 Aberrant miRNA profiles have been associated with several 
animal models of pain and inflammation as well as painful conditions in humans.93 Further, 
miRNA profiling represents a novel and clinically-relevant approach for patient stratification 
of pain-related conditions.121 Emerging evidence also suggests a role for miRNAs in 
psychological conditions such as depression and anxiety.303 Lastly, miRNAs regulate genes 
involved in activation of immune cells and secretion of inflammatory cytokines.104 This 
suggests that miRNAs are key contributors to the pain amplification, psychological distress 
and enhanced inflammation characteristic of IPDs such as VBD. 
Here, we aimed to elucidate novel clinical features and biological pathways unique to 
women with VBD and to those with VBD plus a commonly co-occurring IPD, IBS 
(VBD+IBS). The primary aim was to identify miRNAs that differ in expression between 
groups. Secondary aims were to describe differences among clinical groups in pain-related 
phenotypes signifying clinical, psychological, pain-relevant, and inflammatory 
characteristics. We found that women with VBD have pain localized to the pelvis, normal 
self-reported pain and psychological profiles, increased levels of pro- and anti-inflammatory 
cytokines, and dysregulation of miRNAs predicted to be involved in pain processing and 
estrogen signaling. Women with VBD+IBS have greater pain sensitivity at remote bodily 
sites, enhanced self-reported pain and somatization, imbalanced pro- and anti-inflammatory 
responses, and dysregulation of miRNAs predicted to be involved in pain processing, 
cellular physiology, and central sensory pathways. Collectively, these results suggest 
miRNA profiles may be useful for understanding the shared and unique mechanisms of 
localized versus widespread pain conditions. 
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4.2 Materials and Methods 
4.2.1  Subject Consent and Enrollment 
All subjects were enrolled after giving informed consent as approved by the 
Biomedical Institutional Review Board of the University of North Carolina at Chapel Hill 
(UNC).  
4.2.2  Inclusion and Exclusion Criteria 
This study utilized data from 78 women (33 VBD, 23 VBD+IBS, and 22 HC). 
Subjects in VBD and VBD+IBS groups were recruited at the UNC Pelvic Pain Clinic and 
subjects in the HC group were recruited through fliers placed on campus and in the local 
community between August 2008 and August 2010. Sample sizes were based upon prior 
miRNA studies.115,121,304,305 Preliminary eligibility assessment of interested subjects was 
conducted via a phone interview. Subjects were excluded for a positive response to any of 
the following criteria: 1) age <21 or >45; 2) breastfeeding, pregnant, or menopausal; 3) 
significant medical conditions such as seizure disorder, diabetes, or thyroid disorder; and 4) 
known diagnosis of comorbid urogenital pain conditions such as interstitial cystitis. Subjects 
without vulvovaginal complaints were recruited as potential controls.  
 Subjects were then clinically assessed during a standardized gynecological exam 
during which they rated pain using the modified Gracely Pain Scale.306 VBD was diagnosed 
in women who reported a history of pain during intercourse or tampon insertion and who 
experienced tenderness to touch upon palpation of the vestibule with a cotton swab during 
the exam.307 The threshold for pain history was a rating of 3 or more using the Gracely Pain 
Unpleasantness Scale. During the clinical exam, subjects with suspected dermatological 
disorders (e.g., lichen sclerosis, contact dermatitis) and vaginismus were excluded. All 
exams were performed by a single examiner. 
Subjects were also assessed for other pain disorders including IBS, FM, TMD, and 
migraine headaches. IBS case status was determined using 4 abdominal pain questions in 
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accordance with Rome III Criteria.308 Multicenter Criteria were used to classify FM, defined 
by widespread pain in combination with tenderness at 11 or more of the 18 specific tender 
point sites.309 Classification of TMD was based on the Research Diagnostic Criteria for 
temporomandibular disorders, with the defining characteristics being a history of facial pain 
and examiner-evoked pain reported in the cheeks, jaw muscles, temples, or jaw joints.310 
Migraine headaches (with or without aura) were classified by the International Classification 
of Headache Disorders (ICHD-2) criteria.311 As the majority of the VBD subjects with co-
occurring pain syndromes had IBS, the following 3 groups were created: subjects with VBD 
alone, subjects with VBD and IBS (including those with or without additional co-occurring 
pain disorders), and pain-free healthy controls. Healthy controls were excluded if they 
reported any psychological or pain-related conditions. 
4.2.3  Mucosal Pressure Pain Measurement 
Twelve pressure points of the vestibule were defined with reference to a clinical 
drawing annotated with a conventional clock face. The 12 o’clock position marked the 
anterior midline and the 6 o’clock position marked the posterior (in dorsal lithotomy position). 
Six sites were assessed for pain: 3 on the upper vestibule at positions 2, 10, and 12; and 3 
on the lower vestibule at points 5, 7, and 6, in that order.306 To account for subject-to-subject 
variability, anatomical landmarks were also used to standardize the location of vestibular 
sites between women. For each pelvic mucosal pain assay averaging the 6 site scores 
together created an aggregate score. 
Intensity: To assess pain sensitivity in the vestibule the examiner applied pressure to 
each site with a Q-tip and instructed the subject to rate her pain on a scale of 0-10 (0=no 
pain, 10=worst imaginable). For mucosal intensity assays: HC N=21, VBD N=33, and 
VBD+IBS N=23. 
! 75 
Threshold: A digital vestibular pressure algometer designed by the Center for Pain 
Research and Innovation at UNC and first described by Zolnoun et al306 was used to record 
the threshold to pressure pain sensitivity in the vestibule. The algometer is attached to a 
cotton swab that was applied to each site beginning at 1N and increasing until the subject’s 
first sensation of pain, at which time the subject was instructed to click a computer mouse. 
The latency was recorded in real-time. This test was repeated on each site 3 times with an 
interstimulus interval of 2 seconds. Results report the average score of the 3 tests. For 
mucosal threshold assays: HC N=13, VBD N=31, and VBD+IBS N=20. 
4.2.4  Muscle Pressure Pain Detection Measurement 
To test muscle pressure pain of the vulvovaginal muscles, a pressure sensor was 
affixed to a plastic thimble that was worn over the investigator’s right index finger. The 
algometer pressure sensor, which measured forces ranging from <1N to >98N, was used for 
direct and isolated palpation of the right and left puborectalis levator muscles (sites 5 and 7) 
and perineal muscle complex (site 6). An aggregate score was calculated as the average of 
the 3 muscular sites. The exam to test for muscle pressure pain was conducted 
transvaginally in accordance with conventional clinical practice.306 
Intensity: Examiner applied pressure to each site on the lower vestibule and had the 
subject rate her pain (0=pressure, 1=low, 2=moderate, and 3=severe). For muscle intensity 
tests: HC N=21, VBD N=33, and VBD+IBS N=23. 
Threshold: Subjects were instructed to click a computer mouse at the first sensation 
of pain to find the muscle pain perception threshold, which was recorded in real-time by the 
computer. The examiner terminated the pressure if she was unable to apply additional force 
to reach the subject’s threshold. For muscle threshold tests: HC N=16, VBD N=30, and 
VBD+IBS N=19. 
! 76 
Tolerance: The subject was then given the option to undergo tolerance testing, which 
was performed after a 5-minute rest period. 61/78, or 78% of subjects opted to participate. 
Subjects were instructed to click the computer mouse when they were no longer able to 
tolerate the pressure. For muscle tolerance tests: HC N=15, VBD N=28, and VBD+IBS 
N=18. 
4.2.5  Remote Bodily Pressure Pain Threshold Measurement 
A digital algometer (Wagner, Greenwich, CT, USA) was applied for 3 trials to each 
side of the trapezius and the temporomandibular joint (TMJ) beginning at a pressure of 1 N 
and increasing until the subject’s first sensation of pain, at which time the threshold force 
was recorded in Newtons. Final scores report the average of left and right thresholds for 
each site. For remote bodily pressure pain measurements: HC N=23, VBD N=30, and 
VBD+IBS N=20. 
4.2.6  Remote Bodily Thermal Windup Measurement 
Thermal stimuli of 50°C were applied repeatedly to the right hand to evaluate the 
temporal summation of thermal heat pain “windup”.312 Ratings of pain in response to 10 
repeated stimuli were evaluated. Stimuli of 0.5 sec duration were repeated once every three 
seconds and pain was rated on a 0–100 numerical rating scale (NRS). The procedure was 
stopped if the participant reported a rating of 100 or if she asked that it be stopped.  For 
thermal windup measurements: HC N=21, VBD N=30, and VBD+IBS N=19. 
4.2.7  Assessment of Psychological and Self-reported Health Phenotypes 
Prior to clinical examination, subjects completed questionnaires that collectively 
assessed affective components of pain, somatic symptoms related to pain, perceived 
control, self-rated health and mood. The McGill Pain Questionnaire (MPQ) assessed 
sensory components of pain using 11 verbal describers and affective qualities related to 
pain using 5 describers. Responses on 4-point scales were summed to compute scores for 
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each section.32 The Short Form 12 version 2 (SF12v2) assessed 6 domains: global health, 
physical functioning, physical roles, emotional functioning, emotional roles, and pain 
interference; using an algorithm313 based on answers to 12 physical and mental health 
related questions. Each scale ranged from 0 to 100, with higher values signifying better 
function and mood.32 Answers to 54 questions on the Pennebaker Index of Limbic 
Languidness (PILL) questionnaire were used to create a summary score of somatic 
symptoms (e.g., itchy eyes, dizziness). Frequency for each symptom was recorded on a 
five-point Likert scale ranging from “never or almost never” to “more than once a week”.32 
The Comprehensive Pain and Symptom Questionnaire (CPSQ) assessed various 
components and effects of bodily pain (e.g., face, jaw, head, and lower back pain) using 
individual scaled scores from answers to 55 questions.14 The Symptom Checklist 90-
Revised (SCL-90R) used 90 questions in to assess a broad range of psychological 
symptoms such as anxiety and depression.314 
4.2.8  Assessment of circulating cytokine protein levels 
During the clinic visit, whole blood was collected into ethylenediaminetetraacetic 
acid-coated Vacutainer tubes (BD Biosciences, Franklin Lakes, NJ, USA) and placed on ice. 
Plasma was isolated by centrifuging at 1520 RPM for 10 minutes at 4°C and aliquoted into 
Cryotubes (Nalge Nunc International, Lima, OH, USA), frozen with liquid nitrogen and stored 
at -80°C. Samples were thawed on ice and the Fluorokine MAP Multiplex Human Cytokine 
Panel A (R&D Systems, Minneapolis, MN, USA) was used to measure the levels of 22 
cytokines, including monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory 
protein-1α (MIP-1α), macrophage inflammatory protein-1β (MIP-1β), regulated upon 
activation normal t-cell expressed and secreted (RANTES), epithelial-derived neutrophil-
activating peptide 78 (ENA-78), fibroblast growth factor basic (FGF basic), granulocyte 
colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-
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CSF), interferon-γ (IFN-γ), interleukin-1α (IL-1α), interleukin-1β (IL-1β), interleukin-1 
receptor antagonist (IL-1ra), interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-5 (IL-5), 
interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), interleukin-17 (IL-17), tumor 
necrosis factor α (TNFα), thrombopoietin (Tpo), and vascular endothelial growth factor 
(VEGF). A full list of cytokines including detection thresholds can be found here: 
http://www.rndsystems.com/product_detail_objectname_fmaphumansample.aspx.  
Plasma samples were incubated first with a set of color-coded beads pre-coated with 
antibodies for each of the 22 cytokines and then with corresponding biotinylated secondary 
antibodies. Samples were then incubated with streptavidin-phycoerythrin conjugate and 
read with a Luminex dual laser analyzer (Luminex Corporation, Austin, TX, USA), which 
detects the magnitude of the phycoerythrin signal to determine cytokine levels. Standards 
were measured in duplicate and then the mean fluorescent intensity was calculated for each 
sample. The experimenter was blinded to experimental groups for all cytokine assays. 
4.2.9  miRNA Profiling 
During the clinical visit, whole blood was also collected in PAXgene Blood RNA 
tubes (BD Biosciences, Franklin Lakes, NJ, USA) and stored at -80°C. After thawing tubes, 
RNA was isolated from blood using PAXgene blood miRNA kits (Qiagen, Germantown, MD, 
USA). RNA concentrations were measured on a NanoDrop 1000 (NanoDrop Technologies, 
Wilmington, DE, USA) and normalized to 20ng/uL using TE buffer. cDNA synthesis was 
performed using the TaqMan Reverse Transcription Kit, along with human Pool A and B 
Megaplex RT primers. cDNA was preamplified using TaqMan Preamplification Master Mix 
and human primers that corresponded to the Pool A and B RT primers. Samples were 
prepared and loaded onto OpenArray plates by the AccuFill Robot System (Life 
Technologies, Grand Island, NY, USA) using the protocol recommended by the vendor. 
Loaded OpenArray plates were run through the QuantStudio 12K Flex Real-Time 
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OpenArray PCR System (Life Technologies, Grand Island, NY, USA) to assess expression 
of 761 commonly-studied miRNAs. RT-PCR was used to verify results for 5 miRNAs of 
interest using the Taqman Universal PCS Master Mix, Taqman miRNA Assays (Life 
Technologies, Grand Island, NY, USA) and the protocol recommended by the vendor. The 
experimenter was blinded to experimental groups for all miRNA assays.  
4.2.10  miRNA Pathway Analysis 
MiRNA expression profiles in blood may inform us of both peripheral and central pain 
processes affected in subtypes of IPDs. Samples of circulating blood provide a rich source 
of pain-relevant molecules, including neurochemicals released by sympathetic nerve 
terminals and inflammatory mediators released by circulating immune cells.315 Furthermore, 
studies have shown that whole blood shares significant gene316 and miRNA317 expression 
similarities with CNS tissues.  
To determine the genes and pathways affected by miRNA expression in women with 
VBD and VBD+IBS, we performed pathway analysis using the in silico Multiple MicroRNA 
Analysis Software provided by the Diana Lab 
(http://diana.cslab.ece.ntua.gr/pathways/index_multiple.php). This software program 
identifies predicted and experimentally validated gene targets of miRNAs using an advanced 
algorithm that is based on levels of interactions between miRNAs and their target genes. 
The program next organizes these genes of interest into Kyoto Encyclopedia of Genes and 
Genomes (Kegg) pathways. For each pathway, a union –ln(p-value) that accounts for all 
genes regulated by miRNAs of interest was also generated. 
4.2.11  Statistical Analysis 
Summary scores from questionnaires and clinical assessments were compared 
among cases and controls using 2-tailed t-tests with the Benjamini-Hochberg procedure for 
multiple testing corrections. For all mucosal, muscle, and remote bodily pressure pain 
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measurements, groups were compared using one-way ANOVA and the Dunnett correction 
method. The thermal windup data were analyzed using a linear mixed model for repeated 
measures. The participant dependent variable was the numeric rating of pain in response to 
each stimulus.  Fixed effects were clinical case classification (3 groups, modeled as a 
categorical variable), the stimulus sequence (continuous variable, 1-10), and the square of 
the stimulus sequence (continuous variable, 1-100). Interaction terms between case-
classification and each of the continuous variables were included to test for differences in 
the rate of windup among clinical sub-groups.  The random effect was person (categorical 
variable) and a variance components covariance structure was specified for the random 
effects. Cytokine expression levels were compared among groups using one-way ANOVA 
and the Dunnett correction method. All comparison analyses were completed using 
GraphPad Prism (Prism, La Jolla, CA, USA).  
4.2.12  miRNA Data Analysis 
Raw data of miRNA Cycle Threshold (CT) were filtered by at least 3 expressed (i.e., 
CT<32) samples within either HC group or combined case group. This filtration process 
permitted assessment of miRNAs that were present in all groups, as well as those that were 
largely increased or decreased in either case or control groups. Of the 761 human miRNAs, 
250 were excluded, leaving 511 miRNAs for analysis. The filtered data were imported into 
DataAssist (Life Technologies, Grand Island, NY, USA) to calculate fold changes versus 
controls using CT values and the 2--CT method. Data were normalized by the Global 
Normalization method318 using median CTs with maximum allowable CT of 32 and including 
max CT in the calculations option, then 2--CT values were exported from DataAssist software 
as relative expression values. Secondary normalization using Variance Stabilization 
method319 were performed with the vsn package in Bioconductor 
(http://www.bioconductor.org/) and the output is log2 transformed normalized relative 
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expression values. Differential expression of miRNAs between case and control groups was 
tested by ANOVA or ANCOVA models using Partek GenomicSuite software (Partek, St. 
Louis, MO, USA). Including run and plate as fixed effect factors in the models controlled for 
batch effect between different runs and assay plates. An ANCOVA model was used to 
remove the effect of age as a covariate on the results. miRNAs of interest from the 
differential expression analyses were picked based on combination of p-value and fold 
change filters indicated in the report. Linear regression analyses between miRNAs and 
intermediate phenotypes were performed in Partek, with correlation p-values adjusted for 
multiple testing using the Benjamini-Hochberg (step-up) false discovery rate. Reported 
correlations are with r<-0.40 or r>0.40, and adjusted p<0.05. 
 
4.3 Results  
4.3.1  Presence of Comorbid Pain Conditions: 
Data were collected from 33 women with VBD, 23 with VBD+IBS, and 22 HC. Of 
those with VBD+IBS, 8 displayed additional pain conditions: TMD (n=4) or TMD and FM 
(n=4) Subjects were demographically similar (Table 4.1). 
4.3.2  Pelvic Pressure Pain Associated with Case Status: 
Pain evoked in response to pressure applied to the pelvic muscles and mucosa is a 
primary symptom of VBD. Average responses to pelvic muscle tests were similar at each 
site (Figure 4.2) therefore data were collapsed across all 3 muscle sites. Compared to HC, 
women with VBD and VBD+IBS had increased stimulus-evoked muscle pressure pain. 
Women with VBD+IBS reported the greatest evoked muscle pain intensity ratings 
(F2,228=19.74, p<0.0001; Figure 4.1A) and the lowest muscle threshold scores (F2,191=10.02, 
p<0.0001; Figure 4.1B). No differences in muscle pain tolerance were observed (Figure 
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4.2G-I). Average verbal intensity and threshold responses to pelvic mucosal stimulation 
were similar at each site (Figure 4.3); therefore data were collapsed across all 6 mucosal 
sites. Compared to HC, women with VBD and VBD+IBS reported enhanced pain intensity in 
response to pressure applied to the pelvic mucosa (F2,459 =37.26, p<0.0001; Figure 4.1C). 
Women with VBD and VBD+IBS did not, however, exhibit reductions in pelvic mucosal pain 
thresholds (Figure 4.1D) as compared to HC. These data suggest that muscular pain, which 
is characterized by increased pain intensity and decreased thresholds, is a primary feature 
of VBD and VBD+IBS. The magnitude of pain evoked by mucosal stimulation is less 
pronounced in VBD and VBD+IBS compared to pain evoked by muscle stimulation. 
4.3.3  Remote Bodily Pain Associated with Case Status: 
Pain at remote bodily sites was evaluated to determine if pain was generalized to 
other body regions. When a pressure stimulus was applied to the trapezius (Figure 4.1E) or 
the TMJ (Figure 4.1F), women with VBD+IBS exhibited a tendency towards reduced pain 
thresholds compared to HC or women with VBD alone. Similar group differences were 
observed in response to thermal heat repeatedly applied to the forearm. The 1st stimulus 
elicited similar ratings for all groups. Successive stimuli then elicited greater pain among 
VBD+IBS subjects compared to controls whose pain ratings plateaued after the 6th pulse, 
indicating that women with VBD+IBS have a greater capacity to temporarily summate heat 
pain. Intermediate effects were observed for the VBD group (Figure 4.1G). In sum, these 
data suggest that women with VBD+IBS experience enhanced pain in response to pressure 
and thermal stimuli at remote bodily regions, indicative of central sensitization. 
4.3.4  Self-reported Clinical Pain and Psychological Characteristics Associated with 
Case Status 
Compared to HC, women with VBD+IBS displayed greater levels of affective, aching, 
tender, and stabbing pain (Table 4.2). Women with VBD+IBS also demonstrated decreases 
in perceived general and physical health status, while women with VBD demonstrated lower 
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perceived mental health status. Additionally, VBD+IBS subjects reported more somatization. 
Lastly, women with VBD+IBS demonstrated a greater number of headaches and impact of 
pain on daily activity in the past 6 months. In sum, VBD subjects were similar to HC in self-
reported pain and psychological characteristics, whereas VBD+IBS subjects reported 
greater clinical pain and decreased perceived health. Although not tabulated, no differences 
in SCL-90R subscale scores were observed between groups. Significance is p<0.05 and 
overall p-values for all variables are reported (Table 4.2). 
4.3.5  Cytokines Associated with Case Status 
Circulating cytokine levels were measured in subjects to determine if inflammatory 
mediators correlate with case status. Of the cytokines measured, IL-8 and IL-1ra were 
statistically significant between groups. Of the remaining 20 cytokines, 9 failed to exhibit 
differences between groups (MCP-1, MIP-1β, ENA-78, FGF basic, G-CSF, IL-6, TNFα, Tpo, 
and VEGF) and 11 were undetectable (MIP-1α, RANTES, GM-CSF, IFN-γ, IL-1α, IL-1β, IL-
2, IL-4, IL-5, IL-10, and IL-17). Compared to HC, women with VBD and VBD+IBS had 
increased expression of pro-inflammatory cytokine IL-8 (F2,79=6.337, p=0.0028; Figure 
4.4A). Women with VBD, but not with VBD+IBS, displayed a compensatory increase in anti-
inflammatory cytokine IL-1ra (Figure 4.4B). These data suggest that women with VBD+IBS, 
but not VBD alone, have an impaired anti-inflammatory response. 
4.3.6  miRNAs Associated with Case Status 
We measured miRNA expression profiles to determine if miRNAs map onto 
distinguishing clinical features of IPDs. Compared to HC, VBD subjects had downregulation 
of 7 (miR-449b, miR-34b, miR-645, miR-503, miR-485-5p, miR-1294, miR-520f) and 
upregulation of 3 miRNAs (miR-200b, miR-133b, miR-520D-3p) at p-value<0.05 (Figure 
4.5A). VBD+IBS subjects had downregulation of 6 (miR-1825, miR-1288, miR-593, miR-
485-5p, miR-1294, miR-520f) and upregulation of 5 miRNAs (let-7f-2#, miR-512-3p, miR-
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125a-3p, miR-661, miR-520D-3p) (Figure 4.5B). Downregulated miRNAs (fold change < -2) 
are depicted by red dots and upregulated miRNAs (fold change > 2) by blue dots (Figure 
4.5A-B). All miRNAs are listed with corresponding fold change and p-value. miRNAs listed 
under “Both” were dysregulated in VBD and VBD+IBS subjects (Figure 4.5C). Results were 
verified for 5 of the dysregulated miRNAs using RT-PCR (Figure 4.6). 
Specific miRNAs were associated with pain-relevant cytokines and intermediate 
phenotypes, with the direction of correlation varying according to miRNA and phenotype 
(Table 4.3) Specifically, 3 miRNAs were associated with IL-1ra expression and 2 miRNAs 
were associated with IL-8 expression. MiRNAs were also associated with self-reported pain 
and function, such that 12 miRNAs were associated with ‘stabbing pain’, 1 miRNA was 
associated with ‘affective pain’ and 2 miRNAs were associated with impact of pain on daily 
activity. Finally, miRNAs were associated with experimental pressure pain, such that 9 
miRNAs were associated with pressure applied to the TMJ and 11 miRNAs were associated 
with pressure applied to the trapezius. Some miRNAs (miR-645, RNU44, miR-543, and miR-
213) were associated with more than one phenotype and, thus, may play a key role in pain-
relevant processes. All correlations with absolute values >0.40 and p<0.05 are reported 
(Table 4.3). 
4.3.7  miRNA Pathways Associated with Case Status 
We performed in silico pathway analysis using DIANA-miRPath v2.0 to identify 
genes and downstream pathways affected by miRNA dysregulation in IPDs.320 In both 
groups, miRNA dysregulation is predicted to disrupt transforming growth factor beta (TGF-
β), mitogen-activated protein kinase (MAPK) and Wnt signaling pathways (Figure 4.7, 
green). For example, upregulation of miR-520D-3p causes decreased levels of SMADs in 
the TGF- β pathway. Downregulation of miR-485-5p and miR-520f causes increased levels 
of MAPK genes such as protein kinase B (AKT1) and mitogen-activated protein 3-kinase 14 
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(MAP3K14). Downregulation of miR-485-5p results in increased levels of myc-associated 
factor X (MAX), another MAPK gene. Upregulation of miR-520D-3p causes increased levels 
of deubiquitinating enzymes (DUSPs), which act as MAPK phosphatases.321 MAPKs and 
SMADs are also involved in Wnt signaling. 
In VBD, but not VBD+IBS, the dorsal-ventral axis formation, gonadotropin-releasing 
hormone (GnRH), and gap junction pathways may be affected (Figure 4.7, blue). For 
example, downregulation of miR-34b and miR-449b leads to increased levels of dorsal-
ventral axis proteins including receptor tyrosine-protein kinase erbB-4 (ERBB4), protein C-
ets-1 (ETS1), and RAF proto-oncogene serine/threonine-protein kinase (RAF1). 
Downregulation of miR-200b causes increased levels of many gap junction proteins 
including: epidermal growth factor receptor (EGFR), GTPase KRas (KRAS), adenylate 
cyclase type 9 (ADCY9), phospholipase C beta-4 (PLCB4), cAMP-dependent protein kinase 
catalytic subunit beta (PRKACB), protein kinase C (PRKCA), and lysophosphatidic acid 
receptor 1 (LPAR1). Many of these proteins (i.e., RAF1, ADCY9, KRAS, PLCB4, PRKACB, 
and PRKCA) are also vital to the GnRH pathway. 
In VBD+IBS, but not VBD, the extracellular matrix (ECM), insulin resistance, and 
dentatorubral-pallidoluysian atrophy (DRPLA) pathways may be affected (Figure 4.7, red). 
Downregulation of miR-593 causes increased expression of ECM proteins including 
fibronectin type III domain containing 1 (FNDC1) and integrin alpha 5 (ITGA5). Upregulation 
of let-7f and miR-661 causes decreased levels of ECM proteins alpha-1 type I collagen 
(COL1A1) and dystroglycan 1 (DAG1), respectively. Upregulation of miR-125a-3p and miR-
512-3p causes decreased levels of integrin beta 1 (ITGB1), another ECM protein; and 
insulin (INS), insulin receptor (INSR), and phosphatidylinositol-4,5-bisphosphate 3-kinase 
catalytic subunit alpha (PIK3CA), each of which is involved with insulin resistance. The 
insulin resistance and DRPLA pathways greatly overlap, sharing proteins such as INS and 
INSR. Full lists of the top 20 affected pathways for each group are reported with names and 
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union –ln(p-values) for target genes (Tables 4.4 and 4.5). Shared and unique pathways 
identified in VBD versus VBD+IBS may provide insight on the mechanisms underlying 
localized and widespread pain. 
 
4.4 Discussion  
IPDs are heterogeneous in nature and have limited effective therapeutic options. 
Here, we identify two subtypes of chronic pain patients, those with localized pain (VBD) and 
those with widespread pain (VBD+IBS) that differ with respect to pain phenotypes, 
psychological profiles, circulating cytokine expression and miRNA profiles. Pathway analysis 
of miRNA targets further suggests mechanisms that are common and unique to VBD and 
VBD+IBS. 
Historically, VBD has been defined as a vulvar mucosa condition.306 Our results, 
however, demonstrate that enhanced pelvic pressure pain in VBD and VBD+IBS is 
experienced predominantly in the muscles, suggesting modest increases in mucosal pain 
may exist as a byproduct of muscle pain. These data are in line with recent evidence that 
proposes a complex pathophysiology for VBD, involving the muscles as well as the 
peripheral and central nervous systems.322 This suggests that VBD is, and should be treated 
as, a musculoskeletal pain condition. 
Although VBD and VBD+IBS groups had similar pelvic pain phenotypes, they 
differed in remote bodily pain phenotypes and psychological profiles. Increased responses 
to mechanical and thermal stimuli at remote bodily sites in VBD+IBS indicates central 
enhancement in the processing of pain-evoking sensations.40 Our results are in line with 
those from studies that suggest chronic pain conditions such as VBD likely reflect localized 
sensory dysregulation in the affected area323 whereas widespread bodily pain often involves 
dysregulation in central pain processing, perhaps due to sensitization of spinal 
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nociceptors324 or impairments in descending noxious control systems.325 This probably 
explains why there was co-occurrence of TMD or FM for several of the VBD+IBS subjects 
and it raises the possibility that those, or other, overlapping pain conditions might likewise 
be associated with circulating cytokine expression and miRNA profiles. Unfortunately, there 
were too few TMD and FM subjects to address that question with sufficient power in this 
study, although it merits investigation in future studies. 
Women with VBD also differed from those with VBD+IBS in circulating cytokine 
expression. Women with VBD had elevated levels of pro-inflammatory cytokine IL-8 and 
anti-inflammatory cytokine IL-1ra. This is consistent with studies that have demonstrated 
elevated inflammatory cytokine levels in pain conditions such as TMD and FM.326,327 Women 
with VBD+IBS had elevated levels of IL-8 with no compensatory increase in IL-1ra. IL-1ra, a 
negative regulator of inflammation, can suppress IL-8 expression and block IL-8-induced 
mechanical pain.328,329 Our finding is similar to that of a study that indicates an imbalance 
between IL-8 and IL-1ra in individuals with TMD plus widespread pain.32 In sum, women in 
this study can be divided into two subsets: (1) those with localized pelvic pain, whose pain at 
other bodily sites resembles that of HC, who otherwise report good health, and who have 
intact anti-inflammatory responses; and (2) those with co-occurring pain conditions, more 
pain at remote bodily sites, poorer self-reported health, and impaired anti-inflammatory 
responses.  
As miRNAs are key regulators of processes related to pain, psychological variables, 
and inflammatory responses, we explored their expression in VBD and VBD+IBS by miRNA 
profiling. Shared dysregulation of miRNAs may help to elucidate the mechanisms underlying 
IPDs. Both VBD and VBD+IBS groups in this study demonstrate dysregulation of miR-485-
5p, miR-1294, miR-520f, and miR-520D-3p. Previous studies have found the same miRNAs 
to be associated with other diseases. For example, miR-485-5p330,331 and miR-520D-3p332 
have been linked with cancer, and miR-1294 has been linked to Alzheimer’s 333 and 
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Parkinson’s disease.334 While little is understood about the function and role of miR-520f in 
human disease, the miR-520 family is known to regulate IL-8.335 Downregulation of miR-
520f, but not upregulation of miR-520D-3p, can explain the increased IL-8 levels measured 
here in women with VBD and VBD+IBS. It is important to note that miRNA regulation is 
dynamic and complex. MiRNA expression can be affected by the presence of downstream 
mRNAs or proteins, and can be indirectly influenced by miRNAs within the same family. 
Several interactions, particularly in the form of negative or positive feedback loops, have 
been established within miRNA families.336 Additional experiments are necessary to confirm 
the relationship between the miR-520 family and IL-8 in VBD and VBD+IBS, and to measure 
the concerted effect of these and other miRNAs on cytokine expression. 
To further understand how these miRNAs could contribute to IPDs, we performed 
pathway analysis of predicted downstream targets. Both the VBD and VBD+IBS groups 
share predicted disruption of pain-relevant pathways. For example SMADs, which are 
downregulated in IPDs, are responsible for regulating anti-inflammatory cytokines of the 
TGF-β family and controlling inflammatory response.337,338 Our results are in line with those 
from the TMD study previously mentioned that demonstrates suppression of the TGF-β 
pathway in individuals with either TMD or TMD plus widespread pain.32 We demonstrate 
potential upregulation of AKT1, MAP3K14, MAX, and DUSPs in IPDs, each of which may 
contribute to pain sensitization, pro-inflammatory mediator synthesis and the development of 
chronic pain via the MAPK pathway.109,321,339-341 MAPKs and SMADs are also involved in 
Wnt signaling, a pathway that alters production of pro-inflammatory cytokines and sensitivity 
of peripheral sensory neurons, thereby contributing to development of neuropathic 
pain.342,343 We conclude that dysregulation of miRNAs and downstream pathways may 
promote a constant state of inflammation and pain in women with VBD and VBD+IBS. 
Dysregulated miRNAs that do not overlap between the two groups may represent 
unique pathways of vulnerability. Women with VBD have dysregulation of miR-449b, miR-
! 89 
34b, miR- 645, miR-503, miR-200b, and miR-133b. MiR-449b,344 miR-34b,345 miR-645,346 
miR-503347,miR-200b,348 and miR-133b 349 have been implicated in cancer. Notably, miR-
449b is known to regulate neurokinin-1 receptor (NK1R) in chronic bladder pain syndrome 
(BPS). 350 The NK1 pathway is important for pain transmission and neuroimmune 
modulation351 and may be affected similarly in VBD and BPS. 
Based upon miRNA dysregulation, our pathway analysis predicts that women with 
VBD have increased levels of ERBB4, ETS1, and RAF1, each of which may contribute to 
inflammation or the development of neuropathic pain.352-355 Other proteins targeted in VBD 
include EGFR, KRAS, ADCY9, PLCB4, PRKACB, PRKCA, and LPAR1, which are all linked 
to inflammation.356-358 Interestingly, another common denominator of the genes and 
pathways affected in VBD is estrogen.359-363 RAF1, ADCY9, KRAS, PLCB4, PRKACB, and 
PRKCA are vital to the GnRH pathway, in which neuropeptide GnRH interacts with estrogen 
via a negative feedback loop to maintain hormone levels.364 Other affected targets, such as 
ETS1, ERBB4, and LPAR1 interact directly with estrogen or estrogen receptors.360,365,366 Our 
results predict that women with VBD will have blunted estrogen and GnRH activity. This 
provides a possible explanation for why estrogen and GnRH effectively reduce pain in 
endometriosis and other pelvic pain conditions.367,368 From these results we conclude that 
miRNA dysregulation of estrogen-relevant genes contributes to localized pelvic pain 
characteristic of VBD. 
We found that subjects with VBD+IBS show dysregulation of miR-1825, miR-1288, 
miR-593, let-7f-2#, miR-512-3p, miR-125a-3p, and miR-661. MiR-1825,369 miR-593,370 let-7f-
2#,371 miR-512-3p,372 miR-125a-3p,373 and miR-661374 have all been shown to contribute to 
cancer. In addition, miR-1825 has been associated with avian influenza;375 miR-1288 with 
ectopic pregnancy;376 and let-7f-2# with lupus.377 Most relevant to our results, miR-125a-3p 
has been shown to promote orofacial pain through upregulation of p38 MAPK.378 
In VBD+IBS, our pathway analysis predicts that miRNA dysregulation will affect 
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genes of the ECM including COL1A1, ITGB1, and ITGA5. Alterations in the ECM, which 
provides structural and mechanical support to surrounding tissue, have been previously 
linked to many painful conditions.379,380 INS and INSR, also affected in VBD+IBS, have been 
implicated in nociception via the insulin resistance pathway.381 In addition, each of the 
pathways and molecules affected by miRNA dysregulation in VBD+IBS share an 
involvement in both muscle function and sensory processing. For example, COL1A1 has 
been implicated in skeletal muscle atrophy.382 Decreases in ITGB1, PIK3CA, and INS have 
all been linked to impairments in muscle development and function.383-385 ITGA5 interacts 
with fibronectins to influence astrocyte physiology386 and ITGB1 is necessary for normal 
axon formation.387 Decreased DAG1 expression is associated with abnormal myelin sheath 
folding and muscle impairment.388 In sum, dysfunction of pathways such as muscle and 
sensory nerve processes may lead to central sensitization and generalized body pain in 
VBD+IBS.  
While the present study did not enroll women with IBS alone, an emerging literature 
demonstrates the contribution of miRNAs, particularly the miR-29 family, to IBS.389,390 
Interestingly, we did not observe an overlap between the miRNAs associated with IBS in 
other cohorts and those associated with VBD or VBD+IBS in our cohort. This might reflect 
the differential expression of miRNAs in different sample types (e.g., whole blood used in 
the present study versus colon tissue and microvesicles commonly used in IBS studies). 
Further, it might indicate that the pathophysiological processes that drive IBS are distinct 
from those that drive VBD or VBD+IBS.  
In conclusion, we presented potentially separate pathways for localized versus 
widespread pain as predicted by miRNA profiles. miRNA dysregulation in VBD is predicted 
to affect estrogen-relevant pathways, explaining why pain is localized to the pelvis. In 
contrast, miRNA dysregulation in VBD+IBS may be linked to alterations in muscle, nerve, 
and glial cell function, thereby contributing to widespread pain. While these results suggest 
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that miRNAs hold promise as biomarkers for chronic pain, it is important to note that existing 
miRNA studies of human IPDs are underpowered statistically and our knowledge of miR-
1294, miR-645, miR-1825, and miR-1288 is extremely limited. Further studies are required 
to 1) identify miRNA profiles in a larger population of chronic pain patients; 2) observe 
miRNA expression profiles in sample types other than whole blood (e.g., plasma, tissue, 
specific cell types); 3) validate changes in the expression levels of the predicted targets 
(e.g., estrogen and insulin); 4) correlate miRNA profiles with response to treatments that 
target different pathophysiologic processes (e.g., topical estrogen therapy to improve local 
vestibular tone391 versus anticonvulsant medication to calm the activity of nociceptive 
neurons392-394); and 5) assess the effectiveness of targeting miRNAs and downstream 
pathways to reduce and manage symptoms of chronic pain patients. Accomplishing these 
next steps will facilitate the use of miRNA screening tools in the clinic to determine the most 
effective treatment with minimal risk for patients with chronic pain. Such studies should help 
inform the development of novel therapeutics targeted against one of several key elements 
along the canonical pathway from gene to protein.  
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Table 4.1 Demographic Data 
Demographic Data HC VBD VBD+IBS 
N 22 33 23 
Age 26.09 (1.04) 28.06 (1.10) 28.13 (1.36) 
Weight (kg) 69.90 (0.66) 63.63**** (0.45) 60.88**** (0.66) 
RACE 
White 
Black 
Hispanic 
Other 
 
16 
2 
1 
3 
 
25 
4 
1 
3 
 
16 
2 
0 
5 
EDUCATION 
High school 
Some college 
College grad 
Post grad 
 
1 
3 
6 
12 
 
1 
4 
13 
15 
 
1 
4 
10 
8 
INCOME 
0-39k 
40-79k 
80-149k 
150k+ 
refused or left blank 
 
7 
7 
2 
3 
3 
 
12 
9 
6 
2 
4 
 
10 
6 
2 
1 
3 
COMORBID CONDITIONS 
VBD + IBS only 
VBD + IBS + TMD 
VBD + IBS + TMD + FM 
 
N/A 
N/A 
N/A 
 
N/A 
N/A 
N/A 
 
15 
4 
4 
Abbreviations: healthy control (HC), vestibulodynia (VBD), irritable bowel syndrome (IBS), 
temporomandibular joint disorder (TMD), fibromyalgia (FM). For age and weight, data are mean 
(SEM). For other categories, N is reported for each group. ****p<0.0001 compared to HC. 
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Table 4.2 Self-reported pain, function, and psychological characteristics 
associated with case status 
 
Phenotype Questionnaire HC VBD VBD + IBS Adjusted 
P-value 
Affective Pain MPQ 11.67 (0.41) 12.50 (0.62) 14.78*** (0.8) 0.001 
Aching Pain MPQ 1.14 (0.10) 1.23 (0.10) 2.06†††† (0.17) <0.0001 
Tender Pain MPQ 1.10 (0.06) 1.37 (0.13) 1.61** (0.16) 0.003 
Stabbing Pain MPQ 1.00 (0.00) 1.13 (0.10) 1.39* (0.20) 0.038 
General Health SF12v2 4.51 (0.11) 4.31 (0.15) 4.01* (0.15) 0.012 
Mental Health SF12v2 51.82 (1.87) 45.01* (1.96) 46.41 (2.20) 0.069 
Physical Health SF12v2 55.83 (1.12) 57.58 (0.85) 50.54†† (1.26) 0.003 
Somatization PILL 89.79 (4.15) 98.44 (3.60) 115.61†† (4.61) 0.0002 
Headache Types CPSQ 1.37 (0.19) 1.93 (0.19) 2.37** (0.23) 0.009 
Impact of Pain on Daily Activity CPSQ 0.30 (0.20) 0.81 (0.37) 2.05* (0.64) 0.028 
Data are expressed as Mean (SEM). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 compared to HC. ††p<0.01, 
††††p<0.0001 as compared to HC and VBD.  
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Table 4.3 MicroRNA expression is correlated with intermediate phenotypes 
 
Intermediate Phenotype miRNA Correlation (r) Adjusted 
p-value 
IL-1ra expression miR-99b 
miR-373 
miR-627 
-0.74 
0.44 
0.42 
<0.0001 
0.020 
0.034 
IL-8 expression miR-125a-5p -0.44 0.052 
Stabbing Pain (MPQ) miR-1305 
miR-425# 
miR-30d 
miR-1255B 
miR-454# 
miR-302b 
miR-15b# 
miR-320B 
miR-551b 
miR-570 
miR-1254 
miR-487a 
0.56 
-0.54 
-0.54 
-0.52 
-0.51 
0.51 
-0.51 
-0.49 
0.43 
0.42 
-0.41 
0.40 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.01 
0.015 
0.023 
0.027 
0.037 
Affective Pain (MPQ) miR-551b 0.49 0.015 
Impact of Pain on Daily 
Activity (CPSQ) 
miR-491-3p 
miR-10b 
0.48 
0.46 
0.029 
0.035 
Remote Bodily Pressure 
Pain (Masseter) 
RNU44 
miR-645 
miR-1274A 
miR-213 
miR-543 
RNU48 
miR-192# 
miR-1274B 
-0.55 
-0.47 
-0.45 
-0.42 
-0.41 
-0.41 
-0.40 
-0.40 
<0.001 
0.010 
0.016 
0.036 
0.037 
0.037 
0.041 
0.041 
Remote Bodily Pressure 
Pain  (Trapezius) 
RNU44 
RNU48 
miR-543 
miR-645 
miR-1274A 
miR-1270 
miR-1179 
miR-589 
miR-378 
miR-213 
miR-1180 
-0.56 
-0.44 
-0.44 
-0.44 
-0.43 
-0.43 
-0.43 
-0.42 
-0.42 
-0.41 
-0.40 
<0.001 
0.019 
0.019 
0.019 
0.019 
0.019 
0.019 
0.020 
0.022 
0.024 
0.027 
Abbreviations: Interleukin 1 receptor antagonist (IL-1ra), interleukin 8 
(IL-8), McGill Pain Questionnaire (MPQ), Comprehensive Pain and 
Symptom Questionnaire (CPSQ). 
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Table 4.4 MicroRNA Pathway Dysregulation in VBD 
 
MiRNAs Target Genes ln(p-val) 
Wnt Signaling 
miR-34b 
miR-
449b 
miR-503 
miR-645 
miR-
200b 
miR-
133b 
CCND2, CTNNB1, DKK1, FZD4, FZD5, MAP3K7, VANGL2, 
DAAM1, LEF1, MYC, NFAT5, PLCB1, SMAD2, SMAD4, TP53, 
WNT1, BTRC, CCND2, CCND2, CCND3, FOSL1, MAP3K7, NKD1, 
PPP3CB, WNT3A, PPP3CB, CTBP2, EP300, FBXW11, JUN, 
MPAK9, PLCB4, PPP2R2C, PRKACB, PRKCA, RAC1, RHOA, 
SIAH1, WNT16, CTBP2, CXXC4, FBXW11, NFAT5, NFATC2, 
PLCB4, PPP2CA, PPP2CB, PSEN1, TBL1X, TCF7, WNT4 
21.37 
 Adherens Junction  
miR-34b 
miR-
449b 
miR-503 
miR-
200b 
miR-
133b 
CTNNB1, MAP3K7, LEF1, MET, PTPRM, PVRL1, SMAD2, 
SMAD4, VCL, WASF1, IGF1R, MAP3K7, PVRL1, WASL, EP300, 
LMO7, PVRL1, PVRL4, RAC1, RHOA, WASF1, WASF3, EGFR, 
FGFR1, IGF1R, INSR, MLLT4, TCF7, TGFBR1, WASF2, YES1 
18.76 
Colorectal Cancer 
miR-34b 
miR-
449b 
miR-503 
miR-
200b 
miR-
133b 
CTNNB1, FZD4, FZD5, GRB2, PIK3R3, LEF1, MAP2K1, MET, 
MYC, PDGFRA, SMAD2, SMAD4, TP53, AKT3, BCL2, CCND1, 
CDD, IGF1R, MAP2K1, PIK3R1, RAF1, ACVR1C, APPL1, BCL2, 
JUN, KRAS, MAPK9, RAC1, SOS1, EGFR, IGF1R, TCF7, TGFBR1 
18.33 
Prostate Cancer 
miR-34b 
miR-
449b 
miR-503 
miR-
200b 
miR-
133b 
CREB1, CREB3, CREB3L1, CTNNB1, GRB2, PDGFA, PIK3R3, 
CREB1, CREB3L1, E2F3, LEF1, MAP2K1, PDGFRA, TP53, AKT3, 
BCL2, CCND1, CCNE1, CREB5, E2F3, IGF1R, IKBKB, MAP2K1, 
PIK3RI, RAF1, BCL2, CCNE2, CDK2, CDKN1B, CREB5, E2F3, 
EP300, IKBKB, KRAS, SOS1, CREB5, EGFR, FGFR1, IGF1R, 
TCF7 
17.01 
Chronic Myleoid Leukemia 
miR-34b 
miR-
449b 
miR-503 
miR-
200b 
miR-
133b 
GRB2, PIK3R3, E2F3, HDAC1, MAP2K1, MYC, SMAD4, TP53, 
AKT3, CCND1, E2F3, IKBKB, MAP2K1, PIK3R1, RAF1, ACVR1C, 
CBL, CDKNN1B, CRKL, CTBP2, E2F3, IKBKB, KRAS, PTPN11, 
SHC1, SOS1, BCL2L1, CRK, CTBP2, EVI1, TGFBR1 
14.95 
Renal Cell Carcinoma 
miR-34b GRB2, PIK3R3, RAP1B, ARNT2, ETS1, MAP2K1, MET, AKT3, 14.35 
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miR-
449b 
miR-503 
miR-
200b 
miR-
133b 
MAP2K1, PIK3R1, RAF1, VEGFA, CRKL, EGLN1, EP300, ETS1, 
GAB1, JUN, KRAS, PAK6, PAK7, PTPN11, RAC1, RAP1B, SOS1, 
TCEB1, VEGFA, CRK 
ErbB Signaling Pathway 
miR-34b 
miR-
449b 
miR-503 
miR-645 
miR-
200b 
miR-
133b 
ERBB4, GRB2, NCK2, PIK3R3, RPS6KB1, MAP2K1, MYC, 
RPS6KB1, AKT3, MAP2K1, PIK3R1, RAF1, HBEGF, CBL, 
CDKN1B, CRKL, GAB1, JUN, KRAS, MAPK9, PAK6, PAK7, 
PLCG1, PRKCA, RPS6KB1, SHC1, SOS1, CRK, EGFR, MAP2K4 
12.44 
 Melanogenesis  
miR-34b 
miR-
449b 
miR-503 
miR-
200b 
miR-
133b 
CREB1, CREB3, CREB3L1, CTNNB1, FZD4, FZD5, CREB1, 
CREB3L1, KITLG, MAP2K1, MITF, PLCB1, WNT1, GNAI3, 
MAP2K1, RAF1, WNT3A, ADCY2, ADCY9, EP300, GNAI3, KRAS, 
PLCB4, PRKACB, PRKCA, WNT16, ADCY5, ADCY6, CALM1, 
PLCB4, TCF7, WNT4 
10.51 
 Focal Adhesion  
miR-34b 
miR-
449b 
miR-503 
miR-
200b 
miR-
133b 
CCND2, CTNNB1, GRB2, ITGA2, PDGFA, PIK3R3, RAP1B, 
RELN, VAV3, MAP2K1, MET, PDGFRA, THBS1, VCL, AKT3, 
BCL2, CCND1, CCND2, CCND3, IGF1R, MAP2K1, MYLK, 
PIK3R1, RAF1, VEGFA, BCL2, CRKL, FLT1, FM1, JUN, KDR, 
LAMC1, MAPK9, MYLK, PAK6, PAK7, PRKCA, RAC1, RAP1B, 
RELN, RHOA, SHC1, SOS1, TLN2, VEGFA, XIAP, COL1A1, 
COL5A3, COL6A3, CRK, EGFR, IGF1R, TNR 
10.21 
 MAPK Signaling Pathway  
miR-34b 
miR-
449b 
miR-503 
miR-645 
miR-
200b 
miR-
133b 
CACNB2, GRB2, MAP3K1, MAP3K7, MAP3K7IP2, PDGFA, 
RAP1B, CACNB1, CACNB3, FGF23, HSPA1B, MAP2K1, MAP4K4, 
MYC, PDGFRA, RPS6KA4, RRAS, TAOK1, TP53, AKT3, FGF2, 
FGF7, IKBKB, MAP2K1, MAP3K7, MAPK8IP2, NF1, PPP3CB, 
PTPRR, RAF1, MEF2C, PPP3CB, ACVR1C, CACNA2D1, 
CACNB2, CRKL, DUSP1, IKBKB, JUN, KRAS, MAP2K5, MAP3K1, 
MAP3K5, MAP4K3, MAP4K4, MAPK9, NTF3, PRKACB, PRKCA, 
RAC1, RAP1B, RPS6KA3, SOS1, SRF, CRK, DUSP1, EGFR, EV1, 
FGF1, FGFR1, MAP2K4, MAP3K3, NFATC2, TGFBR1 
10 
 Regulation of Actin Cytoskeleton  
miR-34b 
miR-
449b 
miR-503 
miR-
CFL2, ITGA2, NCKAP1, PDGFA, PIK3R3, PIP5K1B, PIP5K3, 
VAV3, FGF23, IQGAP2, MAP2K1, MYH9, PDGFRA, RDX, RRAS, 
VCL, WASF1, FGF2, FGF7, MAP2K1, MYH10, MYLK, PIK3R1, 
RAF1, WASL, CFL2, CRKL, FGD1, FN1, KRAS, LIMK1, MSN, 
MYLK, PAK6, PAK7, PIP4K2B, PIP5K3, PPP1R12B, RAC1, 
9.67 
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200b 
miR-
133b 
RHOA, SOS1, SSH2, WASF1, ARPC1A, ARPC5, CRK, DIAPH2, 
EGFR, FGF1, FGFR1, IQGAP2, MSN, MYH9, PFN2, PIP4K2B, 
PIP5K3, WASF2 
 Pancreatic Cancer  
miR-34b 
miR-
449b 
miR-503 
miR-
200b 
miR-
133b 
PIK3R3, E2F3, MAP2K1, RALA, SMAD2, SMAD4, TP53, AKT3, 
CCND1, E2F3, IKBKB, MAP2K1, PIK3R1, RAF1, VEGFA, 
ACVR1C, BRCA2, E2F3, IKBKB, KRAS, MAPK9, RAC1, VEGFA, 
BCL2L1, EGFR, JAK1, TGFBR1 
9.57 
 Axon Guidance  
miR-34b 
miR-
449b 
miR-503 
miR-645 
miR-
200b 
miR-
133b 
CFL2, DPYSL2, EPHA7, NCK2, NTNG1, ABLIM3, EFNB1, MET, 
NFAT5, SEMA4C, SEMA4F, DCC, EFNB2, EPHA7, GNAI3, 
PPP3CB, SEMA3D, SEMA6D, PPP3CB, SEMA3F, SEMA6D, 
CFL2, EFNA1, EFNB2, GNA13, KRAS, LIMK1, PAK6, PAK7, 
PLXNA2, RAC1, RHOA, SEMA3F, SEMA6D, EFNA4, EPHA7, 
EPHB4, NFAT5, HFATC2, SRGAP2, SRGAP3 
8.58 
 Notch Signaling Pathway  
miR-
449b 
miR-503 
miR-
200b 
miR-
133b 
APH1A, DLL1, HDAC1, JAG1, NCSTN, NOTCH2, NUMBL, NUMB, 
CTBP2, EP300, JAG2, KAT2B, NUMB, CTBP2, PSEN1, RBPJ 
8.32 
 Thyroid Cancer  
miR-34b 
miR-
449b 
miR-503 
miR-
200b 
miR-
133b 
CCDC6, CTNNB1, LEF1, MAP2K1, MYC, RET, TP53, CCND1, 
MAP2K1, KRAS, TCF7, TFG 
8.21 
 Glioma  
miR-34b 
miR-
449b 
miR-503 
miR-
200b 
miR-
133b 
GRB2, PDGFA, PIK3R3, E2F3, MAP2K1, PDGFRA, TP53, AKT3, 
CCND1, E2F3, IGF1R, MAP2K1, PIK3R1, RAF1, E2F3, KRAS, 
PLCG1, PRKCA, SHC1, SOS1, CALM1, EGFR, IGF1R 
8.06 
 TGF-Beta Signaling Pathway  
miR-34b 
miR-
ACVR2A, ID2, RP26KB1, SMURF1, ACVR2B, E2F5, MYC, 
RPS6KB1, SMAD2, SMAD4, THBS1, ACVR2A, ACVR2B, 
7.82 
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449b 
miR-503 
miR-
200b 
miR-
133b 
BMPR1A, SMAD7, SMURF1, SMURF2, ACVR1C, ACVR2A, 
EP300, NOG, PPP2R2C, RHOA, RPS6KB1, SMURF2, ID4, 
LTBP1, PPP2CA, PPP2CB, SP1, TGFBR1 
 Acute Myleoid Leukemia  
miR-34b 
miR-
449b 
miR-503 
miR-
200b 
miR-
133b 
GRB2, PIK3R3, RPS6KB1, LEF1, MAP2K1, MYC, RPS6KB1, 
AKT1, CCND1, IKBKB, MAP2K1, PIK3R1, RAF1, IKBKB, KRAS, 
PIM2, RPS6KB1, SOS1, JUP, PML, TCF7 
7.67 
 Oxidative Phosphorylation  
miR-
449b 
miR-
200b 
miR-
133b 
SDHC, NDUFS4, NDUFS3 7.21 
 Dorso-Ventral Axis Formation  
miR-34b 
miR-
449b 
miR-503 
miR-
200b 
miR-
133b 
ERBB4, GRB2, ETS1, MAP2K1, NOTCH2, MAP2K1, RAF1, ETS1, 
ETS2, KRAS, SOS1, EGFR 
7.18 
The top 20 pathways, as determined by the Diana Lab DNA Intelligent Analysis, affected by 
miRNA dysregulation in women with VBD are shown with the names and union –ln(p-value) 
of target genes affected in each pathway. Genes are linked to miRNAs by color. 
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Table 4.5 MicroRNA Pathway Dysregulation in VBD+IBS 
 
MiRNAs Target Genes ln(p-val) 
MAPK Signaling Pathway 
miR-593 
let-7f-2# 
miR-125a-
3p 
miR-512-3p 
miR-661 
PDGFA, PDGFB, PTPN5, PTPRR, RAP1B, RPS6KA1, TAOK3, 
TGFB2, ACVR1B, ACVR1C, CACNA1D, CASP3, DUSP16, 
DUSP1, DUSP4, DUSP9, FGF11, FGF5, FLNA, MAP3K1, 
MAP3K3, MAP3K7IP2, MAP4K3, MAP4K4, MAPK11, MAPK8, 
NGF, NLK, PAK1, PDGFB, PPP3CA, RPS6KA3, TGFBR1, TP53, 
IL1R1, NF1, NLK, RPS6KA3, AKT1, CRK, DUSP1, EVI1, FGF19, 
MAP3K14, MAP3K1, MAPK10, MEF2C, MKNK2, PAK2, PPP3CA, 
RPS6KA2, RPS6KA3, RPS6KA5, SOS1, TGFBR2, DUSP3, 
FLNA, MAP3K10, MAP3K3, PLA2G6 
16.5 
 TGF-Beta Signaling Pathway  
miR-593 
let-7f 
miR-125a-
3p 
miR-512-3p 
miR-661 
ACVR1, BMPR2, NOG, SP1, TGFB2, ACVR1B, ACVR1C, 
ACVR2A, ACVR2B, CHRD, E2F5, GDF6, TGFBR1, THBS1, 
ZFYVE16, ACVR2B, BMPR2, CUL1, E2F5, INHBB, LEFTY1, 
LEFTY2, PITX2, RBL1, RBL2, SMAD2, TGFBR2, PPP2R1A 
16.07 
Chronic Myleoid Leukemia 
miR-593 
let-7f 
miR-125a-
3p 
miR-512-3p 
miR-661 
CDK6, CTBP2, SHC4, TGFB2, ACVR1B, ACVR1C, BCL2L1, CBL, 
CCND1, CDKN1A, RB1, TGFBR1, TP53, E2F3, ACVR1C, APPL1, 
BCL2, JUN, KRAS, MAPK9, RAC1, SOS1, EGFR, IGF1R, TCF7, 
TGFBR1 
15.09 
Colorectal Cancer 
miR-593 
let-7f 
miR-125a-
3p 
miR-512-3p 
miR-661 
CREB1, CREB3, CREB3L1, CTNNB1, GRB2, PDGFA, PIK3R3, 
CREB1, CREB3L1, E2F3, LEF1, MAP2K1, PDGFRA, TP53, 
AKT3, BCL2, CCND1, CCNE1, CREB5, E2F3, IGF1R, IKBKB, 
MAP2K1, PIK3RI, RAF1, AKT1, CCND1, CDK4, CRK, E2F3, 
EVI1, PIK3CA, RUNX1, SOS1, TGFBR2, CBL, CDK6 
11.98 
Focal Adhesion 
miR-593 
let-7f 
miR-125a-
3p 
miR-512-3p 
miR-661 
COL4A6, ITGA10, ITGA5, PDGFA, RAP1B, SHC4, CCND1, 
CCND2, COL11A1, COL1A1, COL1A2, COL3A1, COL4A1, 
COL4A6, COL5A2, FLNA, IGF1, IGF1R, ITGB3, MAPK8, PAK1, 
PDGFB, THBS1, VAV3, FYN, IGF1R, ITGB1, ACTG1, AKT1, 
CCND1, CCND2, CRK, FLT1, IGF1R, ITGB8, LAMA3, MAPK10, 
PAK2, PAK7, PIK3CA, SOS1, COL6A3, FLNA, ITGA10, KDR 
11.35 
Axon Guidance 
miR-593 
let-7f 
miR-125a-
3p 
miR-512-3p 
miR-661 
EPHB3, SRGAP3, EPHA4, EPHB1, LIMK2, PAK1, PPP3CA, 
SEMA4C, SEMA4F, SEMA4G, CFL2, DCC, FYN, ITGB1, 
SEMA5B, ABLIM1, CFL2, DPYSL5, EFNB2, EPHA2, EPHA8, 
NTN4, PAK2, PAK7, PLXNA1, PPP3CA, SEMA3C, GNAI2, 
SEMA4G, SLIT1, SRGAP3 
10.33 
Pancreatic Cancer 
miR-593 
let-7f 
CDK6, TGFB2, ACVR1B, ACVR1C, BCL2L1, CCND1, MAPK8, 
RB1, TGFBR1, TP53, CASP9, E2F3, AKT1, CCND1, CDK4, 
8.91 
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miR-125a-
3p 
miR-512-3p 
miR-661 
E2F3, MAPK10, PIK3CA, SMAD2, TGFBR2, CDK6 
 ECM Receptor Interaction  
miR-593 
let-7f 
miR-125a-
3p 
miR-512-3p 
miR-661 
COL4A6, FNDC1, ITGA10, ITGA5, COL11A1, COL1A1, COL1A2, 
COL3A1, COL4A1, COL4A6, COL5A2, FNDC3A, ITGB3, THBS1, 
ITGB1, CD44, FNDC3A, LAMA3, COL6A3, DAG1, ITGA10 
8.61 
 Oxidative Phosphorylation  
miR-512-3p 
 
ATP5E 6.81 
 Glioma  
miR-593 
let-7f 
miR-125a-
3p 
miR-512-3p 
miR-661 
CDK6, PDGFA, PDGFB, SHC4, CCND1, CDKN1A, IGF1, IGF1R, 
PDGFB, RB1, TP53, E2F3, IGF1R, AKT1, CCND1, CDK4, E2F3, 
IGF1R, PIK3CA, SOS1, CDK6 
6.7 
 Melanoma  
miR-593 
let-7f 
miR-125a-
3p 
miR-512-3p 
miR-661 
CDK6, PDGFA, CCND1, CDKN1A, FGF11, FGF5, IGF1, IGF1R, 
PDGFB, RB1, TP53, E2F3, IGF1R, AKT1, CCND1, CDK4, E2F3, 
FGF19, IGH1R, PIK3CA, CDK6 
6.27 
 Adherens Junction  
miR-593 
let-7f 
miR-125a-
3p 
miR-512-3p 
miR-661 
TCF7, ACVR1B, ACVR1C, IGF1R, INSR, NLK, TGFBR1, WASL, 
FYN, IGF1R, INSR, NLK, SNAI1, ACTG1, IGF1R, LEF1, SAMD2, 
SSX1P, TGFBR2, PVRL2, WASL 
6.27 
 Prostate Cancer  
miR-593 
let-7f 
miR-125a-
3p 
miR-512-3p 
CREB3L1, PDGFA, TCF7, CCND1, CDKN1A, IGF1, IGF1R, INS, 
PDGFB, RB1, TP53, CASP9, E2F3, IGF1R, INS, AKT1, CCND1, 
CREB5, E2F3, IGF1R, LEF1, PIK3CA, SOS1 
5.65 
 Type II Diabetes  
let-7f 
miR-125a-
3p 
miR-512-3p 
miR-661 
CACNA1D, INSR, IRS2, MAPK8, SOCS1, SOCS4, INS, INSR, 
MAPK10, PIK3CA, SLC2A4, SOCS4 
5.3 
 mTOR Signaling Pathway  
miR-593 
let-7f 
miR-125a-
RPS6KA1, IGF1, INS, RICTOR, RP26KA3, TSC1, ULK2, INS, 
RPS6KA3, AKT1, PIK3CA, RPS6KA2, RPS6KA3, ULK1, ULK2 
4.77 
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3p 
miR-512-3p 
miR-661 
 Dentatorubropallidoluysian Atrophy (DRPLA)  
miR-593 
let-7f 
miR-125a-
3p 
miR-512-3p 
ITCH, CASP3, INSR, INS, INSR, MAGI1 4.75 
 Bladder Cancer  
let-7f 
miR-125a-
3p 
miR-512-3p 
CCND1, CDKN1A, IL8, RB1, THBS1, TP53, E2F3, CCND1, 
CDK4, DAPK2, E2F3, IL8, RPS6KA5 
4.52 
 Wnt Signaling Pathway  
miR-593 
let-7f 
miR-125a-
3p 
miR-512-3p 
miR-661 
CTBP2, FOSL1, FXD7, NKD1, PRICKLE2, TCF7, VANGL1, 
VANGL2, CCND1, CCND2, FZD4, MAPK8, NKD1, NLK, PPP3CA, 
SENP2, TP53, VANGL1, VANGL2, WNT1, CSNK1E, NLK, 
CCND1, CCND2, CUL1, LEF1, MAPK10, PPP3CA, SMAD2, 
FZD4, FZD8, PPP2R1A 
4.08 
 ErbB Signaling Pathway  
miR-593 
let-7f 
miR-125a-
3p 
miR-512-3p 
miR-661 
ERBB4, NRG3, SHC4, ABL2, CBL, CDKN1A, MAPK8, PAK1, 
NRG1, AKT1, CRK, MAPK10, PAK2, PAK7, PIK3CA, SOS1, CBL 
3.75 
 Regulation of Actin Cytoskeleton  
miR-593 
let-7f 
miR-125a-
3p 
miR-512-3p 
miR-661 
ITGA10, ITGA5, ITGB1, PDGFA, SCIN, DIAPH2, FGF11, FGF5, 
ITGB3, LIMK2, PAK1, PDGFB, RDX, SSH1, VAV3, WASL, CFL2, 
INS, ITGB1, ACTG1, CFL2, CRK, FGF19, ITGB8, PAK2, PAK7, 
PFN2, PIK3CA, RDX, SOS1, SSH2, ARHGEF4, ITGA10, 
PIP4K2B, WASL 
3.65 
The top 20 pathways, as determined by the Diana Lab DNA Intelligent Analysis, affected by 
miRNA dysregulation in women with VBD+IBS are shown with the names and union –ln(p-
value) of target genes affected in each pathway. Genes are linked to miRNAs by color. 
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Figure 4.1 Pelvic muscle and mucosa pressure pain is enhanced in women with VBD 
and VBD+IBS, while remote bodily muscle pain and thermal windup is enhanced only 
in women with VBD+IBS. Women with VBD or VBD+IBS reported greater pain intensity 
and decreased pain thresholds in the pelvic muscle (A-B) and mucosa (C-D). Women with 
VBD+IBS demonstrated a trend towards decreased pressure pain thresholds in the 
trapezius (E) and temporomandibular joint (F) as compared to HC and VBD. (G) For the 
thermal data, there was a significant interaction between study group and stimulus 
sequence, although not between study group and the square of stimulus sequence.  
VBD+IBS women exhibit the greatest degree of pain in response to the windup thermal heat 
assay. Data are Mean ± SEM. *p<0.05, ***p<0.001, ****p<0.0001 compared to HC; †p<0.05 
as compared to HC and VBD. Abbreviations: healthy control (HC), irritable bowel syndrome 
(IBS), vestibulodynia (VBD), standard error of the mean (SEM), temporomandibular joint 
(TMJ). 
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Figure 4.2 Pelvic muscle pressure pain is enhanced in patients with VBD and 
VBD+IBS. Patients with VBD alone exhibit modest increases in pain intensity (A-C) and 
decreases in mechanical threshold (D-F) at all 3 pelvic muscle sites, while those with 
VVS+IBS report dramatic increases in intensity and decreases in thresholds. No differences 
in tolerance were reported across groups (G-I). Data are Mean ± SEM. *p<.05, **p<.01, 
***p<.001 compared to HC. Abbreviations: healthy control (HC), irritable bowel syndrome 
(IBS), Newtons (N), vestibulodynia (VBD), standard error of the mean (SEM). 
 
 
 
0.0
0.5
1.0
1.5
2.0
2.5
***
HC
VBD
VBD+IBS
0.0
0.5
1.0
1.5
2.0
2.5
**
0.0
0.5
1.0
1.5
2.0
2.5
***
**
0
5
10
15
20
25
**
0
5
10
15
20
25
0
5
10
15
20
25
**
0
5
10
15
20
25
0
5
10
15
20
25
0
5
10
15
20
25
In
te
ns
ity
Pa
in
 R
at
in
g
Th
re
sh
ol
d
Fo
rc
e 
(N
)
To
le
ra
nc
e
Fo
rc
e 
(N
)
Pelvic Muscle Pressure Pain
Site 7 Site 6 Site 5A. B. C.
D. E. F.
G. H. I.
! 105 
 
 
Figure 4.3 Pelvic mucosa pressure pain is enhanced in patients with VBD and 
VBD+IBS. VBD and VBD+IBS patients reported trends of enhanced pain intensity (A-F) and 
decreased pain thresholds (G-L) at all 6 pelvic mucosal sites. Data are Mean ± SEM. 
Abbreviations: healthy control (HC), irritable bowel syndrome (IBS), Newtons (N), 
vestibulodynia (VBD), standard error of the mean (SEM). 
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Figure 4.4 Cytokine expression is altered in women with VBD and VBD+IBS. 
Compared to HC, women with VBD exhibit elevated levels of pro-inflammatory cytokine IL-8 
(A) and anti-inflammatory cytokine IL-1ra (B). Women with VBD+IBS exhibit elevated levels 
of IL-8, but no compensatory increase in IL-1ra. Data are Mean ± SEM. *p<0.05, **p<0.01 
compared to HC; †p<0.05 compared to HC and VBD+IBS. Abbreviations: healthy control 
(HC), interleukin (IL), irritable bowel syndrome (IBS), vestibulodynia (VBD), standard error of 
the mean (SEM). 
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Figure 4.5 MicroRNA expression signatures are altered in women with VBD and 
VBD+IBS. Compared to HC, women with VBD exhibit significant downregulation of 7 and 
upregulation of 3 miRNAs (A), while women with VBD+IBS exhibit significant 
downregulation of 6 and upregulation of 5 miRNAs (B). Red dots represent downregulated 
miRNAs and blue dots represent upregulated miRNAs compared to HC. Four miRNAs are 
dysregulated in both VBD and VBD+IBS women. Dysregulated miRNAs are listed with fold 
change and FDR-adjusted p-values (C). Abbreviations: false detection rate (FDR), healthy 
control (HC), irritable bowel syndrome (IBS), miRNA (microRNA), vestibulodynia (VBD). 
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Figure 4.6 MicroRNA expression in VBD and VBD+IBS is validated by real-time PCR. 
Consistent with our miRNA array results, women with VBD (N=5) have decreased miR-449b 
and increased miR-133b whereas women with VBD+IBS (N=5) have decreased miR-1288 
and increased miR-661 as compared to HC (N=5). Women in both groups have decreased 
miR-485-5p as compared to HC. Abbreviations: healthy control (HC), irritable bowel 
syndrome (IBS), vestibulodynia (VBD). 
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Figure 4.7 MicroRNA dysregulation affects multiple genes and pathways in women 
with VBD and VBD+IBS. miRNA dysregulation in women with VBD and VBD+IBS leads to 
dysregulation of genes involved in pain-relevant pathways including the TGFβ, MAPK, and 
Wnt signaling pathways (shown in green). Pathways that do not overlap between women 
with VBD and VBD+IBS represent separate pathways of vulnerability. Pathways unique to 
VBD (shown in blue) include the dorso-ventral axis formation, GnRH signaling, and gap 
junction pathways. Pathways unique to VBD+IBS (shown in red) include the ECM, DRPLA, 
and insulin resistance pathways. A considerable amount of interaction and communication is 
demonstrated between genes and across pathways. Abbreviations: healthy control (HC), 
irritable bowel syndrome (IBS), miRNA (microRNA), vestibulodynia (VBD). See Appendix 1 
for all other abbreviations.  
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CHAPTER 5 
 
SUMMARY 
 
 The studies presented in this dissertation aim to explore the roles of, and the 
relationship between, catechol-O-methyltransferase (COMT) and microRNAs (miRNAs) in 
idiopathic pain disorders (IPDs):  
The first set of studies identifies a site of action for COMT-dependent pain. Chapter 2 
utilizes a pharmacologic rat model to demonstrate that the initiation of persistent COMT-
dependent pain is mediated via peripherally located β2- and β3ARs. Chapter 3 utilizes a 
genetic mouse model to demonstrate that established COMT-dependent pain is not 
mediated via peripherally located β2- and β3ARs. These exciting findings suggest that β2- 
and β3AR antagonist therapy may be effective, particularly for blocking the development of 
pain in individuals experiencing prolonged elevations in catecholamines associated with 
environmental stressors or epigenetic events. Still, more research is required to identify the 
cell types and elucidate the pathways involved in the onset and maintenance of COMT-
dependent pain and to discover an effective treatment for established COMT-dependent 
pain. 
The next set of studies identifies miRNA dysregulation and downstream pathways 
affected by persistent idiopathic pain. Specifically, Chapter 4 demonstrates that miRNA 
dysregulation is also present in clinical IPDs and that miRNA expression profiles can 
differentiate between IPD subtypes with distinct phenotypic characteristics. These exciting 
results suggest that miRNAs may possess utility as biomarkers, both to diagnose and to 
differentiate between subtypes of COMT-dependent pain and IPDs. They also suggest that 
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miRNAs may represent treatment targets for persistent idiopathic pain. Ongoing studies by 
our group are currently focused on linking the COMT story with miRNAs by observing 
miRNA expression in the pharmacologic rat model of COMT-dependent pain. The 
preliminary results for this work can be found in Appendix 1. It is important to note that these 
miRNA studies are a narrow view of an extremely complex regulatory system. Extensive 
research is necessary to elucidate the role of individual miRNAs in IPDs and to identify 
downstream proteins and pathways affected by miRNA dysregulation, so that more effective 
therapeutics can be developed.  
Idiopathic pain is a major healthcare problem, difficult to prevent and ineffectively 
treated due to its unclear etiology and heterogeneous presentation. The diverse array of 
molecular, cellular, physiological, and psychological IPD attributes makes understanding the 
complexities of persistent idiopathic pain an ambitious task. Success will require a multi-
disciplinary effort that forces specialists to collaborate and think outside the box. The studies 
presented in this dissertation link the known fact that COMT is associated with IPDs with the 
idea that miRNAs may play a role in IPDs. The results of these studies work to unravel 
some of the complexities of persistent idiopathic pain, identifying novel mechanisms 
underlying IPDs as well as possible avenues that may lead to effective therapeutics. 
 
 
 
 
 
 
 
 
 
! 112 
APPENDIX 1:  
ONGOING RODENT STUDIES EXPLORING THE RELATIONSHIP BETWEEN 
MICRORNA EXPRESSION AND CATECHOL-O-METHYLTRANSFERASE-DEPENDENT 
PAIN 
 
Introduction 
 Though the etiologies underlying idiopathic pain disorders (IPDs) are not well 
understood, emerging evidence indicates a role for catechol-O-methyltransferase (COMT), 
as well as β-adrenergic receptors (βARs). Idiopathic pain has been previously associated 
with both diminished activity of COMT,127,128 an enzyme responsible for catabolizing 
catecholamines, as well as increased levels of circulating catecholamines.131-133 
Furthermore, functional variants in the COMT gene that reduce COMT activity128,196,197 are 
associated with increased susceptibility to IPDs141,145,146,198-200 as well as enhanced 
experimental pain141,201 and impaired response to treatment.139,202 Previous work performed 
by our group utilized a pharmacologic rat model to demonstrate that sustained 
administration of the COMT inhibitor OR486 causes enhanced mechanical and thermal 
hypersensitivity. This hypersensitivity, however, can be blocked by sustained peripheral 
administration of β2- and β3AR antagonists, demonstrating that the initiation of COMT-
dependent pain is mediated via peripherally located β2- and β3ARs (Chapter 2).274 Recent 
work has demonstrated that β2- and β3ARs drive COMT-dependent pain by increasing the 
production of inflammatory mediators such as nitric oxide and pro-inflammatory cytokines.396 
More research is necessary, however, to understand the mechanisms downstream of βAR 
activation that lead to alterations in expression of pain-relevant molecules.  
 Emerging evidence suggests that epigenetic mechanisms can silence expression of 
genes that are pro- or anti-nociceptive, thus altering pain pathways.86,87 MicroRNAs 
(miRNAs), for example, are a type of epigenetic regulation that could affect pain-relevant 
processes.67 MiRNAs are small, non-coding RNAs that can regulate or control gene 
expression by inhibiting protein translation or degrading downstream target mRNAs.297 
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Dysregulation of miRNAs can cause subsequent dysregulation of downstream pathways 
and processes, often resulting in disease. MiRNA dysregulation has been observed in 
various diseases including, but not limited to, multiple sclerosis,94 peripheral artery 
disease,95 major depressive disorder,96 cardiovascular disease,97 liver injury,98 and cancer.99 
Circulating miRNAs are ideal biomarkers because they are stable in serum and plasma.101 
Understanding miRNA expression profiles for persistent pain would be extremely beneficial 
to the field, as it would help us to identify pathways of interest for treatment. Additionally, 
identifying miRNA biomarkers of persistent pain would be groundbreaking, as there are 
currently no objective diagnostic tests that can assess an individual’s severity and type of 
pain.397 
 MiRNAs play an important role in many pain-relevant processes. They are necessary 
for development and normal function of the immune system. Abnormal immune system 
function can lead to overproduction of inflammatory mediators (e.g., cytokines), contributing 
to chronic pain conditions.102,103 Several miRNAs have been identified as regulators or 
modulators of pain-relevant pathways such as the nuclear factor kappa-light-chain-enhancer 
of activated B cells (NF- ĸB),109,110 mitogen-activated protein kinase (MAPK),398 and janus 
kinase and signal transducer and activator of transcription (JAK-STAT)399,400 pathways, as 
well as of catecholamine184 and βAR signaling pathways.180,182,401 Rodent studies have 
linked miRNA expression to both inflammatory111,112 and neuropathic112,114,115 pain, as well 
as to nociceptor excitability and pain thresholds.116 Intrathecal injections of pain-regulating 
miRNAs have been shown to prevent and alleviate pain in rodents.117,118 In humans, miRNA 
dysregulation has been linked to pain-relevant conditions such as osteoarthritis (OA),120 
complex regional pain syndrome (CRPS), 121 chronic visceral pain,402 fibromyalgia,122 
bladder pain syndrome (BPS),123 migraines,124 vestibulodynia (VBD),395 and irritable bowel 
syndrome (IBS).395 MiRNA expression in COMT-dependent pain, however, has yet to be 
studied.  
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Identifying miRNA expression patterns and affected downstream pathways will help 
us to better understand epigenetic regulation of COMT-dependent pain as well as to 
elucidate new therapeutic targets. We hypothesize that aberrant catecholamine signaling 
and overstimulation of βARs in COMT-dependent pain is associated with miRNA 
dysregulation. To test this hypothesis, we examined miRNA expression profiles in rats 
receiving COMT inhibitor OR486 alongside vehicle or βAR antagonists. Though the results 
are preliminary at this time, miRNA dysregulation was observed in both groups. MiRNA 
dysregulation overlapped slightly between groups, suggesting that not all OR486-induced 
miRNA dysregulation is dependent on βAR signaling. We also found that OR486 
administration alongside vehicle, but not βAR antagonists, causes dysregulation of 
circulating miRNAs responsible for regulating pain-relevant pathways. Ongoing investigation 
of these data will help to confirm these results and elucidate the role of miRNAs in COMT-
dependent pain. 
 
Materials and Methods 
Animals 
Adult female Sprague-Dawley rats (N=20) were bred in house, weighed between 200 
and 400g, and had ad libitum access to standard laboratory chow and water. All animal 
procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at 
the University of North Carolina at Chapel Hill (UNC). Though rodent models of pain only 
partially correlate with human conditions, rats were chosen for these experiments because 
an extensive body of literature exists regarding nociceptive pathways and behavior in this 
species, and because rat pain behavior assays are readily available and well 
characterized.7,205,206 Females were chosen for the present study because despite the fact 
that persistent pain conditions are more prevalent in females than in males,192 basic science 
experiments in all fields of study, including pain, utilize male animals almost exclusively.403  
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General Experimental Conditions 
 Previous work has characterized a rat model for the initiation of persistent COMT-
dependent pain, demonstrating that persistent administration of the COMT inhibitor OR486 
leads to enhanced mechanical and thermal pain. This pain can be blocked by peripheral 
administration of the selective β2AR antagonist ICI-118,511 (ICI) or the selective β3AR 
antagonist SR59230A (SR) (See Chapter 2).274 Here, we aimed to identify miRNAs that are 
dysregulated following sustained COMT inhibition and to determine the ability of β2- and 
βsAR antagonists to prevent COMT-dependent abnormalities in miRNA expression. 
Separate groups of rats received persistent subcutaneous (s.c.) administration of OR486 or 
Vehicle (Veh) for a 2-week period via a 2002 Alzet osmotic mini-pump (Durect Corporation, 
Cupertino, CA) together with peripheral administration of either ICI-SR or Veh via a second 
osmotic mini-pump. Pumps were implanted surgically on Day 0 to deliver Veh/Veh, 
OR486/Veh, Veh/SR-ICI and OR486/SR-ICI (N=5 per group) and whole blood collected on 
Day 14 of the experimental paradigm. 
Drug Preparation 
 OR486 (Tocris, Ellisville, MO), ICI (Tocris, Ellisville, MO), and SR (Tocris, Ellisville, 
MO) were each dissolved in a 5:3:2 ratio of dimethylsulfoxide (DMSO), 0.9%saline, and 
ethanol.147 Drug solutions were injected into pumps, which were placed in 15mL conical 
tubes containing sterile 0.9% saline and primed overnight in a dry heat bath (Lab Armor, 
Cornelius, OR) at 37 degrees Celsius. Subcutaneous delivery of OR486 was at a constant 
rate of 15mg/kg/day for the two-week period. Peripheral delivery of propranolol ICI-118,511 
was at 1.5mg/kg/day and SR59230A was at 1.67mg/kg/day, also for the two-week period. 
Surgical Procedures 
For all surgical procedures, rats were anesthetized by isoflurane inhalation (5% 
induction, 1.5-5% maintenance). Incision sites were shaved and disinfected with ethanol and 
betadine. Sterile technique was employed throughout the duration of all procedures 
! 116 
according to IACUC requirements. Stainless steel wound clips (Braintree Scientific, 
Braintree, MA) were used to close the wounds. A small incision was made over the shoulder 
blades of the rat. Hemostats were used to create a small subcutaneous pocket, in which 
both pumps were placed (the first for OR486 or Veh and the second for ICI-SR or Veh).  
miRNA Profiling 
 Whole blood was collected from rats in PAXgene Blood RNA tubes (BD Biosciences, 
Franklin Lakes, NJ, USA). Tubes were stored at room temperature for 48 hours, as 
recommended by the vendor, and then used immediately for RNA isolation. RNA was 
isolated from blood using the PAXgene blood miRNA kit (Qiagen, Germantown, MD, USA). 
The quantity and quality of the RNA was measured using a NanoDrop 1000 (NanoDrop 
Technologies, Wilmington, DE, USA); and the Agilent 2100 Bioanalyzer (Agilent 
Technologies, Santa Clara, CA, USA), respectively. RNase-free water was used to 
normalize all samples to ~250ng/uL. RNA Integrity Number (RIN) values can be found in 
Table 4.1. RNA samples were then shipped to the Next Generation Sequencing and 
Bioinformatics Core at the University of Texas Health Science Center at San Antonio for 
small RNA sequencing using the Illumina HiSeq 2000 (Illumina Inc., San Diego, CA, USA) 
with the TriLink Small RNA Library Prep Kit (three biological replicates; Trilink, San Diego, 
CA, USA).  
Statistical Analysis 
 MiRNA expression was quantified using a previously described small RNA-
sequencing Read Mapping Pipeline.404 This pipeline, which allows for identification of 
established miRNAs as well as potential novel miRNAs, utilizes the Bowtie405 and 
SHRiMP406 software packages. This pipeline has been used in previous studies to predict 
candidate miRNAs that may act as regulatory hubs for a particular disease. All miRNAs with 
p<0.06 are reported in the present study. 
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miRNA Pathway Analysis 
MiRNA expression profiles in blood may inform us of both peripheral and central pain 
processes affected by persistent OR486-induced COMT-dependent pain. Samples of 
circulating blood provide a rich source of pain-relevant molecules, including neurochemicals 
released by sympathetic nerve terminals and inflammatory mediators released by circulating 
immune cells.315 Furthermore, studies have shown that whole blood shares significant 
gene316 and miRNA317 expression similarities with CNS tissues. To determine the genes and 
pathways affected by miRNA expression in our rat model of COMT-dependent pain, we 
performed pathway analysis using the in silico DIANA miRPath v2.0 analysis software:320 
(http://diana.imis.athena-innovation.gr/DianaTools; False Discovery Rate Correction: ON; 
Conservative Stats Setting: ON). The analysis generated a list of genes affected by changes 
in miRNA expression in each group and organized them into Kyoto Encyclopedia of Genes 
and Genomes (Kegg) pathways. For each pathway, a p-value that accounts for all affected 
genes was also generated. Information on miR-451-5p, miR-17-1-5p, miR-17-1-3p, and 
miR-17-2-5p is extremely limited, therefore they are not included in the pathway analysis.  
 
Preliminary Results and Discussion 
As miRNAs are key regulators of processes related to pain, psychological variables, 
and inflammatory responses, and because they have been linked to IPDs, we explored their 
expression in rats receiving the COMT inhibitor OR486 alongside Vehicle or ICI-SR. Thus 
far, we have completed miRNA isolation, sequencing, and preliminary analysis of the whole 
blood samples. RNA concentrations and RNA integrity numbers (RINs) can be found in 
Table A1.1. The length distribution of small RNA reads (max=50) ranges between 14 to 42 
nucleotides for these samples, with the most prevalent lengths falling between 18 to 24 and 
29 to 31 nucleotides. The most prevalent length observed for small RNAs in these samples 
was 22 nucleotides (26.63% of reads; Figure A1.1). Our results are consistent with those of 
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previous studies that have recognized the most common length for miRNAs to be 21 to 22 
nucleotides.407,408 Our results are also consistent with that of previous length distribution 
studies, which have shown similar length distribution curves for small RNAs in both human 
and mouse samples.409 The increased prevalence of small RNAs in the 29 to 31 nucleotide 
range in our samples may suggest the presence of stress-induced tRNA-derived RNAs, 
which are generally 30 to 35 nucleotides in length.410 
Preliminary sequencing analysis has demonstrated that the most statistically relevant 
miRNAs in the pharmacologic rat model of COMT-dependent pain (OR186/Veh) as 
compared to the control group include miR-133a-3p, miR-451-5p, miR-93-5p, miR-872-5p, 
miR-17-1-3p, miR-30e-5p, miR-17-1-5p, miR-181d-5p, miR-17-2-5p, and miR-652-3p (Table 
A1.2). Though these miRNAs do not overlap with those found to be dysregulated in IPD 
patient populations (Chapter 4),395 predicted pathways affected by OR486/Veh miRNA 
dyrsregulation include the mitogen-activated protein kinase (MAPK) and the tumor growth 
factor beta (TGF-β) pathways (Table A1.3). Each of these pathways were also pathways of 
interest for VBD and VBD+IBS patients (Chapter 4). These data parallel those of various 
previous studies, linking the MAPK and TGF-β pathways to pain, inflammation, and IPDs.395 
We next observed circulating miRNA expression profiles of rats receiving OR486 
alongside coadministration of ICI and SR, which are βAR antagonists known to block the 
development of OR486-induced pain (Chapter 2). The most statistically relevant miRNAs in 
the OR486/ICI-SR group include miR-182, miR-106b-3p, miR-150-5p, miR-99b, miR-30e-
5p, miR-16-5p, miR-342-3p, miR-93-5p, miR-93-5p, miR-181d-5p, let-7d-5p, and let-7b-5p 
(Table A1.2). The miRNA expression profile of this group as compared to the Veh/Veh 
group differed from that of the OR486/Veh group, demonstrating that ICI-SR administration 
may help to alleviate OR486-induced pain via alteration of miRNA expression. Three of the 
miRNAs overlapped with those of the OR486/Veh group (miR-93-5p, miR-30e-5p, miR-
181d-5p), demonstrating that some OR486-induced miRNA alterations occur independent of 
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βAR-signaling. Unlike the OR486/Veh group, miRNA dysregulation in the OR486/ICI-SR 
group is not predicted to affect the pain-relevant MAPK and TGF-β pathways (Table A1.4). 
These results suggest that βAR antagonists may block the development of COMT-
dependent pain by altering miRNA expression and thereby preventing the activation of pain-
relevant pathways (e.g., MAPK, TGF-β). Of note, the number of predicted genes affected 
per pathway is very small in the OR486/ICI-SR group (Table A1.4) compared to that of the 
OR486/Veh group (Table A1.3). Further, there are far less total predicted pathways affected 
(3 in OR486/ICI-SR vs 29 in OR486/Veh), suggesting that βAR antagonists are protective of 
miRNA expression alterations and downstream pathway dysregulation initiated by OR486 
administration. Only one miRNA was dysregulated in the Veh/ICI-SR group as compared to 
controls (miR-133a-3p; FC=0.321; p<0.033). This miRNA is also downregulated in the 
OR486/Veh group, suggesting it may be altered in response to the vehicle used for dilution 
of OR486 and antagonists. 
Collectively, these data demonstrate that βAR antagonist treatment may alleviate 
OR486-induced pain by blocking the development of miRNA and pathway dysregulation 
downstream of βAR-signaling. Together with Chapter 4, these data suggest an important 
role for the MAPK and TGF-β pathways in IPDs as well as COMT-dependent pain. These 
pathways, along with the specific miRNAs identified in these studies, may represent target 
treatments for patients who suffer from persistent pain. Further investigation will help to 
elucidate the role of each individual miRNA, gene, and pathway identified in this preliminary 
analysis, allowing us to develop more efficient treatment plans for those who suffer from  
IPDs.  
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Table A1.1 RNA Concentrations and RIN Values 
 
 
Rat ID 
Number 
Group Original 
Concentration  
RIN 
1 OR486/Veh 302 ng/uL 7.4 
2 OR486/ICI-SR 482 ng/uL 6.8 
3 Veh/Veh 351 ng/uL 4.1 
4 Veh/ICI-SR 460 ng/uL 6.7 
5 OR486/Veh 388 ng/uL 7.3 
6 OR486/ICI-SR 449 ng/uL 6.9 
7 Veh/Veh 1492 ng/uL 6.1 
8 Veh/ICI-SR 1618 ng/uL 6.2 
9 OR486/Veh 767 ng/uL 6.1 
10 OR486/ICI-SR 788 ng/uL 6.3 
11 Veh/Veh 256 ng/uL 7.8 
12 Veh/ICI-SR 1797 ng/uL 6.3 
13 OR486/Veh 862 ng/uL 5.6 
14 OR486/ICI-SR 407 ng/uL 6.7 
15 Veh/Veh 318 ng/uL 7.3 
16 Veh/ICI-SR 1350 ng/uL 5.2 
17 OR486/Veh 811 ng/uL 3.5 
18 OR486/ICI-SR 944 ng/uL 5.6 
19 Veh/Veh 745 ng/uL 6.9 
20 Veh/ICI-SR 905 ng/uL 5.6 
Abbreviations: ICI118,511 (ICI), RNA Integrity Number (RIN), 
SR59230A (SR), Vehicle (Veh). 
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Table A1.2  MicroRNA Dysregulation in a Rodent Model of OR486-Induced COMT-
Dependent Pain 
 
 miRNA Fold Change p-value 
 
 
 
 
OR486/Veh 
miR-133a-3p 0.156  0.032 
miR-451-5p 0.540 0.025 
miR-93-5p 0.500 0.036 
miR-872-5p 0.494 0.036 
miR-17-1-3p 0.589 0.038 
miR-30e-5p 0.539 0.051 
miR-17-1-5p 0.454 0.054 
miR-181d-5p 0.631 0.054 
miR-17-2-5p 0.458 0.059 
miR-652-3p 0.693 0.059 
 
 
 
 
 
OR486/ICI-SR 
miR-182 0.788 0.008 
miR-106b-3p 0.614 0.024 
miR-150-5p 2.466 0.027 
miR-99b-5p 1.512 0.029 
miR-30e-5p 0.581 0.031 
miR-16-5p 0.394 0.032 
miR-342-3p 2.026 0.038 
miR-93-5p 0.579 0.038 
miR-181d-5p 0.728 0.042 
let-7d-5p 0.680 0.044 
let-7b-5p 0.744 0.057 
MicroRNAs with differential expression as compared to the Veh/Veh 
group (p<0.06) are shown here with corresponding fold change and p-
values. Upregulated miRNAs are shown in blue and downregulated 
miRNAs are shown in red. Overlapping miRNAs are shown in bold. 
Abbreviations: Vehicle (Veh), ICI-118,551 (ICI), microRNA (miRNA), 
SR59230A (SR). 
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Table A1.3  Predicted miRNA Pathway Dysregulation in Rats Receiving OR486/Veh 
Pathway p-value # genes 
Axon guidance <0.0001 41 
MAPK signaling pathway <0.0001 31 
Osteoclast differentiation <0.0001 26 
Regulation of actin cytoskeleton <0.0001 29 
Transcriptional misregulation in cancer <0.0001 22 
Endocytosis 0.0001 18 
Mucin type-O-Glycan biosynthesis 0.0001 4 
Long-term potentiation 0.0001 15 
Prostate cancer 0.0001 14 
Circadian rhythm 0.0002 10 
ErbB signaling pathway 0.0002 20 
T cell receptor signaling pathway 0.0003 19 
Chronic myeloid leukemia 0.0003 14 
Glutamategic synapse 0.0006 19 
VEGF signaling pathway 0.0010 11 
Neurotrophin signaling pathway 0.0026 21 
Acute myeloid leukemia 0.0052 10 
TGF-beta signaling pathway 0.0059 14 
Glioma 0.0075 11 
Calcium signaling pathway 0.0085 22 
The top 20 pathways, as determined by the DIANA miRPath v2.0 Analysis Software, 
affected by miRNA dysregulation in rats receiving OR486 alongside Veh, as compared 
to the Veh/Veh group. Pathways in bold overlap with that of the OR486/ICI-SR Group. 
Abbreviations: ICI-118,551 (ICI), mitogen-activated protein kinase (MAPK), SR59230A 
(SR), tumor growth factor beta (TGF-beta), vascular endothelial growth factor (VEGF) 
 
 
 
 
 
 
 
 
 
 
 
! 124 
Table A1.4  Predicted miRNA Pathway Dysregulation in Rats Receiving OR486/ICI-SR 
Pathway p-value # genes 
Pathways in cancer 0.0001 4 
Renal cell carcinoma 0.0174 2 
Glioma 0.0316 2 
Axon Guidance 0.0432 2 
All pathways (p<0.05), as determined by the DIANA miRPath v2.0 Analysis Software, 
affected by miRNA dysregulation in rats receiving OR486 alongside the β2- and β3AR 
antagonists ICI and SR, as compared to the Veh/Veh group. Pathways in bold overlap with 
that of the OR486/Veh Group. Abbreviations: hypoxia-inducible factor 1 (HIF-1), ICI-118,551 
(ICI), mitogen-activated protein kinase (MAPK), SR59230A (SR), vascular endothelial 
growth factor (VEGF). 
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Figure A1.1  Small RNA Reads Length Distribution 
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APPENDIX 2: ABBREVIATIONS FOR FIGURE 5.7 
Abbreviations: insulin (INS), insulin receptor (INSR), extracellular signal-regulated kinases 
(ERK), insulin receptor substrate 2 (IRS2), phosphatidylinositol-4,5-Bisphosphate 3-Kinase, 
Catalytic Subunit Alpha (PIK3CA), brain-specific angiogenesis inhibitor 1-associated protein 
2 (BAIAP2), dentatorubral-pallidoluysian atrophy (DRPLA), caspase 3 (CASP3), suppressor 
of cytokine signaling 1 (SOCS), alpha-1 type I collagen (COL1a1), laminin alpha-3 (LAMA3), 
fibronectin type III domain containing 1 (FNDC1), thrombospondin 1 (THBS1), integrin 
alpha-5 (ITGA5), integrin beta-1 (ITGB1), dystroglycan 1 (DAG1), extracellular matrix 
(ECM), transforming growth factor beta (TGF-B), TGF-B receptor 2 (TGFBR2), TGF-B 
receptor 1 (TGFBR1), death domain-associated protein (DAXX), RAC-alpha 
serine/threonine-protein kinase (AKT1), mitogen-activated protein kinase (MAPK), ribosomal 
protein S6 kinase 90kDa polypeptide 3 (RPS6KA3), cell division cycle 25B (CDC25B), MYC-
associated factor X (MAX), myocyte enhancer factor 2C (MEF2C), protein phosphatase 2 
regulatory subunit A beta (PPP2R1B), Rho-associated coiled-coil containing protein kinase 
1 (ROCK1),  E2F transcription factor 5 p130-binding (E2F5), cyclin-dependent kinase 4 
inhibitor B (p15), inhibin beta B (INHBB), activin A receptor type II-like 1 (ACVRL1), 
wingless-type MMTV integration site family member 3A (WNT3A), frizzled class receptor 10 
(FZD10), phospholipase C beta 4 (PLCB4), protein phosphatase 3 catalytic subunit alpha 
isozyme (PPP3CA), nuclear factor of activated T cells cytoplasmic calcineurin-dependent 2 
(NFATC2), jun proto-oncogene (c-JUN), disheveled segment polarity protein 3 (DvI3), 
glycogen synthase kinase 3 beta (GSK-3B), beta-catenin (B-catenin), transcription factor 7- 
like 2 (TCF7L2), disheveled-associated activator of morphogenesis 1 (Daam1), ras homolog 
family member A (RhoA), VANGL Planar Cell Polarity Protein 1 (VANGL1), dual-specificity 
protein phosphatase (DUSP), platelet-derived growth factor alpha polypeptide (PDGFA), 
PDGF receptor alpha polypeptide (PDGFRA), growth factor receptor-bound protein 2 
(GRB2), son of sevenless homolog 1 (SOS1), methyl ethyl ketone (MEK), MAPK interacting 
serine/threonine kinase 2 (MKNK2), cyclic adenosine monophosphate (cAMP), protein 
kinase cAMP-dependent catalytic beta (PRKACB), member of ras oncogene family 
(RAP1A), MAPK kinase 4 (MKK4), c-Jun N-terminal kinase (JNK), nuclear factor kappa beta 
(NFkB), Kirsten rat sarcoma viral oncogene homolog (KRAS), proto-oncogene c-RAF 
(RAF1), v-ets erythroblastosis virus E26 oncogene homolog (ETS), broad-complex (BR-C), 
gonadotropin-releasing hormone (GnRH), luteinizing hormone beta polypeptide (LHB), 
alpha gonadotropin (aGSU), follicle-stimulating hormone beta subunit (FSHB), heparin-
binding EGF-like growth factor (HB-EGF), epidermal growth factor receptor (EGFR), proto-
oncogene c-Src (Src), cell-division control protein 42 homolog (CDC42), v-erb-b2 avian 
erythroblastic leukemia viral oncogene homolog 4 (ERBB4), protein kinase cGMP-
dependent type I (PRKG1), protein kinase C alpha (PRKCA), PRK cAMP-dependent 
catalytic beta (PRKACB), adenylate cyclase 1 (ADCY1), G protein alpha inhibiting activity 
polypeptide 3 (GNAI3), guanylate cyclase 1 alpha 3 (GUCY1A3), inositol 1,4,5- 
trisphosphate receptor type 1 (ITPR1), phospholipase C beta 4 (PLCB4), lysophosphatidic 
acid receptor 1 (LPAR1), lipoprotein (LPA), serotonin receptor (HTR2). 
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